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ABSTRACT OF DISSERTAION

PRION CHARACTERIZATION USING CELL BASED APPROACHES

Prions are the causative agents of a group of lethal, neurodegenerative conditions
that include sheep scrapie, bovine spongiform encephalopathy (BSE), and human
Creutzfeldt-Jakob disease (CJD). Prions are derived from the conversion of a normal,
primarily alpha-helical, cellular prion protein (PrPC), to an infectious, beta sheet-rich
conformer (PrPSc). Many unresolved issues surround the process of PrP conversion, and
we know very little about cellular responses to these unique pathogens. Our lack of
knowledge relates, in part, to the difficulty of infecting cells in vitro with prions. While
expression of PrPC is an absolute requirement for prion propagation, I show here that not
all cells that express PrPC are capable of propagating PrPSc. The goal of this thesis is to
understand the role that host factors play in sustaining prion infection and to develop
systems in which the cellular response to prion infection can be assessed. We hypothesize
that cellular permissiveness to prion infectivity is co-dependent on unidentified additional
cellular factors. To study the role of PrPC expression in susceptibility to prion infectivity,
and identify these cofactors in cell culture, we utilized cells which fail to express
endogenous PrPC, but become susceptible to prions following stable expression of PrPC.
Following transfection of a species specific PrP expression construct and isolation of
single cell clones, we assessed PrP expression and susceptibility to prion infectivity by
measuring accumulation of protease resistant PrPSc. Differential gene expression studies
suggest significant transcriptional differences between susceptible and resistant clones.
Using three independent gene expression databases our analyses suggest that the resistant
transcriptional profile favors cell division/cycle and chromosomal regulation pathways,
while the sensitive transcriptional profile is involved in protein homeostasis and quality
control. The results of these studies will not only lead to a greater understanding of PrP
cell biology and the mechanisms of prion pathogenesis, but should ultimately lead to
sensitive and expedient methods for detecting and characterizing prion infectivity from a
wide range of sources.
KEYWORDS: Prions; Cellular Permissiveness; Cellular PrPC; Protease Resistant PrPSc;
Transcriptional Differences
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Chapter 1
I: General Introduction to Prion Biology

I-A: Prion History
Transmissible spongiform encephalopathies (TSE's), which are commonly known
as prion diseases, cause incurable, progressively fatal neurodegeneration in humans and
animals. Biochemically, the propagative mechanism entails the conformational change of
the cellular prion protein (PrPC) into the pathogenic, more stable, and partially protease
resistant scrapie prion protein (PrPSc). The prion (PrPSc) is considered to be the central
component to TSE. Scrapie, the prototypic prion disease affecting sheep and goats, is
prevalent worldwide and has been known in Europe for centuries (Cuillé and Chelle
1939). Other known animal prion diseases include bovine spongiform encephalopathy
(BSE) affecting cattle, chronic wasting disease (CWD) of cervids, and transmissible mink
encephalopathy (TME) affecting farmed raised mink. Human prion diseases include
Creutzfeldt-Jacob disease (CJD), Gertsmann-Straussler-Scheinker syndrome (GSS), fatal
familial insomnia (FFI) and Kuru (Glatzel, Stoeck et al. 2005). Currently, there is no
medical treatment in existence for these diseases.
Although cellular toxicity and neuronal death are universally shared features of
protein misfolding neurodegenerative diseases such as Alzheimer’s (AD), Parkinson’s
(PD1) and Huntington disease (HD), prion diseases are unique because of their infectious
transmission properties (Aguzzi and Calella 2009). Human prion diseases can be
contracted through various sources. They can originate through exposure to contaminated
source, for example variant CJD (vCJD) through the consumption of BSE, or iatrogenic
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(iCJD). Genetic inheritance of an autosomal dominant mutation in the PRNP gene
(familial form) also causes disease. Lastly, prion disease in humans can be sporadic with
an unknown etiology (sCJD) (Mead 2006).
Early in the 20th century, sheep scrapie was described as a transmissible (Cuillé
and Chelle 1939) disease that caused pathology in muscle (M'Gowan 1914; M'Fadyean
1918). The novel biochemical nature of this infectious agent began to emerge in the
1950’s and 1960’s. Specifically, filtration methodology and several denaturing
techniques revealed that the infectious agent was small and proteinaceous (Wilson,
Anderson et al. 1950; Alper, Haig et al. 1966; Alper, Cramp et al. 1967). Based on all the
biochemical evidence gathered in 1967, Griffith, J.S. formulated the hypothesis that the
infectious agent causing scrapie is a self-replicating protein (Griffith 1967). In the 1980’s,
Dr. Stanley Prusiner’s biochemical experiments ultimately led to elucidating and
characterizing the nature of the scrapie agent. Sifting for differences between the scrapie
infected and uninfected brains, the endogenously expressed cellular prion protein was
identified subsequent to purification and characterization of PrPSc, and subsequently
demonstrated to have direct association with prion disease development. Additionally,
because of the lack of nucleic acids and the proteinaceous properties of this infectious
agent, Prusiner formulated the “protein only” hypothesis which defined the causative
agent of scrapie to consist of “proteinaceous infectious particles lacking nucleic acids” or
simply “prions”(Prusiner 1982).
I-B: Human Prion Diseases
Human prion diseases cause widespread neurodegeneration and share several
important clinical features. The symptoms are multifaceted that effect both the cognitive
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and motor functions (Collinge 2001). Common to all human prion diseases is the rapid
progression of dementia, myoclonus, ataxia, vision loss, insomnia and final onset of
akinetic mutism prior to death (Collinge 2001). CJD was described by two independent
German doctors, neurologist Hans Gerhard Creutzfeldt and Alfons Maria Jacob
(Creutzfeldt 1920; Jakob 1921). sCJD is the most common human prion disease. With an
unknown etiology, sCJD occurs at rate of 1 person per million worldwide (Collinge
2001). This disease accounts for 85% of all human TSE’s. fCJD, GSS and FFI are
inherited through an autosomal dominant mutation in the PRNP gene, and account for 1520% of all presented cases (Aguzzi and Calella 2009). The etiology of acquired CJD
varies. The consumption of BSE contaminated meat from infected cattle was
hypothesized to directly link with the etiology of vCJD (Collinge, Sidle et al. 1996).
Accidental transmission of prions through iatrogenic methods that include direct
exposure through contact with contaminated neurosurgical equipment, inoculation with
contaminated human growth hormone and/or prion contaminated corneal graft treatment
are all example sources for acquired human prion diseases (Job, Maillard et al. 1992;
Martínez-Lage, Poza et al. 1994; Mitrova and Belay 1999; Croes, Roks et al. 2002).
Recent findings provided evidence for direct iatrogenic transmission of human prions
from a preclinical vCJD patient through blood transfusion to other individuals, suggesting
that the risk to prion exposure is significantly higher than previously thought (Peden,
Head et al. 2004; Panigaj, Brouckova et al. 2010). Finally, Kuru, which affected the
indigenous people of the Eastern Highlands of Papua New Guinea was transmitted
through cannibalistic rituals (Collinge 2001). Importantly, Kuru was the first human
prion disease to be transmitted in laboratory animals (Gajdusek, Gibbs et al. 1966).
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I-C: Animal Prion Diseases
Scrapie, was described in Europe in the 18th century that became the prototypic
experimental agent in prion research two centuries later (M'Fadyean 1918). It is readily
transmitted in sheep and goat, although the actual mechanism of dispersion is not
completely understood (van Keulen, Bossers et al. 2008). Clinical and neuropathological
characteristics vary amongst scrapie-infected animals. These differences have strong
dependence on the genetic background of the infected animal and prion strains, which
will be described in another section of this chapter in greater detail. The incubation time
of ovine scrapie can range from 2 to 5 years, with death occurring within 6 months after
the onset of clinical signs (Jeffrey and Gonzalez 2007). The most common clinical signs
associated with scrapie is pruritus (itching), which leads to rubbing, scraping and the
eventual loss of wool but other behavioral, and motor dysfunctional symptoms also exist
(Jeffrey and Gonzalez 2007). Atypical scrapie in sheep and goats has recently been
described, which differs from classical scrapie by its biochemical and neuropathological
features (Benestad, Sarradin et al. 2003; Orge, Galo et al. 2004; Le Dur, Beringue et al.
2005; Everest, Thorne et al. 2006; Konold, Davis et al. 2007). Major neurological signs
of atypical scrapie include ataxia and incoordination and the absence of pruritus
(Benestad, Sarradin et al. 2003). Polymorphism in the PRNP gene is strongly correlated
with the animal’s susceptibility to contracting classical scrapie (Baylis and Goldmann
2004). While, atypical scrapie is prevalent in animals that have a polymorphism that is
linked with resistance to classical scrapie (Benestad, Arsac et al. 2008).
BSE, also known as “Mad Cow” disease, emerged in the mid 1980’s as a
previously unknown epidemic in cattle of Great Britain. This epidemic ravaged the
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agricultural industry, destroying cattle farms throughout Europe (Aguzzi and Calella
2009). The incubation time for classical BSE ranges between 2 to 8 years (Wells, Scott
et al. 1987; Novakofski, Brewer et al. 2005) . Transmission and biochemical studies
revealed that classical BSE was a prion disease (Hope, Reekie et al. 1988; Collinge,
Palmer et al. 1995). The disease peaked in the early 90’s and declined to rare occurrences
as the dietary supplementation of protein from rendered cattle became prohibited.
Importantly, classical BSE is considered to be the direct causative agent of vCJD, which
has been experimentally supported through biochemical and histopathological similarities
(Collinge, Sidle et al. 1996; Bruce, Will et al. 1997; Scott, Will et al. 1999; Clewley,
Kelly et al. 2009). Additionally, atypical BSE was identified through active BSE
surveillance programs in Europe (Biacabe, Morignat et al. 2008; Ducrot, Arnold et al.
2008) and subdivided into two strains, L-type and H-type (Buschmann, Biacabe et al.
2004; Casalone, Zanusso et al. 2004). These BSE’s differ by incubation times in cattle
and in transmissions through transgenic mice expressing bovine PrPC, glycopatterns of
PK digested PrPSc, and neurohistological profiles (Buschmann, Gretzschel et al. 2006).
Chronic wasting disease (CWD) of elk, deer and moose is an emerging prion
disease that is causing public concern. Originally described in the 1980’s as a TSE in
captive mule deer (Williams and Young 1980), the disease has spread to free ranging
deer, elk and moose throughout North America and South Korea. Clinical signs in
cervids include patchy coats, a lowered head with drooping ears, weight loss, ataxia along
with behavioral alterations (Williams and Young 1980). Central nervous system (CNS)
assessment of CWD infected cervids shows neuronal vacuolation, neuropil spongiosis,
astrocytic hypertrophy, hyperplasia and amyloid plaques (Williams and Young 1980;
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Bahmanyar, Williams et al. 1985). Even though CWD affects cervids, the zoonotic
potential of this disease has not been well characterized.
Transmissible mink encephalopathy (TME) is a TSE of farmed mink first
recognized in the Wisconsin and Minnesota mink farms in the late 1940’s but described
in 1965 (Burger and Hartsough 1965; Hartsough and Burger 1965). The origin of TME is
unknown, but is hypothesized to have originated from rendered prion infected cattle used
as protein source to feed the animals (Marsh, Bessen et al. 1991). Transmission studies of
Stetsonville TME into cattle produced prion disease with an incubation time of 18.5
months, followed by back passaging the bovine TME into mink, which also resulted in
the development of prion disease (Marsh, Bessen et al. 1991). Recent transmission
studies compared TME, bovine passaged TME and 3 distinct natural BSE (classical, L-,
H-type) in ovine PrPC expressing transgenic mice (TgOvPrP4) (Baron, Bencsik et al.
2007). The results of this study, which included incubation time, lesion profiling and
biochemical properties of the PK resistant materials demonstrated that TgOvPrP4 mice
were susceptible to bovine passaged TME, classical BSE and L-Type BSE but not H-type
BSE, suggesting that L-type BSE is the most likely related to TME (Baron, Bencsik et al.
2007). Clinical signs in mink include the progressive lack of grooming, weight loss,
ataxia and incoordination, behavioral changes, curled tail and mutilation (Hartsough and
Burger 1965).

Neuropathology of TME includes spongiform degeneration and

astrocytosis throughout the CNS (Hartsough and Burger 1965; Eckroade, ZuRhein et al.
1973; Guiroy, Marsh et al. 1993). Transmission studies of TME into the Syrian golden
hamster led to the identification of two biologically distinct prion strains, Hyper (HY)
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and Drowsy (DY) (Bessen and Marsh 1992; Bessen and Marsh 1992), which are
described in greater detail below.
Other rare TSE’s described in animals include the exotic ungulate encephalopathy
(EUE) effecting exotic zoo ruminants, and feline spongiform encephalopathy (FSE) of
domestic and captive wild cats. Both EUE and FSE are considered to be linked to BSE
contaminated

feed

sources

(Cunningham,

Wells

et

al.

1993),

http://www.cfsph.iastate.edu. Clinical and neurohistological data supports these diseases
to be part of the TSE disease family (Pearson, Wyatt et al. 1992; Kirkwood, Cunningham
et al. 1993). A brief overview of prion diseases is presented in table 1.
In summary, prions cause fatal, neurodegenerative disease that affects both
humans and animals. Clinical manifestations of these diseases are complex which include
both cognitive and muscle-motor deficits. The causative agent of the disease is the βsheet rich, protease resistant and detergent insoluble, PrPSc, derived through
conformational conversion process from the endogenously expressed and posttranslationally modified PrPC. Prion diseases have a broad etiological range that includes
genetic predisposition through polymorphism in the PRNP gene, transmissibility by
exposure to the infectious agent and/or through other ill-defined origins. The molecular
mechanisms that govern the etiology of prion diseases are beginning to be better
understood, which ultimately have much wider implications for our understanding of
protein misfolding “conformational” diseases.
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Table 1.1 Human and animal prion diseases

	
  

Disease
Kuru
Sporadic Creutzfeldt-Jacob
disease (sCJD)
Familial Creutzfeldt-Jacob
disease (fCJD)
Iatrogenic CreutzfeldtJacob disease (iCJD)
Variant Creutzfeldt-Jacob
disease (vCJD)

Host
Human
Human

Source
Ritualistic Cannibalism
Spontaneous or somatic mutation

Human

PRNP mutations

Human
Human

Acquired accidentally from medical
procedures
Acquired from BSE

Gertsmann-StrausslerScheinker syndrome (GSS)

Human

PRNP Mutations

Fatal Familial Insomnia
(FFI)

Human

PRNP haplotype 178N-129M

Scrapie
Transmissible Mink
Encephalopathy (TME)
Chronic Wasting Disease
(CWD)
Bovine Spongiform
Encephalopathy (BSE)
Feline Spongiform
Encephalopathy (FSE)
Exotic Ungulate
Encephalopathy (EUE)

Sheep, Goats
Mink

Unknown
Infection from either sheep or cattle

Cervid (Elk,
Deer, Moose)
Cattle

Unknown

Cats

BSE

Nyala, Kudu,
Oryx, bison

BSE
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Unknown

I-D: The Cellular Prion Protein
Unique biochemical properties associated with the infectious scrapie agent were
crucial for the identification of the PrPC. These distinguishing properties included
resistance towards nucleic acid inactivation (scrapie agent remained infectious) but not
towards protein denaturation (Prusiner 1982). The partial resistance to protease
degradation and insolubility in detergents allowed for the identification of a unique
protein that was associated with scrapie diseased hamster brains but not in the healthy
counterparts (Prusiner, Groth et al. 1980). Further subcellular fractionation of scrapie
infected hamster brains led to the purification of the protease resistant peptide that had a
migration pattern on the SDS-PAGE yielding a size of approximately 27-30 kDa,
designated as PrP27-30(Prusiner, Bolton et al. 1982). The purification of PrP27-30
facilitated reverse sequencing of the amino terminal end of the polypeptide, enabling the
identification of the host encoded gene for PrP (Oesch, Westaway et al. 1985) (Basler,
Oesch et al. 1986). PrPC was determined to be a host-encoded protein that is located on
chromosome 20 in humans and chromosome 2 in mice (Sparkes, Simon et al. 1986). The
PrP open reading frame (ORF) is confined within one exon and prior to processing and
posttranslational modifications, the human prion protein is 253 amino acids in length
(Kretzschmar, Stowring et al. 1986).
I-D-1: PrPC Structure
PrPC peptide has two signal sequence motifs: at the N-terminus (1-22aa) for
targeting to the endoplasmic reticulum (ER) where the protein undergoes posttranslational modification; and at the C-terminus, where the glycosylphosphatidylinositol
(GPI) anchor is attached for cell surface presentation within lipid rafts on the plasma
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membrane (Fig. 1.1A) (Stahl, Borchelt et al. 1987). The N-terminus of PrP spans the
residues 23 to124 aa and is primarily unstructured (Fig. 1.1A). This region of the protein
contains octapeptide repeats that bind copper ions (Hornshaw, McDermott et al. 1995).
The central portion of the protein consists of a hydrophobic core that overlaps the Nterminus, encompassing the amino acids residues 111 to 134. The hydrophobic core has a
transmembrane tethering function (Lopez, Yost et al. 1990), which upon deletion causes
spontaneous neurodegeneration in transgenic mice (Shmerling, Hegyi et al. 1998)
(Chiesa, Piccardo et al. 1998) (Baumann, Tolnay et al. 2007). The C-terminus of PrP is
the globular structured region that consists of three α-helices and two β-sheet strands
(Fig. 1.1A) (Riek, Hornemann et al. 1996). As a glycoprotein, PrPC can present itself in a
di-, mono- or un glycosylated form. N-linked glycosylation occurs at Asn-180 and Asn197 in humans (Kretzschmar, Stowring et al. 1986; Liao, Lebo et al. 1986; Bazan,
Fletterick et al. 1987; Haraguchi, Fisher et al. 1989). Lastly, helices two and three of the
prion protein are linked through an intramolecular disulfide bridge (Turk, Teplow et al.
1988).
I-D-2: PrPC Trafficking and Membrane Topology
The GPI-anchor signal is the predominant localization motif that targets the
protein to the plasma membrane, although two additional transmembrane topological
designations exist (Yost, Lopez et al. 1990). These transmembrane topologies are for
insertion into the lipid bilayer via the central hydrophobic core and are found in lowabundance (<10%). They present themselves with either the C-terminus or the Nterminus outwards facing the lumen while presenting the opposite end towards the
cytoplasm, respectively designated as,
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Ntm

PrP (Fig. 1.1B) (Hegde, Mastrianni

et al. 1998; Holscher, Bach et al. 2001; Stewart, Drisaldi et al. 2001). The C-terminus
topologically oriented

Ctm

PrP retains both the N- and C-terminus signal motifs with

predominant retention in the ER, ultimately targeting the protein for proteasomal
degradation as demonstrated in cell culture models expressing a mutant PrP protein with
Ctm

PrP characteristics (Stewart, Drisaldi et al. 2001). While transgenic mice expressing a

mutant PrP that mimics the

Ctm

PrP topology develop fatal neurodegeneration with

significant neuronal loss in the cerebellum and the hippocampus (Stewart, Piccardo et al.
2005). Cultured neurons form these transgenic mice, localize

Ctm

PrP to the Golgi which

differs from cell culture models that localize CtmPrP to the ER (Stewart and Harris 2005).
Therefore,

Ctm

PrP is hypothesized to be a toxic intermediate for neurodegeneration in

prion disease through the induction of cellular stress pathways that ultimately cause
apoptosis (Shi and Dong 2011). Both transmembrane proteins (NtmPrP and

Ctm

PrP) have

been demonstrated to reduce bcl-2-Associated X protein activity (Bax) (Lin, Jodoin et al.
2008).
Synthesis and posttranslational modification of PrPC occur in the ER. Once passed
through the cell’s protein quality control mechanisms, PrPC is transported into the Golgi
network where it is attached to lipid rafts via the GPI anchor and trafficked to the cell
surface (Taraboulos, Raeber et al. 1992). Alternatively, improper folding of PrPC triggers
the protein quality control mechanisms that ultimately target the protein for degradation
through the ubiquitin-proteasome system (UPS) (Fig. 1.2) (Ma and Lindquist 2001).
Surface retention is short lived and the protein is internalized back into the cytosol where
it is either recycled or degraded in lysosomes (Taraboulos, Raeber et al. 1992).
Furthermore, internalization and trafficking of PrPC appear to be mediated by both
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clathrin-coated pits and/or caveolin mediated endocytic mechanisms (Harris, Huber et al.
1993; Shyng, Huber et al. 1993; Shyng, Heuser et al. 1994; Vey, Pilkuhn et al. 1996).
Additionally, PrPC existence as a secreted protein through enzymatic cleaving at the GPIanchor has been reported (Hay, Prusiner et al. 1987). The intracellular trafficking process
of PrPC is presented in a schematic diagram of figure 1.2.
In summary, discovery of endogenously expressed PrPC was a crucial step
towards understanding the molecular basis of prion diseases. The unique biochemical
properties of the infectious scrapie agent in combination with meticulous deductive
biochemistry enabled the host-encoded gene for the prion protein to be identified
(Prusiner, Bolton et al. 1982; Oesch, Westaway et al. 1985; Basler, Oesch et al. 1986).
Additional experiments began to resolve the cellular biogenesis and structure of PrPC,
thus identifying the cellular localization and structural domains of this protein (Stahl,
Borchelt et al. 1987; Lopez, Yost et al. 1990; Riek, Hornemann et al. 1996). These
analyses laid the foundation towards characterizing the normal physiological functions of
PrPC, which remains an ongoing process, and more importantly its direct role as the
etiological source/substrate for PrPSc conversion in prion diseases.
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Figure 1.1 Schematic representations of the human cellular prion protein (PrPC)
and PrPC’s membrane topology. A. The prion protein consists of two signal sequences
and three distinct domains. The N-terminal target sequence (yellow) is cleaved after
amino acid 22 during the processing of the protein as it transits to the plasma membrane.
The rest of the N-terminus is a charged, and primarily unstructured domain that contains
the Cu2+-Octapeptide repeat binding motif (purple). The central domain consists of a
hydrophobic core (HC, blue) and is associated with neurotoxicity. The C-terminal
domain is structured and consists of three α-helices (H1, H2, and H3, orange) and two βsheet motifs (B1 & B2, black) flanking the first helix. PrPC undergoes post translational
modification by glycosylation at asparagine residues (CHO, 181aa, 197aa). A stabilizing
disulfide bridge forms between helices 2 and 3 (blue arrows, S-S). Finally, a GPI-anchor
signal (green) that anchors the protein to the plasma membrane is at the C-terminus. B.
PrPC’s three topological designations include the cell surface GPI-anchored PrPC, and
two transmembrane spanning PrP’s presenting either the C- or the N- terminus to the
surface, respectively designated CtmPrP and NtmPrP. Figure 1.1B has been adapted from a
previously published review (Harris 2003).
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Figure 1.1 Schematic representations of the human cellular prion protein (PrPC)
and PrPC’s membrane topology.
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Figure 1.2 Intracellular trafficking of PrPC. (1) PrPC is translated and targeted to the
endoplasmic reticulum (ER) by the N-terminal signal sequence. (2-3) In the ER, PrPC
undergoes proper folding and acquires post-translational modifications, where it is
transported to the Golgi network for cell surface presentation in the lipid raft portion of
the plasma membrane tethered by glycosylphosphatidylinositol (GPI) anchor. (3)
Alternatively, subsets of newly synthesized PrPC that does not attain proper
conformational structure are passed through protein quality control mechanisms which
target them for degradation in the ubiquitin-proteasome system (UPS). (4) Once in the
Golgi, PrPC is trafficked towards the cell surface in lipid-raft rich vesicles. (5) PrPC
presentation to the cell surface and internalization is a constitutively recycling process.
(6) Endocytosis and trafficking of PrPC is mediated through multiple endocytic
mechanisms that include both the clathrin-coated pits and caveolae pathways. (7)
Endocytosed PrPC not destined for recycling is trafficked from late endosomal
compartments into lysosome for proteolytic degradation.
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Figure 1.2 Intracellular trafficking of PrPC
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I-E: Prion Replication and Strain Diversity

Prion Replication
Because the novel properties of the scrapie agent distinguish it from viruses,
plasmids, and viroids, a new term “prion” is proposed to denote a small
proteinaceous infectious particle that is resistant to inactivation by most
procedures that modify nucleic acids. Knowledge of the scrapie agent structure
may have significance for understanding the causes of several degenerative
diseases. (Dr. Stanley Prusiner,(Prusiner 1982))
Characterization of PrPSc replication and conversion is a biologically complex
process that requires an experimentally combinatorial approach. Unlike the viral strain
classification system, which is based on nucleic acid compositions and follows the central
dogma of molecular biology, molecular classification of prion strains is based on the
transfer of information through conformational changes in association with the “protein
only” hypothesis (Fig. 1.3A). As earlier discussed, protein sequencing and reverse
genetics facilitated the identification of the host encoded prion protein (PrPC), which laid
the supporting foundation for the “protein only” hypothesis regarding prion diseases
(Griffith 1967; Prusiner 1982; Prusiner, Groth et al. 1984; Westaway and Prusiner 1986).
This hypothesis postulated that PrPC is the main substrate for the replication of the more
stable, conformationally altered and partially protease resistant PrPSc lacking nucleic
acids. Under this hypothesis, there are two central models for prion replication. The
template-directed refolding model postulates that PrPC to PrPSc conformational change
requires the addition of an exogenous template to modulate PrPC structure to a more
stable isoform. This reaction is driven by the continuous addition of PrPC substrate (Fig.
1.3B). In the second model, termed “the seeded nucleation” model, PrPC and PrPSc are
both present (Fig. 1.3C). PrPSc develops spontaneously although at an unfavorable
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equilibrium as compared to PrPC.

The initial seeding of PrPSc is energetically

unfavorable and extremely slow, but once PrPSc becomes ordered, the process begins to
seed the formation of larger aggregates leading to the formation of infectious particles
(Jarrett and Lansbury 1993). Protein Misfolding Cyclic Amplification (PMCA) has
provided supporting evidence towards the “protein only” hypothesis by demonstrating the
formation of infectious PK resistant protein aggregates in vitro (explained below)
(Saborio, Permanne et al. 2001).

I-F: Prion Strains
Describing the diversity of prion strains and the transfer of conformational
information lacking nucleic acids to transmit and cause disease has been challenging. The
intrinsic difficulty of describing this diversity is based on our lack of understanding
protein-mediated conformational transfer of information. It is hypothesized that PrPSc
acts as the template to convert the PrPC isoform (Prusiner 1982; Basler, Oesch et al.
1986; Büeler, Aguzzi et al. 1993). This process requires that both PrP isoforms maintain
near identical primary structure for efficient transmission, thus explaining why
interspecies prion transmission is generally less efficient than intraspecies transmission,
(Scott, Groth et al. 1993; Telling, Scott et al. 1994).
At the molecular level, the diversity and specificity of individual prion strains is
proposed to be associated with the different conformational states that the PrP molecule
acquires. The evidence to support this hypothesis was experimentally investigated using
biochemical and spectroscopic techniques (Safar, Wille et al. 1998; Kuczius and
Groschup 1999; Wadsworth, Hill et al. 1999; Safar, Cohen et al. 2000). Moreover,
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numerous PrPSc strains have been identified within mammalian prion diseases, which
indicate that the selection process for these strains is co-dependent on several factors. The
conformational selection model suggests that PrPSc replication is strongly dependent on
host encoded PrP homology and thermodynamically favorable conformations of the
outcompeting PrPSc (Collinge 1999; Collinge and Clarke 2007). Specifically, it is the
competition between thermodynamically favorable PrPSc conformational states
(Levinthal’s paradox on protein folding estimates 10143 possible conformation a protein
may take, (Zwanzig, Szabo et al. 1992)), structural similarity to the host encoded PrPC,
and the kinetic rate of conversion as compared to the rate of clearance that is mediated by
the endogenous protein quality control mechanism that are designed to prevent
aggregation.
Evidence supporting conformational selection was experimentally validated using
synthetic yeast (PSI+) prions derived from the Sup35 substrate protein, which can be
used to adopt distinct infectious conformations in vitro (Tanaka, Collins et al. 2006).
Using this yeast prion system, it was demonstrated that distinct conformations of the
synthetically generated PSI+ prions had profound effects on the growth and division
phases of prion particle formation and aggregation thus indicating that the variation in
aggregate formation represents a mechanisms by which specific prion strain phenotype
dominates selection (Tanaka, Collins et al. 2006). Significantly less is understood for the
selection and replication mechanisms in animals.
Experimentally, prion strain properties are analyzed through transmission studies
in animal models and subsequently assessed histologically and biochemically (Bruce,
McBride et al. 1989). Biological prion strain characteristics are described using
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incubation times in animal models, clinical signs at onset of disease, neuropathological
analysis, and PrP deposition within brain sections (Bruce and Dickinson 1979; Bruce,
McBride et al. 1989). Serial transmission and cloning of prion strains in the respective
host is required to identify the specific phenotypic property of the infectious agent. These
properties are influenced by the genetic background of the host and may alter upon
interspecies transmission (Pattison 1965; Westaway, Goodman et al. 1987).
Biochemically, prion properties are described using denaturing agents that break
(denature) prions in a concentration dependent manner using conformational stability
assay (Peretz, Scott et al. 2001). Protease digestion by proteinase K (PK), glycoform
ratios and electrophoretic migration patterns on SDS-PAGE gels are characteristic
properties used to distinguish prion strains as well (Collinge, Sidle et al. 1996).
Furthermore, strain specificity has also been analyzed through conformational-dependent
immuno assays and conformational alterations dictated through metal-ion occupancy
binding assays (Safar, Wille et al. 1998; Wadsworth, Hill et al. 1999). Although the
molecular complexities associated with prion strains are slowly being experimentally
defined, many unanswered questions remain regarding prion prevalence and replication
in naturally susceptible animals.
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Figure 1.3 Models for prion replication. A. Schematic models comparing modes of
information transfer between the central dogma of molecular biology, and protein only
information transfer model. B. In template directed model, conversion of PrPC (diamond)
or an intermediate conformation PrP* (pentagon) to PrPSc (hexagon) is slow and
irreversible. C. In the seeded nucleation model, PrPSc formation is not rate limiting, but
the accumulation of PrPSc into an ordered nucleus is slow, once formed, it acts as the seed
to form larger aggregates. (Come, Fraser et al. 1993) (Brown, Goldfarb et al. 1991)
(Griffith 1967) (Jarrett and Lansbury 1993)
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Figure 1.3 Models for prion replication.
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I-F-1: Scrapie Strains
Initial studies describing prion strain properties were through experimental
transmission of sheep and goat scrapie (Pattison and Millson 1961; Pattison and Millson
1961). Two distinct phenotypes designated “drowsy” and “scratching” appeared in goats
after inoculating them with sheep scrapie brain pool-1 (SSBP/1). The name designations
were based directly on behavioral patterns (Pattison and Millson 1961). The two strains
manifested distinctly different clinical syndromes that became more evident with
continuous passage (Pattison and Millson 1961). The diversity of prion strains in goats
has not been well defined although it would be predicted, based on the acquired data from
natural goat scrapie samples, that multiple strains exist. Importantly, the European active
TSE surveillance programs have identified both “atypical” scrapie and BSE in goats
(Eloit, Adjou et al. 2005; Le Dur, Beringue et al. 2005).
Although the exact number of scrapie strains affecting sheep and goats remains to
be determined, it is known that genetic polymorphism in PRNP of these animals greatly
influences there susceptibility to disease (Hunter, Goldmann et al. 2000). Three
polymorphic positions in sheep are particularly associated with susceptibility to scrapie:
Valine/Alanine (V/A) at 136, Arginine/Histidine (R/H) at 154, and Glutamine/Arginine
(Q/H) at 171 (Westaway, Zuliani et al. 1994; Clouscard, Beaudry et al. 1995; Foster,
Wilson et al. 1996; Hunter, Foster et al. 1996). These polymorphisms have been ranked
by their permissiveness towards scrapie. The VRQ/VRQ, ARQ/VRQ and ARQ/ARQ
genotypes are considered to confer greatest susceptibility, while the AHQ and ARR
genotypes confer strong resistance (Hunter, Foster et al. 1996; Dawson, Hoinville et al.
1998; Woolhouse, Matthews et al. 1999; Matthews, Coen et al. 2001; Baylis, Goldmann
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et al. 2002). As previously mentioned, active surveillance for scrapie in Europe identified
new scrapie strain termed “atypical” scrapie (Benestad, Sarradin et al. 2003; Everest,
Thorne et al. 2006), which differs from classical scrapie in several aspects. Atypical
scrapie distinguishable properties include increased incubation time (atypical scrapie
found in older sheep), decreased neuropathological lesions, decreased biochemical
stability of PrPSc and a notably lower electrophoretic migratory band representing ~12
kDa size fragment on a western immunoblots (Benestad, Sarradin et al. 2003; Luhken,
Buschmann et al. 2007).
I-F-2: TME Prion Strains
TME transmission studies have provided evidence for biologically distinct prion
strains. Transmission studies using Syrian golden hamsters model facilitated
identification and characterization of the two TME prion strains called: HY and DY
(Bessen and Marsh 1992; Bessen and Marsh 1992). As indicated by the name, the HY
strain is biologically characterized through short lived hyperactive behavior in the
infected animal that rapidly progresses to cause disease with a mean incubation time of ~
60 days, whereas DY infected animals present themselves with lethargic behavior and a
delayed onset of disease with a mean incubation time of ~165 days (Bessen and Marsh
1992). Biochemical analysis of PrPSc constituting HY and DY demonstrate strain-specific
differences which are best described by their differential sensitivity to protease digestion
and electrophoretic migration on sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) (Bessen and Marsh 1992). The source of TME is
hypothesized to be bovine prions accidentally transmitted to farm raised mink through
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contaminated feed (Marsh, Bessen et al. 1991; Robinson, Hadlow et al. 1994; Baron,
Bencsik et al. 2007).
I-F-3: BSE Prions
In addition to the classical BSE prions described earlier, international surveillance
efforts and careful analysis of prion infected cattle tissue has led to the identification of
two additional BSE variants that until recently have remained unknown (Jacobs,
Langeveld et al. 2007). The identification of the “atypical” BSE L- and H-type strains
directly resulted from rigorous testing of aged, asymptomatic cattle in European
slaughterhouses (Buschmann, Biacabe et al. 2004; Casalone, Zanusso et al. 2004).
Analogous to the description of “atypical” scrapie, L- and H-type BSE differ from
classical BSE. H-type BSE is characterized by a higher molecular weight but
conventional glycoform migration pattern of PrPSc after PK digestion (Biacabe,
Laplanche et al. 2004). PrPSc of L-type BSE has a lower molecular weight and distinctly
different glycoform migration pattern (Casalone, Zanusso et al. 2004). Transmission
studies in transgenic mice expressing bovine PrP using the three BSE strains revealed
significant differences in incubation times and deposition of PrPSc, providing further
evidence towards the existence of unique prion strains amongst cattle (Everest, Thorne et
al. 2006). Furthermore, due to their identification in older, asymptomatic cattle, it has
been hypothesized that the atypical BSE strains could be the result of naturally occurring
sporadic TSE. Evidence supporting this hypothesis was provided from a 10-year-old BSE
H-type positive cow with a mutation (E211K) correlating to a known substitution
frequently associated with familial-CJD (Nicholson, Brunelle et al. 2008; Richt and Hall
2008). Lastly, the comparison of biochemical properties of PrPSc in BSE and vCJD linked
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these two diseases, providing evidence for the abrogation of the species barrier between
humans and domestic cattle through the ingestion of BSE contaminated food (Collinge
1996).
I-F-4: CWD Prions
The characterization of prion strain diversity in cervids has recently begun to
unravel. As with other species-specific prion diseases, CWD susceptibility is dependent
on the genetic background of the host and the polymorphisms in PRNP (Green, Browning
et al. 2008). Using transgenic mice expressing cervid PrPC, it was possible to successfully
transmit CWD and characterize biological and biochemical properties of this infectious
agent (Browning, Mason et al. 2004; LaFauci, Carp et al. 2006; Tamguney, Giles et al.
2006; Meade-White, Race et al. 2007). Recently, two novel CWD strains types, referred
to as CWD1 and CWD2, were identified in natural elk field isolates in transgenic mice
referred to as Tg(CerPrP)1536+/- mice, expressing deer PrPC (Angers, Kang et al. 2010).
These studies demonstrated distinct strain differences based on incubation time and
neuropathology that were composed of PrPSc with indistinguishable characteristics. In an
attempt to understand these strain profile differences between deer and elk, it was
hypothesized that the difference of a single amino acid in the primary structure of cervid
PrP (deer PrPC-Q226 and elk PrPC-E226) dictates the selection and propagation stability
of these CWD strains (Angers, Kang et al. 2010; Telling 2011).
Concluding Summary
Undoubtedly, understanding the underlying mechanisms that dictate proteinmediated conformational transfer of information in the context of protein misfolding
diseases is important. The unique properties that allow prions to infect, propagate and
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transfer their strain information to animal hosts without nucleic acids make them a
tractable system in which to study general mechanisms of protein-misfolding diseases.
Equally important to understand are the mechanisms that dictate the interactions,
compatibility and species barriers in the selection process of a specific prion strain
amongst a vast pool of conformationally distinct PrPSc molecules (Collinge 1999;
Collinge and Clarke 2007). The mutability and diversity of prion strains among animals
raises a greater concern for the zoonotic potential, as already seen with the BSE-vCJD
connection in the mid 1990’s (Collinge, Sidle et al. 1996; Bruce, Will et al. 1997;
Collinge 1999). The uses of transgenic mouse models, cell culture models and in vitro
prion conversion assays have greatly enabled us to address these fundamental questions.

II: Experimental Approaches To Analyze Prions
II-A: Prnp0/0 Knockout Mice & PrPC Transgenic Mice
Transgenic animal models have become very important tools for studying prion
biology. These models help identify and understand the physiological function of PrPC.
The cellular prion protein is highly conserved and has been identified in birds (Harris,
Lele et al. 1993), reptiles (Simonic, Duga et al. 2000), amphibians (Strumbo, Ronchi et
al. 2001) and fish (Gibbs and Bolis 1997), which would suggest significant biological
importance. A commonly used method to elucidate the physiological function of a
protein is to delete or mutate it, and to characterize the resulting phenotype(s) (Capecchi
1989). Although high PrP homology and conservation among animals would suggest a
crucial physiological function, Prnp0/0 knockout mice were not embryonic lethal and
demonstrated normal development with no gross-phenotypic abnormalities (Büeler,
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Fischer et al. 1992). More importantly, these knockout mice were completely resistant to
scrapie prion infection (Büeler, Aguzzi et al. 1993; Sailer, Bueler et al. 1994). Subsequent
phenotypic characterization of Prnp0/0 mice suggested that PrPC is functionally
multifaceted. These functions include roles in circadian/sleep regulation (Tobler, Gaus et
al. 1996; Tobler, Deboer et al. 1997), oxidative stress response and metal ion metabolism
(Klamt, Dal-Pizzol et al. 2001; Wong, Liu et al. 2001; Brown, Nicholas et al. 2002;
Singh, Kong et al. 2009), immune system signaling and phagocytosis (de Almeida,
Chiarini et al. 2005; Ballerini, Gourdain et al. 2006), cell adhesion (Schmitt-Ulms,
Legname et al. 2001; Malaga-Trillo, Solis et al. 2009), neuronal excitability and
neuroprotection (Collinge, Whittington et al. 1994; Manson, Hope et al. 1995; Hoshino,
Inoue et al. 2003; Gains, Roth et al. 2006), neurite outgrowth (Santuccione, Sytnyk et al.
2005) and behavior (Coitinho, Roesler et al. 2003; Nico, de-Paris et al. 2005). An
interesting study utilizing a Cre-lox system to postnatally delete PrPC in mice
demonstrated reversal of neuropathology and improved motor and behavioral deficits
post prion infection (Mallucci, Ratte et al. 2002; Mallucci, Dickinson et al. 2003).
Neurological recovery and full restoration in the life span of these mice further confirm
the importance PrPC function in vivo.
The generation of the Prnp0/0 knockout mice facilitated the subsequent creation of
other transgenic mouse models that express heterologous prion proteins from various
species. These transgenic models enable scientists to address many of the unresolved
prion biology questions, which include prion strain diversity, mechanisms of prion
replication, species barriers and disease transmission (Scott, Foster et al. 1989; Hsiao,
Scott et al. 1990; Telling, Scott et al. 1995; Weissmann, Fischer et al. 1998; Agrimi,
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Nonno et al. 2008; Telling 2011). Specifically, PrPC transgenesis in mice enabled to
experimentally address the species barrier of BSE and the zoonotic potential of CWD
using mice expressing human PrPC(Collinge, Palmer et al. 1995; Bruce, Will et al. 1997;
Kong, Zheng et al. 2008; Sandberg, Al-Doujaily et al. 2010). Moreover, transgenic mice
expressing heterologous PRNP genes with polymorphic mutations have become
functional models to assess spontaneously acquired prion diseases in humans (Telling,
Haga et al. 1996; Mastrianni, Capellari et al. 2001; Nazor, Kuhn et al. 2005). Although
transgenic mouse models are crucially important to understanding prion diseases and
physiological functions of PrPC, the complexities associated with multicellular organisms
make it difficult to address the aforementioned unknowns at the cellular level.
II-B: Prion Cell Models
Cell culture models have helped characterize PrPC processing, intracellular
trafficking, localization within cellular compartments and likely interacting molecules
(Harris, Lesko et al. 1993; Shyng, Huber et al. 1993; Shyng, Heuser et al. 1994; Shyng,
Lehmann et al. 1995; Pauly and Harris 1998; Taylor and Hooper 2007; Hooper 2011).
Furthermore, cell models simplify the analysis of PrPSc conversion mechanisms by
reducing the complexity of the system from animal tissue to monolayer cells (mouse
brain contains ~ 7.5e7 neurons, 2.3e7 glia, 7.0e6 endothelial cells, 3~4e6 misc. cells (data
derived from the mouse brain library database, http://www.mbl.org/)). Analysis of PrPSc
replication in cell culture supports the identification of cellular factors that
enhance/promote infectivity, enabling the use of these cells for anti-prion drug screening.
The development of the Scrapie Cell Assay (SCA) for mouse-adapted prion
strains was the “proof of principle” that demonstrates the utility of cell culture systems

	
  

29	
  

for rapid prion titer calculation in vitro, albeit that particular assay did not include natural
field prion isolates (Mahal, Demczyk et al. 2008). Recent improvements in this assay
using a different cell model, validated titer calculations in CWD derived from field
isolates, further supporting the multiple advantages cell culture models provide for prion
analysis (Bian, Napier et al. 2010).
Initial cell culture models for scrapie replication were developed and described in
the 1970’s. These cells were produced by cultivating explants from scrapie-infected
mouse brains which became known as SMB cells (Clarke and Haig 1970). Although
these cells sustain chronic infectivity, the absence of uninfected controls was a drawback.
The use of pentosan-sulfate to “cure” SMB cells solved this issue (Birkett, Hennion et al.
2001). While extensive attempts have been made to infect various cell lines with prions,
only a handful demonstrate the ability to replicate prions and accumulate PrPSc (Table
1.2). These cell lines break down into two key categories: their origin (neuronal/ nonneuronal) and their ability to replicate heterologous (not of same genetic background)
prion strains.
II-B-1: Cell Culture Models Permissive to Experimentally Adapted Mouse Prions
The mouse neuroblastoma (N2a) and the immortalized hypothalamic neuron
(GT1) cell lines, both of neuronal origin, have been demonstrated to be highly permissive
to mouse-adapted scrapie prion replication (Butler, Scott et al. 1988; Schätzl, Laszlo et al.
1997). Sub-cloning N2a cells led to the identification of clonal populations that vary in
susceptibility (Bosque and Prusiner 2000). Typical infection of N2a cells (ScN2a) with
mouse-adapted PrPSc results in a fraction of cells that sustain chronic infectivity amongst
the total population (<2%), which can be enriched through sub-cloning for susceptibility
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(~90%) (Race, Fadness et al. 1987; Butler, Scott et al. 1988; Race, Caughey et al. 1988;
Bosque and Prusiner 2000; Mahal, Baker et al. 2007). Furthermore, the sub-cloning
process of a susceptible N2a cell (N2a-PK1) leads to clones that show preferential
susceptibility towards particular prion strains (Mahal, Baker et al. 2007; Browning, Baker
et al. 2011). Recent findings using the N2a cells to replicate heterologous CWD PrPSc,
suggests that these cells maintain the complete repertoire of cellular factors necessary to
maintain infectivity from various sources (Pulford, Reim et al. 2010).
GT1 cells are highly differentiated gonadotropin-releasing hormone neurons
which have also shown enhanced susceptibility towards replicating mouse-adapted prions
(Table 1.2) (Schätzl, Laszlo et al. 1997). These cells express elevated amounts of PrPC
and demonstrate enhanced sensitivity compared to N2a cells (Nishida, Harris et al. 2000).
Furthermore, the GT1 cells do not require additional cloning for producing chronically
infected prion cultures. The permissiveness of GT1 cells has made them a tractable tool
for analyzing mouse-adapted prion strains in culture (Arima, Nishida et al. 2005) and
have been reported to replicate mouse-adapted human derived CJD PrPSc (Nishida,
Katamine et al. 2005).
II-B-2: Cell Line Permissive to Heterologous Prions: RK13 Cells
The propagation of natural sheep scrapie prion isolates was first demonstrated
using transgenically modified epithelial rabbit kidney cells (RK13) expressing ovine PrPC
(VRQ variant)(Vilette, Andreoletti et al. 2001). RK13 cells do not express endogenous
rabbit PrPC, making them the cell culture equivalent of the Prnp0/0 knockout mouse.
Subsequent work using these cells have shown them to be permissive towards both
natural and mouse-adapted prion strains (Vilette, Andreoletti et al. 2001; Paquet, Sabuncu
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et al. 2004; Paquet, Daude et al. 2007; Courageot, Daude et al. 2008; Bian, Napier et al.
2010). RK13 cells co-expressing HIV-1 Gag and heterologous elk PrPC showed enhanced
CWD prion replication (Leblanc, Alais et al. 2006; Bian, Napier et al. 2010). This
enhancement was subsequently used for the cervid prion cell assay (CPCA) to titer CWD
prions in vitro, a technique modeled after the previously described SCA for mouseadapted prions (Bian, Napier et al. 2010). Additional data characterizing these cells is
described in the subsequent chapters of this thesis. Despite all of these developments for
replicating PrPSc in cell culture systems, cells capable of replicating naturally derived
human prions remain to be identified.
II-C: In Vitro PrPSc Conversion Assays
In vitro methods for detecting PrPSc are unconventional compared to other
infectious agents. Standard polymerase chain reaction (PCR) assays cannot be used for
the detection of prions because they lack nucleic acids (Prusiner 1982). Furthermore,
standard immunological assays, such as the ELISA, cannot easily differentiate PrPSc from
PrPC. Nonetheless, several in vitro assays have been developed for the detection of prions
and studying the conversion PrPSc process. These conversion assays rely on methods that
utilize PrPC as the substrate in a reaction to amplify PrPSc. The semi-quantitative analysis
of PrPC to PrPSc conversion in vitro using these assays provides a tractable means to
calculate conversion PrPSc kinetics. Moreover, these assays accelerate species barrier
adaptation of PrPSc, which otherwise requires multiple transmissions in bioassays (Green,
Castilla et al. 2008). Lastly, these conversion assays may enable the elucidation of
cofactors that participate in the replication and conversion process.
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Table 1.2 Cell culture models for prion replication in vitro.
Cell Type Origin/cell type
Species Prion Strain
Reference
N2a
Neuroblastoma
Mouse Chandler,
(Race, Fadness et al.
Fukuoka-1,
1987; Butler, Scott et al.
RML
1988; Bosque and
Prusiner 2000; Enari,
Flechsig et al. 2001)
N2a #58
Neuroblastoma
Mouse Chandler,
(Nishida, Harris et al.
139A, 22L
2000)
C-1300
Neuroblastoma
Mouse Chandler
(Butler, Scott et al.
1988)
NIE-115
Neuroblastoma
Mouse Chandler
(Markovits, Mutel et al.
1985)
N2a-PK1 Neuroblastoma
Mouse RML, 22L
(Mahal, Baker et al.
2007; Mahal, Browning
et al. 2010; Browning,
Baker et al. 2011)
N2a-R33 Neuroblastoma
Mouse 22L
(Mahal, Baker et al.
2007; Mahal, Browning
et al. 2010; Browning,
Baker et al. 2011)
GT1
Hypothalamic
Mouse Chandler, aSY- (Rubenstein, Carp et al.
cells
CJD, bFU1984; Schätzl, Laszlo et
CJD, RML,
al. 1997; Milhavet,
22L, Fukuoka- McMahon et al. 2000;
1
Nishida, Harris et al.
2000; Arjona, Simarro
et al. 2004; Arima,
Nishida et al. 2005;
Nishida, Katamine et al.
2005)
SMB
Scrapie Mouse
Mouse 139A,
(Clarke and Haig 1970;
Brain cells
Chandler, 22F, Birkett, Hennion et al.
79A
2001; Kanu, Imokawa et
al. 2002)
CAD5
CNS
Mouse RML, 22L,
(Mahal, Baker et al.
catecholaminergic
ME7, 301C
2007; Mahal, Browning
cell line
et al. 2010; Browning,
Baker et al. 2011)
PC12
Pheochromocyto Mouse 139A
(Rubenstein, Carp et al.
ma
1984)
SN56
Septal neuronal
Mouse Chandler,
(Baron, Magalhaes et al.
cells
ME7, 22L
2006)
NSC
Neuronal stem
Mouse RML, 22L
(Giri, Young et al. 2006;
cells
Milhavet, Casanova et
al. 2006)
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MSC80

Schwann like
cells
Hippocampal
cells
Fibroblasts

Mouse

Chandler

Mouse

22L

Mouse

Microglial

Mouse

C2C12

Myoblasts

Mouse

22L, ME7,
RML
Chandler,
mouse BSE,
ME7
22L

HaB

Brain cells

MovS

Schwann like
from Dorsal Root
Ganglia (DRG)
Fibroblast

Hamste
r
Mouse

HpL3-4
NIH/3T3,
L929
MG20

MDB
CGNov
moRK13
voRK13
ovRK13
RKE21+
RKD
RK13SHa-PrPC
a

Neuronal primary
cultures
Epithelial rabbit
kidney cells
(RK13)
Epithelial rabbit
kidney cells
(RK13)
Epithelial rabbit
kidney cells
(RK13)
Epithelial rabbit
kidney cells
(RK13)
Epithelial rabbit
kidney cells
(RK13)
Epithelial rabbit
kidney cells
(RK13)

(Dlakic, Grigg et al.
2007)
Hamster prions (Taraboulos, Serban et
al. 1990)
Natural sheep
(Archer, Bachelin et al.
scrapie
2004)

Deer

CWD

Mouse

Natural sheep
scrapie
Chandler,
Fukuoka-1,
22L, M100
Vole adapted
BSE

(Raymond, Olsen et al.
2006)
(Cronier, Laude et al.
2004)
(Vella, Sharples et al.
2007; Courageot, Daude
et al. 2008)
(Courageot, Daude et al.
2008)

Rabbit

Natural sheep
scrapie

(Vilette, Andreoletti et
al. 2001)

Rabbit

Elk isolate
CWD

(Bian, Napier et al.
2010)

Rabbit

Deer isolate
CWD

Unpublished

Rabbit

Syrian golden
hamster
adapted Hyper
TME

Unpublished

Rabbit
Rabbit

SY, mouse-adapted sporadic CJD (sCJD)
FU, mouse-adapted Fukuoka-1 (Familial GSS)

b

	
  

(Follet, Lemaire-Vieille
et al. 2002)
(Maas, Geissen et al.
2007)
(Vorberg, Raines et al.
2004)
(Iwamaru, Takenouchi
et al. 2007)
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The first assay developed and described to convert PrPC to PrPSc was the CellFree Conversion Assay (CFCA) (Kocisko, Come et al. 1994). This assay-utilized brain
derived PrPSc as seed and radioactively labeled PrPC, which, under the conditions
described in the paper, created partially protease-resistant PrP molecules. The lack of
exogenous energy sources to drive this assay is a key feature that makes it unique from
all of the subsequently described assays. The assay was shown to be specific in
recapitulating prion transmission barriers and strain properties (Bessen, Kocisko et al.
1995; Kocisko, Priola et al. 1995). Yet the primary limitation of the assay is detection and
sensitivity due to the inherent difficulty of distinguishing newly generated PrPSc from
initially seeded material (Hill, Antoniou et al. 1999). Although recent data has been
described using this assay to identify disease specific low-density subcellular fractions
composed of cell membrane and cytoplasmic proteins that enhance prion protein
misfolding (Graham, Agarwal et al. 2010).
Protein misfolding cyclic amplification (PMCA) was the next in vitro conversion
assay developed to amplify PrPSc (Saborio, Permanne et al. 2001). This reaction utilizes
crude brain extract as PrPC substrate in combination with PrPSc seed molecules, which are
amplified through multiple cycles of sonication. Performing sequential rounds of PMCA
enhances the sensitivity of the assay (Castilla, Saa et al. 2005), facilitating the detection
of PrPSc from various biological and environmental sources (Castilla, Saa et al. 2006;
Nichols, Pulford et al. 2009). This conversion assay has successfully been adapted to
amplifying PrPSc from various animal species (Soto, Anderes et al. 2005; Kurt, Perrott et
al. 2007; Murayama, Yoshioka et al. 2007; Green, Castilla et al. 2008; Thorne and Terry
2008).
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PMCA and other in vitro conversion assays, provide an approach to validate the
prion hypothesis. Utilizing PMCA, several groups have provided evidence that
exogenous cofactors participate in prion conversion (Geoghegan, Valdes et al. 2007;
Kim, Cali et al. 2010; Wang, Wang et al. 2010). PMCA was used to identify the three
minimal components required to generate infectious recombinant prions, which were
recombinant PrP (rPrP), POPG (1-palmitoyl-2-oleoylphosphatidylglycerol) and RNA
(Wang, Wang et al. 2010). Concurrently, others reported the production of infectious
prions using prion-seeded bacterially-derived recombinant protein misfolding cyclical
amplification (rPMCA) in the absence of any co-factors (Kim, Cali et al. 2010). They go
on to support this claim through bioassay experiments using hamsters, showing that at
primary passage the rPMCA-produced prions display variable attack rates but stabilize
upon second passage. Finally, PMCA was used to systematically analyze potential
cofactors involved in prion conversion within various tissue sources and the effects of
nucleic acid depletion in the conversion process (Abid, Morales et al. 2010). This study
provided evidence that cellular cofactors for prion conversion that localize to the lipid
raft fractions and cytoplasmic membranes are present within all major mammalian
organs, but are absent in lower organisms such as yeast, bacteria and flies (Abid, Morales
et al. 2010). Additionally, treatments to deplete major classes of chemical molecules did
not alter conversion activity, which suggests that cellular cofactors that enable prion
conversion are numerous and diverse (Abid, Morales et al. 2010). There are several
caveats that must be taken into account when using the PMCA assay. This is an in vitro
assay, which cannot fully recapitulate the phenomenon of PrPC-PrPSc conformational
switching that is associated with living organisms. The specific limitations of the assay
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include the use of sonication to break aggregates of PrPSc, which does not recapitulate the
cellular conversion mechanism. Moreover, this assay utilizes detergents, and cell extracts
which are removed from the environment in which PrPC is converted.
Finally, the Quaking-Induced Conversion Reaction (QuIC) and the real-time
Quaking-Induced Conversion Reaction (RT-QuIC) are additional in vitro conversion
assays utilized for identifying cellular cofactors that facilitate PrPSc conversion. This
assay was first described in 2008, and differs from other conversion assays by methods
used to amplify PrPSc (Atarashi, Wilham et al. 2008). In QuIC, periodic shaking replaces
sonication. Like PMCA, QuIC can successfully discriminate between infected and
uninfected biological samples (Atarashi, Wilham et al. 2008; Orru, Wilham et al. 2009;
Bessen, Shearin et al. 2010). Additionally, the QuIC was improved with supplementation
of thioflavin T (ThT) and the use of a temperature-controlled fluorescence plate reader, to
continuously monitor of newly produced PrPSc in real time (Wilham, Orru et al. 2010).
Due to its sensitivity, high throughput, real-time quantitation and relatively low costs, the
QuIC assay is highly advantages for studying prion conversion in vitro.
In summary, the approaches used for examining PrP biology have significantly
improved our understanding the mechanisms that govern prion replication and disease.
More generally, prion research models aid in the understanding of other conformational
diseases such as AD and PD. The transmissibility of prions in transgenic mice expressing
heterologous PrPC on a Prnp0/0 background recapitulates prion disease that can be
assessed on multiple levels, this is generally not the case for AD or PD animal models.
Moreover, transgenic animal models enable characterization of natural prion isolates, and
model the risks associated with their transmission to other species, including humans. In
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vivo PrPSc conversion can also be analyzed in vitro using cell culture models and cell-free
conversion assays (Castilla, Saa et al. 2006; Green, Castilla et al. 2008; Bian, Napier et
al. 2010; Wang, Wang et al. 2010; Goold, Rabbanian et al. 2011; Nunziante, Ackermann
et al. 2011). Cell culture models have been useful for understanding the fundamental
cellular biology of PrPC and for identifying cellular compartments crucial for PrPSc
conversion (Shyng, Heuser et al. 1994; Vey, Pilkuhn et al. 1996; Pauly and Harris 1998;
Goold, Rabbanian et al. 2011), while in vitro conversion assays provide a facile system
for detecting, converting and generating novel PrPSc molecules (Wong, Xiong et al. 2001;
Castilla, Saa et al. 2005; Deleault, Geoghegan et al. 2005; Castilla, Saa et al. 2006; Kurt,
Perrott et al. 2007; Green, Castilla et al. 2008; Mays, Yeom et al. 2011).
III: PrP Interacting Molecules
The specific cellular mechanisms that support and sustain prion replication remain
undefined. The inherent difficulty of generating infectious prions in vitro without
exogenously added cellular components strongly argues towards the requirement of
endogenous host factors (Supattapone, Deleault et al. 2008; Wang, Wang et al. 2010;
Piro, Harris et al. 2011). Cellular host factors have been shown to be essential
components for other invading pathogens, which act to enhance factors such as
infectivity, replication and/or protection. For example, the HIV retrovirus requires the
CD4 cell surface receptor parallel with other co-receptors for efficient entry into the host
cell (Doms and Moore 2000), Mycobacterium tuberculosis utilizes lipid raft micro
domains to gain entry into both phagocytic and non-phagocytic cells (Munoz, RivasSantiago et al. 2009), and bacteria utilize several different adhesion molecules that
recognize the host cell surface for internalization (Pizarro-Cerda and Cossart 2006).
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Although the infectious entities described above, vary in composition and life cycle, they
follow the central dogma of molecular biology (Fig. 1.3A). To explain and characterize
the infectious protein only (PrPC-PrPSc) replication process in the cell, several important
concepts were proposed.
Initial experiments were designed to characterize the normal biogenesis and life
cycle of PrPC, and to identify interacting proteins. Evidence that PrPC endocytosis was
mediated through clathrin-coated pit internalization indicated that other proteins are
involved (Shyng, Heuser et al. 1994). PrPC protein is predominantly GPI-anchored at the
cell surface (Fig 1.1B) lacking a cytoplasmic domain, which suggests that active
internalization via clathrin-coated pit endocytic mechanism could only occur if there was
direct interaction with an extracellular domain of a proximal transmembrane protein
(Shyng, Heuser et al. 1994).
Other experimental evidence using chimeric-PrP molecules in vivo suggested that
a species-specific cellular chaperone termed “Protein X” was required to for prion
replication (Telling, Scott et al. 1995). Nuclear magnetic resonance (NMR)-derived
structural data demonstrated variation in the putative “Protein X” binding site, implying
that structural constraints of PrPC are also important for efficient prion conversion
(Gossert, Bonjour et al. 2005). Additional approaches have been utilized to identify
cellular proteins that facilitate PrPSc replication. This ongoing exhaustive search for
interacting molecules has already helped identify both extracellular and intracellular
proteins/molecules alongside metal ions (Brown 1999), nucleic acids (DNA/RNA)
(Weiss, Proske et al. 1997) and glycosaminoglycans (GAG) (Priola, Caughey et al. 1994)
that interact with PrP.
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III-A: Protein X
Transmission studies in transgenic mice provided evidence for the involvement of
a third molecule termed protein X in the replication process. Initial experiments in cell
culture to identify PrPC’s structural domains contribution towards PrPSc conversion
provided indications that the first 66aa of the N-terminus and the GPI-anchor sequence of
the C-terminus were unnecessary (Rogers, Yehiely et al. 1993). Additionally, prion
infectivity data using transgenic mice supported the protein X model. The prion species
barrier data using transgenic mice expressing human PrPC on both wild type FVB and
Prnp0/0 mice, indicated that endogenously expressed mouse PrPC in mice co-expressing
human PrPC (Tg(HuPrP)FVB) inhibited the replication of human PrPSc (Fig. 1.4A)
(Telling, Scott et al. 1995). While, expression of a human/mouse chimera PrPC (MHu2M,
96-167aa human sequence) in transgenic mice exhibited efficient replication of human
but not mouse PrPSc in Tg(MHu2M)Prnp0/0 although both PrPSc replicated in
Tg(MHu2M)FVB wt mice (Fig. 1.4B) (Telling, Scott et al. 1994; Telling, Scott et al.
1995). These data suggested that two domains in the PrPC sequence were required for
prion replication, including the central domain of PrPC (96aa-167aa) for PrPC-PrPSc direct
interaction, and the C-terminal domain which binds the predicted protein X to
stabilize/chaperone the replicative process (Fig. 1.4C) (Telling, Scott et al. 1994; Telling,
Scott et al. 1995). Protein X was suggested to have enhanced affinity for endogenous
mouse PrPC compared to overexpressed heterologous PrPC.
Following the prediction that protein X binds the C-terminus of PrPC, mutations
were introduced at positions 214 and 218 of the human/mouse chimera PrP, to assess
their role in PrPSc formation (Kaneko, Zulianello et al. 1997). These two specific resides
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were predicted to protrude from α-helix 3 and form a discontinuous epitope with residues
167 and 171, a region suggested to be crucial for PrPC-PrPSc replication (Donne, Viles et
al. 1997; James, Liu et al. 1997; Kaneko, Zulianello et al. 1997). Using the ScN2a cell
culture model to assess PrPSc replication (Table 1.2), it was demonstrated that these
mutations inhibited PrPSc formation, suggesting that these amino acid form an epitope for
protein X and facilitate PrPSc conversion (Kaneko, Zulianello et al. 1997). Moreover,
NMR analysis of residues connecting β-sheet 2 with α-helix 2 (166-175aa, Fig. 1.1A)
demonstrates variation in structural definition amongst species within that region ranging
from highly structured to unstructured, which coincidentally includes the residues
predicted to interact with C-terminal positions 214 and 218 (Gossert, Bonjour et al.
2005). Although it is hypothesized that PrPC regions encompassing residues 166-175aa,
215aa and 218aa are crucial for the formation of the disease related epitope protein X, the
identification of protein X has not been possible (Telling, Scott et al. 1995; Riek,
Hornemann et al. 1996; James, Liu et al. 1997; Kaneko, Zulianello et al. 1997; Gossert,
Bonjour et al. 2005).
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Figure 1.4 Schematic representation of the protein X hypothesis. A. Over expression
of human PrPC in an FVB wt mouse referred to as Tg(HuPrP)FVB does not facilitate the
replication and conversion of human PrPSc, while expression of human PrPC on a Prnp0/0
background results in prion disease (not shown in figure). These findings indicate that
endogenously expressed mouse PrPC interferes in the replication of human prions. B.
Inoculation of human prions into mice expressing mouse/human chimeric PrPC protein in
a wt FVB mouse, referred to as Tg(MHu2M)FVB produces PrPSc and recapitulates prion
disease. The chimeric PrPC was designed by replacing the central region of the mouse
PrP protein with human sequence 96-167 aa, encompassing the hydrophobic core, β-sheet
1, α-helix 1 and β-sheet 2 (see Figure 1.1A for schematic details). C. The replication of
human prions in Tg(MHu2M)FVB mice indicates that a third molecule, termed protein
X, facilitates replication through a chaperoning/stabilizing mechanism. Hence, two
domains are deemed crucial for PrPSc replication; the central domain, which dictates the
compatibility between the infecting PrPSc and the endogenously expressed PrPC; the Cterminal domain (α-helices 2 and 3) dictate the interactions with protein X. (Telling, Scott
et al. 1994; Telling, Scott et al. 1995)
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Figure 1.4 Schematic representation of the protein X hypothesis
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III-B: PrPC Binding Partners
The surface of the plasma membrane and endosomal compartment trafficking
pathways are implicated as the primary locations for conversion of PrPC-PrPSc
(DeArmond, Qiu et al. 1996; Marijanovic, Caputo et al. 2009; Sarnataro, Caputo et al.
2009; Goold, Rabbanian et al. 2011; Nunziante, Ackermann et al. 2011). Many of the
proteins that interact with PrPC are located in these cellular compartments. Table 1.3
represents the majority of proteins that have been determined to interact with PrPC, while
figures 1.5 and 1.6 schematically depict these interactions. The proteins described thus
far have been experimentally validated as binding partners through multiple biophysical
and immune-based assays. Recent studies using large-scale proteomic analysis identified
additional PrPC interacting proteins but are not described in this section because
validation to ascertain relevance in prion biology is lacking (Satoh, Obayashi et al. 2009;
Zafar, von Ahsen et al. 2011). Experimentally validated evidence suggests that PrPSc
replication includes cell-surface receptors, along with other chaperone proteins which are
present at the surface, to support the stabilization and internalization of the PrPC-PrPSc
complex, leading towards intracellular accumulation of infectious PrPSc with the aid of
intracellular proteins (Table 1.3).
III-B-1 Extracellular Interactors
The extracellular/plasma membrane molecules identified to associate with PrP
include receptor proteins, adhesion proteoglycans with glycosaminoglycan (GAG)
moieties, chaperone proteins, zymogen proteolytic enzymes, metal ions and other
aggregating peptides. These are listed in Table 1.3 and schematically presented in Figure
1.5. These associations implicate PrP’s involvement in internalization and endocytic
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trafficking, intracellular signal cascade activation, survival, and ion homoeostasis.
Evidence for these functions include cell explant data demonstrating PrPC
neuroprotective signaling potential through a cAMP/PKA-dependent pathway (Chiarini,
Freitas et al. 2002) and conversely activating signaling cascades that induce cell death in
vivo (Solforosi, Criado et al. 2004). These, and other observations subsequently
described, suggests that PrP is a multifaceted protein involved in many cellular processes.
III-B-2: PrP Internalization and Signaling From The Cell Surface
As mentioned in previous sections, the predominant GPI-anchorage of PrP to lipid
rafts of the PM and subsequent endocytosis using either the clathrin-coated pit- (Shyng,
Heuser et al. 1994) and/or caveolin-mediated mechanisms (Vey, Pilkuhn et al. 1996)
strongly advocates direct interaction with a surface receptor. Yeast two-hybrid (Y2H)
studies revealed strong interaction between the 37-kDA laminin receptor precursor (LRP)
and PrPC, which were subsequently confirmed in higher order eukaryotic cells. These
studies suggested that LRP was act as the receptor and/or co-receptor for PrPC (Rieger,
Edenhofer et al. 1997). Additional studies confirmed that both LRP and the mature 37kDa/67-kDa laminin receptor (LR) interact with PrPC and PrPSc at the cell surface, and in
endosomal compartments during the internalization process (Table 1.3) (Fig. 1.5A)
(Shmakov, Bode et al. 2000; Gauczynski, Peyrin et al. 2001; Baloui, von Boxberg et al.
2004; Nikles, Vana et al. 2008; Kolodziejczak, Da Costa Dias et al. 2010). Furthermore,
the use of anti-LRP/LR specific antibodies, single-chain fragment antibodies and
polysulfated glycans inhibited prion replication in vivo (Gauczynski, Nikles et al. 2006;
Zuber, Knackmuss et al. 2008; Zuber, Mitteregger et al. 2008; Vana, Zuber et al. 2009).
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Collectively, these findings indicate that interactions between PrP and LRP/LR are
functionally relevant.
Several additional studies have revealed other transmembrane receptors proteins
that interact with PrP, which possibly induce endosomal internalization mechanisms
and/or initiate intracellular signaling cascades. Dystroglycan, is a transmembrane protein
associated with the dystrophin-glycoprotein complex (DGC) that exhibited strong
binding interaction with PrP (Keshet, Bar-Peled et al. 2000). The DGC modulates the
activity of nitric oxide synthase (nNOS), which subsequently synthesizes nitric-oxide
(Bredt and Snyder 1994), a neurotransmitter with crucial functions in muscle and CNS
(Kobzik, Reid et al. 1994; Keshet, Ovadia et al. 1999). Although the exact function for
PrP in the DGC has not been established, a protective role associated with presynaptic
neuroprotection has been hypothesized (Keshet, Bar-Peled et al. 2000). Conversely, the
p75 neurotrophin receptor’s affinity towards recombinant PrP peptides caused
internalization, which subsequently induced cytotoxic effects (Fig. 1.5A, described in the
next section) (Della-Bianca, Rossi et al. 2001). Recent experimental findings have
revealed binding association of amyloid-β to PrPC, designating PrPC as a receptor that
mediates cytotoxic signaling (Fig. 1.5A) (Lauren, Gimbel et al. 2009; Resenberger,
Winklhofer et al. 2011). In addition to transmembrane receptors, internalization of PrPC
has also been demonstrated using Cu2+ and other positively charged metal ions
(Hornshaw, McDermott et al. 1995; Pauly and Harris 1998; Stockel, Safar et al. 1998;
Wadsworth, Hill et al. 1999; Brazier, Davies et al. 2008; Li, Dong et al. 2009; Liu, Jiang
et al. 2011; Stellato, Spevacek et al. 2011).
III-B-3: Outgrowth/Adhesion and Neuroprotection Functions
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In situ cross-linking experiments using N2a cells led to the identification of high
molecular mass (HMM) protein complexes (200-225 kDa), which included the presence
PrPC (Schmitt-Ulms, Legname et al. 2001). Proteomic analyses of these HMM protein
complexes revealed the presence of neuronal adhesion molecules (N-CAM’s).
Subsequent binding studies using N-CAM peptide-library indicated that PrPC’s Nterminus and α-helix bound to the membrane attachment site of N-CAM (Schmitt-Ulms,
Legname et al. 2001). Comparable levels of PrP/N-CAM complexes were identified in
both N2a and ScN2a cells (Schmitt-Ulms, Legname et al. 2001). To ascertain the
functional role of this PrPC-N-CAM interaction, N-CAM-deficient mice were challenged
with scrapie prions, which resulted in prion disease with incubation time of ~122 days
(Schmitt-Ulms, Legname et al. 2001). Elimination of N-CAM molecules in transgenic
mice did not alter prion disease incubation time compared to control mice. Thus, the
interaction between theses two molecules indicates a physiological function not
associated with PrPSc conversion (Schmitt-Ulms, Legname et al. 2001). Additional
evidence for PrPC’s interactions with N-CAM’s has implicated a physiological role in
neurite outgrowth and adhesion (Santuccione, Sytnyk et al. 2005). These findings provide
direct evidence of PrP interaction with N-CAM at the neuronal surface, activating NCAM mediated signaling through Fyn kinase activation (Santuccione, Sytnyk et al.
2005). The disruption of this interaction using neurons deficient in N-CAM’s or PrPC,
and/or use of anti-PrP antibodies, arrested neurite outgrowth (Santuccione, Sytnyk et al.
2005). Additional experimental evidence has associated the extracellular matrix protein,
Vitronectin, as another protein capable of binding PrP to induce axonal growth and
neurite development (Hajj, Lopes et al. 2007; Hajj, Santos et al. 2009). Collectively,
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these data strongly support a physiological role for PrP in neuronal outgrowth/adhesion
through cooperative interaction with the N-CAM signaling receptors and extracellular
matrix proteins (Fig. 1.5B).
PrPC’s role in neuroprotection is mediated through the interaction with several
proteins at the cell surface and other subcellular locations. The extracellular matrix
protein, laminin (LN), triggers cellular responses through direct interactions with cellsurface receptors such as integrins, to promote neurite outgrowth, regeneration and
neuroprotection (Tomaselli and Reichardt 1988; Tashiro, Sephel et al. 1989). To address
PrPC’s role in neuronal development and neuroprotection, binding assays and cell culture
experiments were utilized to identify LN’s interaction with PrPC (Graner, Mercadante et
al. 2000). These studies demonstrated that PrPC binds LN with high affinity with epitope
specificity towards the C-terminus of the γ-1 chain (Graner, Mercadante et al. 2000).
Interestingly, several studies have specified the role of the γ-1 chain in neurite outgrowth
in neocortical and hippocampal neurons (Liesi, Narvanen et al. 1989; Hager, Pawelzik et
al. 1998). PC12 cells (Table 1.2) and explant rat-neuronal cell culture models provide
additional data supporting the direct interaction between PrPC and LN to promote
neuritogenesis, demonstrating direct reduction of growth in the cells upon addition of
anti-PrP antibodies (Graner, Mercadante et al. 2000). Although these experimental
observations support PrPC’s role as a receptor for LN to promote neuritogenesis, the
signaling cascades governing these interactions have not been identified. It is important
to remember that the ablation of the Prnp gene in mice does not inhibit CNS
development (Bueler, Fischer et al. 1992), suggesting signal pathway redundancy that
regulates these important functions. Interestingly, LN has also been shown to bind
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amyloid-precursor protein (APP) and amyloid-β (Narindrasorasak, Lowery et al. 1992),
which very recently was associated to directly interact with PrPC (Fig. 1.5B) (Lauren,
Gimbel et al. 2009; Kessels, Nguyen et al. 2010; Resenberger, Winklhofer et al. 2011).
PrPC has been reported to interact with the stress-inducible protein 1 (STI1) at the
PM to induce neuroprotective signaling. Cell-surface binding studies, co-IP and binding
assays confirmed these interactions, which showed that PrPC (epitope mapped residues
113-128aa) bound STI1 with high affinity (Kd of 10e-7M) to a mapped region designated
for neuroprotective signaling (Fig. 1.5B) (Zanata, Lopes et al. 2002). These interactions
were confirmed using retinal explant cultures from neonatal rats and, while hypothesis
driven interactions of PrPC, LN and ST1 to form a macromolecular complex in the
extracellular space/cell-surface to provide cytoprotective functions were suggested but
the exact mechanisms of the interactions were not defined (Zanata, Lopes et al. 2002).
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Figure 1.5 Molecules associated with PrP interaction in the extracellular/plasma
membrane space. Extracellular and cell surface molecules that demonstrate physical
interaction with PrP are predicted to modulate functions associated with PrPC and/or
PrPSc conversion process. These associated functions include (A) Internalization of PrP
into the endocytic trafficking pathways (Clathrin coated pit- and/or Caveolin mediated
mechanisms) and/or direct association with transmembrane proteins to preform receptortype functions (Signaling), (B) Outgrowth/adhesion and/or neuroprotection of neurons,
and (C) Protein molecules associated with the conversion process of PrPC to PrPSc. The
details of specific interactions between these molecules and PrP (PrPC, PrPSc), which
include mode of interaction/binding, location specificity and references describing the
findings, are summarized in Table 1.3. The question marks (?) in the schematic represent
an unknown interaction/function. The asterisk (*) before Amyloid-β represents its direct
binding with PrPC with undefined mechanisms and/or functions associated with the
interaction. Abbreviations: Neuronal cell-adhesion molecule (N-CAM), Amyloid
precursor like protein 1 (APLP1), Stress-induced Phosphoprotein (STI1), β-secretase 1
(BACE1), Laminin (LN), Cellular prion protein (PrPC), Scrapie prion (PrPSc), Iron (Fe),
Copper (Cu), Zinc (Zn), Manganese (Mn).
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Figure 1.5 Molecules associated with PrP interaction in the extracellular/plasma
membrane space.
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III-B-4: PrPC-PrPSc Conversion At The Cell Surface
The cell surface is hypothesized to be the predominant location for PrPSc
conversion (Goold, Rabbanian et al. 2011). A recently identified cell surface protein
correlated with prion conversion is Glypican-1. Glypican-1 is a PM associated, GPIanchored, heparin sulfate containing proteoglycan co-localized with PrPC to lipid rafts
(Fig. 1.5C) (Cheng, Lindqvist et al. 2006). Also, the addition of Cu2+ ions stimulates
endocytosis of PrPC, which co-internalizes Glypican-1 from the cell surface (Cheng,
Lindqvist et al. 2006). In cell culture models, heparin was shown to displace PrPC from
lipid rafts, directly inducing endocytosis, suggesting that heparin acts as a direct
competitor with endogenous heparin sulphate proteoglycans (HSPG) for PrPC binding
(Taylor, Whitehouse et al. 2009). Likewise, the depletion of glypican-1 displaced PrPC
from lipid rafts triggering internalization into endosomal compartments. Additional colocalization and co-immuno precipitation (co-IP) assays confirmed the interaction
between glypican-1 and PrPC (Taylor, Whitehouse et al. 2009). The relevance of these
interactions to PrPSc conversion was confirmed in ScN2a cells (Table 1.2), where down
regulation of glypican-1 showed significant reduction in PrPSc formation (Taylor,
Whitehouse et al. 2009). Interestingly, previously published data using heparin and
glycosaminoglycans (GAG) have exhibited an inhibitory effect on prion conversion in
both cell culture and animal models (Kimberlin and Walker 1986; Caughey and
Raymond 1993; Beringue, Adjou et al. 2000; Adjou, Simoneau et al. 2003). In contrast
GAGs promote the conversion process in cell-free systems (Wong, Xiong et al. 2001;
Deleault, Geoghegan et al. 2005).
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GAG’s are sulfated polysaccharides that maintain a net negative charge. These
molecules were shown to be present in amyloid plaques in CJD, GSS, and Kuru (Snow,
Kisilevsky et al. 1989). To clarify the relationship of GAG’s with amyloid aggregates,
functional studies were conducted to assess their role in PrPSc conversion. Like other
HSPG’s found on the cell surface, Glypican-1 is competed out by the addition of
exogenous GAG’s (Taylor, Whitehouse et al. 2009). Inhibition of PrPSc conversion
occurs through an obstructive mechanism, which directly inhibits contact of cellular
HSPG’s with PrPC. It suggests that these molecules function as direct scaffolds to
promote interaction between PrPC and PrPSc to enhance conversion (Hooper 2011).
Finally, siRNA depletion of glypican-1 in ScN2a cells reduced but did not completely
inhibit PrPSc conversion (Taylor, Whitehouse et al. 2009), which suggests that PrPSc
conversion is dependent on multiple cellular cofactors (Fig 1.5C). Although the exact
mechanisms that govern these interactions require more experimental characterization,
the effect of GAG’s on PrPSc conversion provides additional insight towards the global
complexity PrPSc replication process.
Another cellular factor exhibiting association with PrPSc conversion is
plasminogen (PLG). Plasminogen (PLG) is a zymogen precursor to plasmin, a serine
protease that functions to dissolve fibrin blood clots (Forsgren, Raden et al. 1987). The
activation and conversion of PLG is mediated by the tissue plasminogen activator
enzyme (tPA) and/or urokinase plasminogen activator (uPA) (Silverstein, Leung et al.
1984). Interaction studies analyzing potential binding partners of PrPC have identified
plasminogen as one of the key proteins that interacts with both PrPC and PrPSc (Fig. 1.5C)
(Fischer, Roeckl et al. 2000; Maissen, Roeckl et al. 2001; Ryou, Prusiner et al. 2003).
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Screening human and mouse serum for prion binding factors showed that plasminogen
was capable of binding disease-associated PrP but not PrPC, which suggested that the
interaction was conformation specific (Fischer, Roeckl et al. 2000). PrP devoid of bound
copper was shown to interact with both tPA and PLG, which caused PLG activation in a
copper-dependent manner (Ellis, Daniels et al. 2002). This PrP mediated activation of
PLG together with copper levels was suggested to be an indicators for the kinetics of
PrPSc conversion, therefore linking PLG as a cellular cofactor (Ellis, Daniels et al. 2002).
In studies designed for identifying “protein X”, phage display cDNA expression library
methods were used to establish PrPC interaction with kringle domains (Ryou, Prusiner et
al. 2003). These kringle domains consist of ~80aa that have three intra-disulfide bonds
between cysteine residues (Castellino and McCance 1997). PLG has five of these kringle
domains originating in the N-terminus (Castellino and McCance 1997). Thus, an
unbiased forward genetic screen confirmed interaction of PrPC with PLG (Ryou, Prusiner
et al. 2003). Recent data using PMCA supported the role of PLG in a concentrationdependent manner to accelerate the PrPSc conversion process (Mays, Yeom et al. 2011).
However, plasminogen-deficient (Plg-/-) mice infected with scrapie revealed no major
effect on the survival of these infected mice (Salmona, Capobianco et al. 2005).
Collectively, the biochemical data indicates that plasminogen is an important cofactor for
PrPSc conversion. However, its exact role in prion disease remains to be characterized.
In summary, the interaction of PrPC with protein molecules at the cell surface is
multidimensional, (Fig. 1.5) suggesting that PrPC has several important physiological
functions that remain to be fully validated. These functions may include the activation of
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intracellular signaling cascades, which promote neuritogenesis, neuroprotection and/or
other intracellular roles that have not yet been defined.
III-C: Intracellular Interactors
PrPC intracellular trafficking and continuous recycling to- and -from the PM (Fig.
1.2) suggests that PrPC-PrPSc conversion is not limited to the cell surface. The specific
intracellular compartments where this conversion occurs have not been specifically
identified but experimental evidence supports the importance for endosomal, lysosomal
and exosomal compartments in this process (Taraboulos, Serban et al. 1990; Borchelt,
Taraboulos et al. 1992; Taraboulos, Raeber et al. 1992; Gilch, Winklhofer et al. 2001;
Aguib, Heiseke et al. 2009; Nunziante, Ackermann et al. 2011). PrPC has been shown to
interact with proteins that mediate cell survival pathways (Kurschner and Morgan 1995),
internalization and vesicle trafficking (Borchelt, Taraboulos et al. 1992; Taraboulos,
Raeber et al. 1992), aggregation/chaperone/protein folding responses (Fernandez-Funez,
Casas-Tinto et al. 2009; Nunziante, Ackermann et al. 2011) and other proteins which
have not been specified with a PrP-interacting function (Strom, Diecke et al. 2006) . A
comprehensive list of the proteins shown to interact with PrPC within intracellular
compartments is presented in Table 1.3 and schematically depicted in Figure 1.6.
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Table 1.3 Prion protein interacting molecules. All data presented is formulated and
adapted from previously published reviews (Lee, Linden et al. 2003; Fasano, Campana et
al. 2006; Nieznanski 2010)
PrPC Interacting
PrP
Cellular
Function
Molecules
Type/Technique Location

Extracellular/Cell Surface/Plasma Membrane
Plasminogen
(PLG)(Fischer, Roeckl et al.
2000; Maissen, Roeckl et al.
2001; Ellis, Daniels et al.
2002; Mays and Ryou 2010)
Laminin (LN)(Graner,
Mercadante et al. 2000;
Musinova, Lisitsyna et al.
2011)
Laminin
Receptor/Precursor
(Rieger, Edenhofer et al.
1997; Gauczynski, Peyrin et
al. 2001; Hundt, Peyrin et
al. 2001; Gauczynski,
Nikles et al. 2006; Nikles,
Vana et al. 2008;
Kolodziejczak, Da Costa
Dias et al. 2010)
Dystroglycan (Keshet, BarPeled et al. 2000)
Vitronectin (Hajj, Lopes et
al. 2007; Hajj, Santos et al.
2009)

Neuronal cell adhesion
molecule (N-CAM)
(Schmitt-Ulms, Legname et
al. 2001; Santuccione,
Sytnyk et al. 2005)
Glypican-1 (Taylor,
Whitehouse et al. 2009;
Hooper 2011)
Metalloproteinases; A
Disintegrin And

	
  

PrPC-PrPSc/Y2H,
Cells, PMCA

Extracellular
/Raft

rPrPC-PrPC/Cells
and cell free

Plasma
Membrane
(PM)/Cell
Surface
Plasma
Membrane

PrPC/Y2H, Cell
lines

Zymogen
(Plasmin
Precursor),
Proteolytic
enzyme
Neurite
Outgrowth
Internalization

PrPC/co-IP, coLocalization, coFractionate
PrPC/ Overlay,
co-Localization,
Binding &
Competition
Assay, PullDown
PrPC/Cell lines

Plasma
Membrane

Plasma
Membrane,
Caveolae

Neurite
outgrowth/
Internalization

PrPC-PrPSc/cell
models, Co-IP

Lipid Rafts,
Plasma
Membrane

PrPC-PrPSc/CellCulture models

Plasma
Membrane

PrPSc conversion,
Cell
division/growth
Regulation
PrP Cleavage
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Plasma
Membrane

Copper
Homeostasis/Unk
nown
Axonal Growth

Metalloproteinase
(ADAM), Matrix
Metalloproteinase (MMP)
(Vincent, Paitel et al. 2001;
Mange, Beranger et al.
2004; Parkin, Watt et al.
2004; Cisse, Sunyach et al.
2005; Hooper 2005; Taylor,
Parkin et al. 2009)
Amyloid precursor like
protein 1 (APLP1)
(Yehiely, Bamborough et al.
1997)
Stress-Induced
Phosphoprotein (STI1)
(Chiarini, Freitas et al.
2002; Zanata, Lopes et al.
2002; Hajj, Santos et al.
2009)
p75 (Della-Bianca, Rossi et
al. 2001)

	
  

rPrPC
fragment/cDNA
library screen

Plasma
Membrane

Unknown

PrPC

Plasma
Membrane

Neuroprotection

PrPC/Cell Culture

Plasma
Membrane,
Caveolae
Plasma
Membrane
Plasma
Membrane

Apoptosis,
Internalization,
Transport

Plasma
Membrane,
Cytosol, ER
Plasma
Membrane,
Extracellular

Chaperone

PrPC/ Co-IP,
ELISA, SPR

Plasma
Membrane,
Endosomes

Proteolytic
enzyme cleaves
APP

rPrPC,
PrPC/Cyclic-

Extra-, Intra
cellular

Ion homeostasis,
Internalization

Tetraspanin-7 (CD231)
(Guo, Huang et al. 2008)
Glycosaminoglycan (GAG)
(Priola, Caughey et al. 1994;
Wong, Xiong et al. 2001;
Pan, Wong et al. 2002)
Clusterin (Xu,
Karnaukhova et al. 2008)

PrPC/Y2H, Colocalization, IP
PrPC/Cell
Culture, Y2H

Amyloid-β (Lauren, Gimbel
et al. 2009; Balducci, Beeg
et al. 2010; Kessels, Nguyen
et al. 2010; Resenberger,
Winklhofer et al. 2011;
Tofoleanu and Buchete
2012)
β-secretase 1
(BACE1)(Parkin, Watt et al.
2007; Griffiths, Whitehouse
et al. 2011) (Parkin, Watt et
al. 2007; Griffiths,
Whitehouse et al. 2011)
Metal Ions (Cu, Mn, Fe,
Zn) (Brazier, Davies et al.

PrPC/Aβ-Biotin
in cell culture,
SPR

PrPC/Y2H, co-IP,
CD
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Internalization

Transcytosis,
Undefined

2008; Zhu, Davies et al.
2008; Li, Dong et al. 2009;
Singh, Mohan et al. 2009;
Liu, Jiang et al. 2011;
Martin, Anantharam et al.
2011; Pushie, Pickering et
al. 2011; Stellato, Spevacek
et al. 2011; Younan,
Klewpatinond et al. 2011)

Voltammetrics,
UVSpectroscopic,
ITC, CD

Intracellular Interacting Molecules
Αβ-Crystallin (Sun, Guo et
al. 2005)
Heat-Shock 60-KD Protein
1(HSPD1/HSP60) (Stockel
and Hartl 2001; Satoh,
Onoue et al. 2005;
Alexeeva, Valieva et al.
2011)
Caveolin-1(MouilletRichard, Ermonval et al.
2000; Vana, Zuber et al.
2007; Schneider, Pietri et al.
2011)
Nuclear factor erythroid
2-like2 (Nrf2) (Yehiely,
Bamborough et al. 1997)
Synapsin 1b (Spielhaupter
and Schatzl 2001)
Growth factor receptorbound protein 2 (Grb2)
(Spielhaupter and Schatzl
2001; Lysek and Wuthrich
2004)
Prion interactor-1 (Pint1)
(Spielhaupter and Schatzl
2001)
Casein Kinase II (Ck2)
(Meggio, Negro et al. 2000;
Negro, Meggio et al. 2000)
B-cell CLL/Lymphoma

	
  

PrPC/Y2H,
cDNA Library,
co-localization,
SPR
rPrP, PrPC/cDNA
Library Screen,
Cell Free

Cytosol

Undetermined

Plasma
Membrane

PrP Aggregation

rPrPC/Cell lines

Caveolae
Rafts

Signaling

rPrP/Phage
screen of
expression
library from
brain cDNA
rPrP, PrPC/ Y2H,
co-IP, cofractionation
rPrP, PrPC,
PrPSc/Y2H, coIP, cofractionation

Cytosol,
Nucleus

Unknown

Cytosol,
Vesicles

Signaling,
Internalization

Cytosol,
Nucleus,
Vesicles

Internalization

rPrPC, PrPC/Y2H,
cell culture

Unknown

rPrP, PrPC/ pulldown, overlay,
SPR, co-IP

Cytosol,
Nucleus,
Extracellula
r Matrix
Cytosol

Signaling,
Internalization,
Transport
Kinase Activity,
Internalization

rPrP,
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Loss of Bcl-2

(Bcl-2) (Kurschner and
Morgan 1995; Rambold,
Miesbauer et al. 2006;
Lisitsyn 2010)
Glial Fibrillary Acidic
Protein (GFAP)(Oesch,
Teplow et al. 1990; Dong,
Wang et al. 2008)
Heat-Shock 70-KD Protein
5 (HSPA5/Bip) (Jin, Gu et
al. 2000)
Nucleic Acids (Cordeiro,
Machado et al. 2001;
Derrington, Gabus et al.
2002; Deleault, Lucassen et
al. 2003; Silva, Vieira et al.
2011)
14-3-3 protein (Satoh,
Onoue et al. 2005; Mei, Li
et al. 2009)
Neuroglobin (NGB)
(Lechauve, Rezaei et al.
2009)
Tubulin (Brown 1998;
Brown 2000; Nieznanski,
Nieznanska et al. 2005;
Nieznanski, Podlubnaya et
al. 2006; Dong, Shi et al.
2008; Giorgi, Di Francesco
et al. 2009; Osiecka,
Nieznanska et al. 2009)
Tau (Tomoo, Yao et al.
2005; Han, Zhang et al.
2006; Wang, Dong et al.
2008)
Aldolase C (Strom, Diecke
et al. 2006)
Neurotrophin receptorInteracting MAGE
Homolog (NRAGE)
(Bragason and Palsdottir
2005)
Mahogunin (Chakrabarti
and Hegde 2009)
Flotillins (Solis, Malaga-

	
  

cytoPrP/Y2H,
co-IP, Affinity

function, induction
of Apoptosis

rPrP, PrPC, PrPSc/
Pull-Down,
Overlay, co-IP

Cytosol

Unknown

PrPC, Mutant
PrP/Cell Lines

Endoplasmi
c Reticulum
(ER)
Nucleus

Chaperoning

rPrP, PrPC, PrPSc/
Pull-Down,
Overlay, co-IP
rPrP/Affinity

Cytosol

Unknown

Cytosol

Aggregation

rPrP, PrPC, PrPSc/
Pull-Down,
Overlay, co-IP,
co-Fractionation,
Cross-Linking,
Affinity

Cytosol

Oligomerization,
Aggregation,
Inhibition of
Microtubule
Assembly

rPrP, PrPC, PrPSc/
Pull-Down, co-IP

Cytosol

Reduction of
binding to tubulin

rPrP,
PrPC/Overlay
rPrP, PrPC,
cytoPrP/PullDown, Y2H, coIP

Cytosol

Unknown

Cytosol

Aggregation,
Mitochondrial
Potential

cytoPrP,
ctm
PrP/PullDown, Affinity
rPrP, PrPC/Y2H,

Cytosol

Aggregation,
Neurodegeneration

Rafts,

Signaling, Raft

PrPC/Cell
Culture, Cell
Free, PMCA
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Chaperoning and
Aggregation

Trillo et al. 2010; Wang,
Zhou et al. 2011)
RAS-Associated Protein
(Rab4, 6a, 7a) (Beranger,
Mange et al. 2002; Zafar,
von Ahsen et al. 2011)
Ferritin (Mishra, Basu et al.
2004; Sunkesula, Luo et al.
2010)

	
  

Cell Culture

Vesicles

Carrier

PrPC/MS/MS, coIP, colocalization

Cytosol,
Vesicles

Intracellular
trafficking

PrPSc/Co-IP, Colocalization, EM

Phagosome,
Vesicles,
Cytoplasm

Ion transport
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III-C-1: Cell Survival and Apoptosis
Initial PrPC binding studies using the Y2H system established selective binding of
the B-cell lymphoma 2 (Bcl-2) protein to PrPC, suggesting that PrPC could have antiapoptotic function (Kurschner and Morgan 1995). The Bcl-2 protein is localized to the
mitochondrial membrane with a predominant function to regulate apoptotic pathways
(Hockenbery, Nunez et al. 1990). Thus direct binding of PrPC to Bcl-2 would imply an
intracellular regulatory function modulating cell survival pathways (Fig. 1.6A). Targeting
PrPC to various cellular compartments exhibited specific cytotoxicity in the cytosol
(Rambold, Miesbauer et al. 2006). Pull-down assays confirmed that the cytosolic PrP
selectively bound the Bcl-2 protein thus causing it to co-aggregate and be sequestered
from its anti-apoptotic function (Rambold, Miesbauer et al. 2006). Interestingly, the
addition of cytosolic chaperones (Hsp70 and Hsp40) interfered in the PrP/Bcl-2
aggregation and reduced cell death (Rambold, Miesbauer et al. 2006). In contrast, other
lines of evidence argue that cytosolic PrP is not cytotoxic in primary human neurons, but
rather protects cells against Bax-mediated (Bcl-2 binding protein) apoptosis (Roucou,
Guo et al. 2003).
The p75 receptor was previously discussed in the context of cell surface
interaction with PrPC, but its main role as the signal transducing receptor to activate
apoptosis in neurons has relevance for the intracellular PrP discussion. The neurotrophin
receptor interacting melanoma antigen (MAGE) homolog (NRAGE) directly interacts
with the cytosolic region of p75 to activate the JNK-mediated mitochondrial apoptotic
pathway (Fig. 1.6A,C) (Salehi, Xanthoudakis et al. 2002). Interestingly, using the Y2H
system and PrPC as bait, NRAGE was identified as an interactor and subsequently

	
  

61	
  

confirmed to bind PrP (Bragason and Palsdottir 2005). Proteins that interact with
NRAGE in the cytosol ultimately activate apoptotic pathways (Salehi, Xanthoudakis et
al. 2002). Although the relevance of PrP binding to either p75 and/or NRAGE must be
functionally determined, the coincidental affinity for both molecules that regulate cell
survival pathways should not be disregarded.
III-C-2: Internalization and Signaling
Several proteins within the endosomal recycling compartments are of interest as
PrP interactors and as cofactors that enable/enhance the PrP misfolding process. These
proteins include the Ras-related GTP-binding protein family (Rab), which predominantly
regulates vesicular trafficking in cells (Davies, Cotter et al. 1997). Experiments using
dominant-negative GTPase Rab4 and Rab6a proteins exhibited increased amounts of
PrPSc in infected cells through the inhibition of the plasma membrane recycling process
(Beranger, Mange et al. 2002). The reduction of the Rab7a protein in cell culture by gene
silencing methods caused PrPC accumulation in Rab9 positive endosome compartments,
therefore implying direct interaction between the Rab proteins and PrPC (Zafar, von
Ahsen et al. 2011). Lastly, systematic impairment of protein trafficking in PrPSc infected
cells, while quantitating the distribution of PrPC and PrPSc strongly designates the
endosomal recycling compartments as the most likely site for prion conversion
(Marijanovic, Caputo et al. 2009), providing additional evidence towards intracellular
mechanisms governing PrP interaction and conversion process.
Additional proteins have been described to interact with PrP inside the vesicle
trafficking compartments. These proteins include the synapsin 1b adaptor-like
phosphoprotein and growth factor receptor-bound protein 2 (Grb2), both involved in
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signal transduction. They bind PrPC with high affinity, as determined with the Y2H
system (Spielhaupter and Schatzl 2001). An additional protein identified in the complex
with PrPC, synapsin and Grb2 was the prion-interactor 1 protein (Pint1), but the function
of this protein remains undefined (Fig. 1.6B) (Spielhaupter and Schatzl 2001).
As briefly alluded to earlier, PrPC has been implicated as a receptor with signal
transduction capabilities. Since PrPC is GPI-anchored protein, which lacks a cytoplasmic
tail to transduce signals intracellularly. Any signal transduction pathways that are
activated upon ligand interaction with PrPC must involve an intermediate protein. Initial
evidence for GPI-anchored cell surface proteins ability to transduce a signal was first
demonstrated using antibody-mediated cross linking of various GPI-linked cluster of
differentiation (CD) proteins on leukocytes, which subsequently activated protein
tyrosine kinases (Stefanova, Horejsi et al. 1991). Applying similar experimental approach
and logic, PrPC exhibited activation of the tyrosine kinase Fyn signal transduction
pathway through an intermediating caveolin-1 protein (Fig. 1.6B) (Mouillet-Richard,
Ermonval et al. 2000). In vivo, antibody-mediated crosslinking of PrPC induced neuronal
apoptosis in the hippocampus (Solforosi, Criado et al. 2004).

Additionally, these

antibody-mediated cross-linking techniques have revealed a spatial link between PrPC
and microdomain-forming protein, flotillin-1 and -2, which collectively contribute
towards PrP signaling capabilities (Solis, Malaga-Trillo et al. 2010). Interestingly, casein
kinase 2 (Ck2), a phosphorylating enzyme involved in signal transduction pathways, was
experimentally validated to bind PrPC and moreover phosphorylate it at the serine 154
position of bovine PrP (Meggio, Negro et al. 2000; Negro, Meggio et al. 2000).
III-C-3: The Interaction with Chaperones and Intracellular Aggregation
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The implication for a host chaperone protein to mediate PrPSc conversion relates
back to the transgenic data, which led to the protein X hypothesis (Telling, Scott et al.
1995). Cellular chaperones play a crucial role in modulating the normal folding process
of PrPC and subsequently become up regulated through the induction of the unfolded
protein response (UPR) that occurs when misfolded protein induces ER stress (Martins,
Graner et al. 1997; Shyu, Harn et al. 2002; Fernandez-Funez, Casas-Tinto et al. 2009;
Luo, Li et al. 2010; Wilkins, Choglay et al. 2010; Shorter 2011). Cell culture models
were used to demonstrate active binding of the ER chaperone heat shock protein 70-kDa
(Hsp70/Bip/HSPA5) to PrPC thereby reducing cytosolic aggregate formation by
selectively targeting these proteins for proteasomal degradation (Fig 1.6C) (Jin, Gu et al.
2000). Subsequent in vitro data revealed that GroEL, a bacterial homolog to the heat
shock protein 60-kDa (Hsp60) binds PrP (recombinant) and actively catalyzes aggregate
formation of chemically denatured and/or folded rPrPC (Stockel and Hartl 2001). This
data, collectively suggests that chaperones are crucial modulators for PrP’s intracellular
fate. Although functionally undefined, Hsp60 was also discovered to form a molecular
complex with PrPC and the 14-3-3 proteins both in cell culture models and in reactive
astrocytes of human brains (Satoh, Onoue et al. 2005). The 14-3-3-protein family is a
group of ubiquitously expressed regulatory molecules throughout eukaryotic cells, which
have been shown to bind and interact with signaling proteins (Nielsen 1991; Xiao,
Smerdon et al. 1995). Although unrelated to this topic, 14-3-3 proteins have been shown
to be present in elevated levels in the cerebrospinal fluid (CSF) of CJD patients
(Takahashi, Iwata et al. 1999). Furthermore, biochemical and biophysical analyses in
combination with the initial Y2H screen revealed that clusterin, a chaperone
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glycoprotein, also interacts with PrPC (Xu, Karnaukhova et al. 2008).

These Y2H

binding analyses facilitate the identification of interacting proteins through mutual
affinity without providing insight in their function, which is the case for several proteins
linked to PrP by affinity binding experiments (Fig. 1.6D).
III-D: Other Interacting Molecules Implicated In PrPSc Conversion
III-D-1: Nucleic Acids
Nucleic

acids

(NA)

and

glycosaminoglycans

(GAG)

molecules

have

longstanding experimental evidence to link them to the prion conversion process
(Cordeiro, Machado et al. 2001; Deleault, Lucassen et al. 2003; Cordeiro and Silva 2005;
Deleault, Geoghegan et al. 2005; Lima, Cordeiro et al. 2006; Gomes, Millen et al. 2008;
Silva, Lima et al. 2008; Marques, Cordeiro et al. 2009). Early hypotheses suggested that
nucleic acids were potential interacting partners for PrPC, and helped facilitate its
conversion to PrPSc (Weissmann 1991). In vitro experiments have validated a
physiological relevance between PrPC and NA (Cordeiro, Machado et al. 2001).
Recently, studies have shown that the N-terminal domain of the prion protein interacts
with DNA and/or RNA molecules to form toxic aggregates (Fig. 1.6) (Cordeiro,
Machado et al. 2001; Gomes, Cordeiro et al. 2008). Moreover, the deletion of the Nterminal domain (23-90aa) in PrPC inhibited RNA binding, and aggregate formation in
N2a cells (Cordeiro, Machado et al. 2001; Gomes, Cordeiro et al. 2008). Highly
structured (shs)RNA binds recombinant human prion protein (hrPrP) with high affinity,
inducing the formation of a protease resistant complex between these molecules (Adler,
Zeiler et al. 2003). Together, these studies indicate that nucleic acids cofactors function in
a chaperone-type mechanism that potentially enhances the PrPSc conversion process. This
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chaperone mechanism could entail a biochemical process that reduces the activation
barrier for PrPSc conformational switching, upon NA binding to PrPC. Conversely, in
vitro conversion assays provide evidence that certain DNA/RNA aptamers inhibit the
formation of PrPSc (Sayer, Cubin et al. 2004; Sekiya, Nishikawa et al. 2005; King, Safar
et al. 2007). The molar range affinities nucleic acids bind PrP implicate the possibility for
an unexplored regulatory function between these molecules, which is still to be defined.
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Figure 1.6 Molecules associated with PrP within the intracellular space of the cell.
Various experimental approaches have identified intracellular proteins that interact with
PrP. These approaches include direct/indirect-binding analyses that include biophysical
affinity calculations and co-localizations within intracellular organelle compartments.
The studies reveal that PrP interacts with proteins that modulate cell survival (A),
followed by proteins that initiate signaling cascades along with regulating
endocytic/exocytic and intracellular trafficking utilizing vesicle transport mechanisms
(B). Moreover, cell-fractionations and pull-down affinity studies have facilitated the
identification

of

proteins

that

associate

with

the

PrPSc

aggregation/stabilization/chaperoning process (C)). While, other proteins identified to
interact with PrP remain without defined association in function (D). The details of
specific interactions between these molecules and PrP (PrPC, PrPSc), which include mode
of interaction/binding, location specificity and references describing the findings, are
summarized in Table 1.3. Abbreviations: Heat-Shock 60-Kda Protein (Hsp60), HeatShock 70-Kda Protein (Hsp70), Nuclear factor erythroid 2-like 2 (Nrf2), Growth factor
receptor-bound protein 2 (Grb2), Prion interactor-1 (Pint1), Casein kinase II (Ck2), B-cell
CLL/Lymphoma (Bcl-2), Glial fibrillary acidic protein (GFAP), Neuroglobin (NGB),
Neurotrophin receptor-interacting MAGE homolog (NRAGE), RAS-Associated protein
(Rab7a), Cellular prion protein (PrPC), Scrapie prions (PrPSc), Transmembranetopological C-terminus cellular prion protein (CtmPrP).
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Figure 1.6 Molecules associated with PrP interaction within intracellular space of
the cell.
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Concluding Summary
Significant amounts of data have been collected in recent years in an attempt to
define the physiological function of PrPC and the cellular cofactors this protein interacts
with. The biogenesis and localization of GPI-anchored PrPC would strongly implicate
function by association with interacting proteins (Figs. 1.1, 1.2, 1.5 and 1.6). Localization
of PrPC to lipid rafts would advocate towards a signaling/regulatory function as observed
with other proteins that co-localize to this highly ordered plasma membrane domain
(Staubach and Hanisch 2011). Moreover, precedence for GPI-anchored proteins to
activate signal transduction pathways has been demonstrated (Stefanova, Horejsi et al.
1991). Therefor the absence of a cytoplasmic tail would again indicate mandatory
interaction with intermediate proteins. Furthermore, as PrP is endocytosed through
clathrin- and/or caveolin mediated mechanism, more opportunity is provided to interact
with intracellular proteins that could assume functional roles or stabilize/enhance PrPCPrPSc conversion (Fig. 1.5, 1.6B). The aforementioned experimental data supplies
additional evidence to support both of these hypotheses (Marijanovic, Caputo et al. 2009;
Goold, Rabbanian et al. 2011; Zafar, von Ahsen et al. 2011). Lastly, besides
understanding the normal function of PrP, the interacting proteins that have already been
identified (Table 1.3) and others yet to be discovered, will also provide insight towards
the mechanisms that govern PrPSc conversion, aggregation and ultimately disease.

Copyright © Vadim Khaychuk 2012
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Dissertation Research
The main objective of my research is to gain an understanding of prion replication
at the cellular level, and to identify host factors associated with this process. My
overarching hypothesis is that permissiveness to prion replication is dependent on
unidentified, endogenous factors that act in concert with PrP. By establishing novel
cell culture systems that express heterologous PrPC from different species, I set out to
identify and describe these factors. We utilized these cell culture models to answer the
following questions:
Question 1: Can prion strain diversity be characterized using in vitro cell culture
models?
Our initial studies describe the behavior of prion strains in cell culture using three
different cell lines (Chapter 3). RK13 cells do not express endogenous PrPC, making
them the ideal in vitro knockout model for genetic manipulation that is analogous to the
Prnp0/0 mouse background used to create transgenic mouse models for bioassay analyses
(Bueler, Fischer et al. 1992; Browning, Mason et al. 2004). Furthermore, unlike other cell
culture systems used in prion studies that replicate only experimentally adapted mouse
prions (Race, Fadness et al. 1987), RK13 cells are capable of replicating heterologous
prions from different species (Chapters 3 & 4). I describe the RK13 cell’s capability to
replicate CWD prions (Chapter 3), mouse prions, and TME, Hyper (HY) and Drowsy
(DY) (Chapter 3). Finally, I describe the production and partial characterization of
susceptible cells expressing genetically removable PrPC using the Cre-lox system
(Chapter 5).
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Question 2: Do endogenous host factors mediate the susceptibility and/or resistance to
prions?
I show that cloning of RK13 cells facilitated the identification of subclones with
wide-ranging susceptibility to PrPSc replication. Despite evidence from in vivo studies
(Westaway, Mirenda et al. 1991; Carlson, Ebeling et al. 1994; DeArmond and Prusiner
1996; Fischer, Rulicke et al. 1996; Telling, Haga et al. 1996), susceptibility and/or
resistance to prion replication in cells was not solely dependent on PrPC expression levels
(Chapter 4). To identify the molecular differences between the sensitive and resistant
cells, we utilized representational difference analysis (RDA) and microarray technologies
to distinguish unique genes and pathways associated with these respective phenotypes
(Chapter 4).

	
  

71	
  

Chapter 2
Materials and Methods

Cell Cultures: N2a, HEK293A and RK13 cells were freshly obtained from the American
Type Culture Collection (ATCC, Manassas, VA) and maintained in 5 % CO2 at 37°C in
Dulbeco’s modified Eagle’s medium (DMEM) (Gibco Life Technologies, Grand Island,
NY) with 10 % fetal bovine serum (FBS) (Gibco Life Technologies, Grand Island, NY)
and Penicillin/Streptomycin (P/S) (Gibco Life Technologies, Grand Island, NY). Cell
clones were derived by limited dilution in 96-well plates (BD Falcon, Franklin Lakes,
NJ) seeded with 100 µl of cell suspension containing 0.3 cells. Cells were cured of PrPSc
by treatment with dextran sulfate-500 (DS-500) (100 ng/ml) (Sigma-Aldrich, St. Louis,
MO), prepared in distilled water and sterilized by passage through a 0.22 µM filter
Genomic DNA Extraction: Homogenization of Brain tissue was homogenized in buffer
(100mM NaCl, 10mM Tris HCl pH 8.0, 25 mM EDTA, 0.5% sodium dodecyl sulphate
(SDS), 0.1mg/ml Proteinase K concentration). Twelve ml of buffer was added per gram
of tissue and incubated overnight at 50°C. The sample was extracted with one volume of
phenol/chloroform (1:1), the phenol having been previously saturated with water or
buffer. The aqueous layer was removed, and 0.5 volume of 5M-ammonium acetate and
two volumes of 100 % ethanol was added. The DNA was precipitated and recovered by
centrifugation at 5000 rpm for 5 min. The DNA in the pellet was dissolved and
resuspended in 2ml of TE (10mM Tris, 1mM EDTA, pH 8.0)
Expression Constructs: The mouse, hamster, deer and elk PrP coding sequences were
PCR amplified with primers containing AflII and EcoRI restriction endonuclease
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recognition sites. Digested amplicons were inserted into pIRESpuro3 vector (Clontech,
Mountain View, CA). The PrP ORF was sequenced in the recombinant vector and
transfected into N2a, RK13 and HEK293A cells (empty vector to produce RKV cells).
RKE, RKD and RK13-SHaPrPC cells were further transfected with pcDNA3-gag
expressing HIV-1 GAG precursor protein, generating RKE-, RKD-, and RK13-SHaPrP-Gag cells. Transfected cells were grown in complete medium containing 1 µg/ml
puromycin (Sigma-Aldrich, St. Louis, MO). Co-transfected RK13 cells expressing both
PrP and HIV-1 Gag genes were supplemented with 1 µg/ml puromycin (Sigma-Aldrich,
St. Louis, MO) and 1 mg/ml neomycin (Sigma-Aldrich, St. Louis, MO). Selection
medium was changed every 3 days.
Cell Transfection: Cells were grown to 75-80 % confluence in 6-well cell culture plates
(BD Falcon, Franklin Lakes, NJ) and maintained in 5 % CO2 at 37°C in DMEM (Gibco
Life Technologies, Grand Island, NY) with 10% FBS (Gibco Life Technologies, Grand
Island, NY) and 1% Penicillin/streptomycin (PS) (Gibco Life Technologies, Grand
Island, NY). Transfection DNA solution was made by combining 5 µl of Lipofectamine
reagent (Invitrogen, Life Technologies, Grand Island, NY) diluted in 100 µl Opti-MEM
(Gibco Life Technologies, Grand Island, NY) with 2.6 µg of plasmid DNA diluted in 100
µl Opti-MEM. The 200 µl combined solution was gently mixed and allowed to incubate
at room temperature for 30 min upon which 800 µl of Opti-MEM was added to bring the
volume of the solution to 1.0 ml. Cells were washed 2x with 5.0 ml Opti-MEM. Each
well to be transfected received 1ml of transfection solution and incubated in 5% CO2 at
37°C for 5 h. The cells were supplemented with 1.0 ml of complete Opti-MEM solution
(20% FBS, 2% PS) and replaced into the incubator for overnight (O/N) incubation in 5 %
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CO2 at 37°C. On the following day, cells were detached from plates by trypsinization and
scaled up to a 10-cm cell culture dish (BD Falcon, Franklin Lakes, NJ). Selection of
transfected cells was completed with the addition of puromycin (1µg/ml), neomycin
(1mg/ml) or a combination of both.
Preparation Of Brain Homogenates: Brain tissues from sacrificed mice were stored
frozen at -80°C. Ten % brain homogenizates was made in PBS lacking Ca2+ and Mg2+ on
ice by repeated passage through 18-, 23-, and 26-gage needles.
Infection Of Transgenic Mice: Isoflurane anesthetized mice were inoculated
intracerebrally (IC) with 1 % elk or mouse brain homogenate. Inocula from cell cultures
were prepared by washing confluent monolayers 2x with cold PBS, collecting cells in
PBS by scraping, followed by three -80°C freeze and thaw cycles. Mice were inoculated
with infected brain and cell culture preparations (infected & uninfected) containing
equivalent amounts of PrPSc quantified by Western blot analysis. Mice were monitored
weekly. Inoculated mice were diagnosed with prion disease displaying at least three
clinical signs, the time from inoculation to the onset of definitive clinical signs being
referred to as the incubation time.
Cell infections: Cells (2 x 105) were plated into 6 well plates one day before prion
infection. Ten % brain homogenates diluted in Opti-MEM medium to 0.2 -2% were
added to cell monolayers, 1.0 ml per well. After 5 h, 2.0 ml of Opti-MEM medium
containing 15 % fetal calf serum (FCS) (Gibco Life Technologies, Grand Island, NY)
was added. Cell lysates were harvested at passage 3 for Western blotting.
Analysis Of PrPC And PrPSc By Western Blotting: For cell culture, confluent cells were
lysed with cold lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.5% sodium
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deoxycholate, 0.5% Igepal CA-630) and total protein concentration was determined by
bicinchoninic acid (BCA) assay (Pierce Biotechnology Inc., Rockford, IL). Lysates and
brain extracts (w/v 2 % sarkosyl) were either untreated or treated with 40 µg/ml
proteinase K (PK) (Pierce Biotechnology Inc., Rockford, IL) for 1 hr at 50°C and the
reaction was terminated with 4 mM phenyl methyl sulfonyl fluoride (PMSF). PrPSc in cell
culture lysates was purified by centrifugation for 1 h at 100,000 x g at 4°C. Proteins were
separated by SDS-PAGE using discontinuous 12 % Tris-Glycine gels, and transferred to
PVDF-FL membranes (Millipore, Billerica, MA). Membranes were blocked in Tris
buffered saline, 0.05 % Tween (TBS-T) and 5% non-fat milk, incubated with the primary
anti-PrP (mAb) 6H4 (Prionics AG, Schlieren-Zurich), 3F4 mAb (Covance, Cat. No. SIG39600) or 9E9 (Telling lab) or total protein control antibody Pan-Actin mAb-5 (Lab
Vision Corporation, Fremont, CA), followed by HRP-conjugated sheep α-mouse IgG
secondary antibody. Membranes were developed using ECL-plus (GE Healthcare
Biosciences, Pittsburgh, PA), and analyzed with a FLA-5000 scanner (Fuji/ GE
Healthcare Biosciences, Pittsburgh, PA).
Cell Lifting Assay And Blot Development: Three passages after prion infection, cells
were subpassaged 1:10 in a 6-well plate, which contains cell culture cover slips (25 mm
diameter, Cat. No. 174985) (NUNC, Rochester, NY). Confluent coverslips were washed
2x with cold PBS, and placed cell side down on nitrocellulose paper (0.45 um, Whatman,
Cat. No. 10485375) soaked in cold lysis buffer, backed with similarly soaked blotting
paper (Bio-Rad, Hercules, CA). Coverslips were pressed firmly for 1 min, and removed.
Membranes were air dried for 2 h. Membranes are rewetted with cold lysis buffer, and
incubated in cold lysis buffer containing 5 µg/ml PK for 90 min at 37°C with constant
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shaking. PK digestion was terminated with PMSF (2 mM) for 20 min. Membranes were
rinsed 4x with dH2O, and immersed in 3M guanidine isothiocyanate/10 mM Tris-HCl,
pH 8.0 for 10 min, then rinsed 4x with dH2O. Membranes were blocked in TBS-T and
5% non-fat milk, incubated with anti-PrP for 2h at room temperature, shaking. The
membranes are than washed 3x with TBS-T, followed by the addition of HRP-conjugated
sheep α-mouse IgG secondary antibody with 1h incubation at room temperature and
shaking. Membranes were washed 3x with TBS-T and developed using ECL-plus (GE
Healthcare Biosciences, Pittsburgh, PA). The blots were exposed to X-ray film and
developed.
Protein Level Evaluation by Densitometry Using The ImageJ Software: Western blot
PrPC protein levels and cell-lifting PK resistant PrPSc was assessed using the densitometry
function of the ImageJ software bundle (Abramoff 2004). The uploaded JPEG image file
of respective membrane blots were normalized with a background correction function
(ImageJ  Process tab  Subtract Background). The total density of each sample (lane
or PK resistant circle from cell lift) was individually measured using the measure
function (ImageJ  Analyze tab  Measure). Empty lanes/blot circles were used as
background to calculate density (density value = background density value – sample
density value).
Histopathological studies: Brains were immersion fixed in 10% buffered formalin.
Tissues were embedded in paraffin and 10 mm thick coronal microtome sections were
mounted onto positively charged glass slides. Immunohistochemistry (IHC) was
performed as previously described using anti-PrP mAb 6H4 as primary antibody and

	
  

76	
  

IgG1 biotinylated goat anti-mouse secondary antibody (Southern Biotech). Detection was
with Vectastain ABC reagents and slides were developed with diaminobenzidine.
Cervid Prion Cell Assay (CPCA): Susceptible Elk21- cells in 96 well plates were
exposed to serial dilutions of Elk CWD brain homogenates ranging from 10-2 to 10-5 in
100 µl per well. Cell cultures were split 3x, first passage cells were split at 1:4 and
thereafter at 1:7. Inclusion of RK13 cells stably transfected with empty vector (RKV
cells) were used as negative controls. At final passage, 20,000 cells were filtered onto
Multiscreen IP 96-well 0.45-µm filter plates (Elispot plates, Millipore, Billerica, MA), or
AcroWell 96-well 0.45-µm BioTrace filter plates (Pall, East Hills,NY). Cells were
subjected to PK digestion and denaturation with guanidiniumthiocyanate (3 M in 10 mM
Tris-HCl, pH 8). CerPrPSc-producing cells were detected by ELISPOT using anti-PrP
mAb 6H4, followed by AP-conjugated secondary anti-mouse IgG, and developed with
nitro-blue tetrazolium chloride/ 5-bromo-4-chloro-3'-indolyphosphate p-toluidine salt
(NBT/BCIP). Images were scanned with CTL ELISPOT equipment, and spot numbers
were determined using ImmunoSpot3 software (Cellular Technology Ltd, Shaker
Heights, OH). Statistical analyses were performed using GraphPad Prism 5.0 for Mac OS
X software (San Diego California USA, www.graphpad.com).
Modified Scrapie Cell Assay: Cells were infected with 0.2% (w/v) prion infected brain
homogenate and passaged three times. At final passage, 20,000 cells were filtered onto
Multiscreen IP 96-well 0.45-µm Elispot plates (Millipore, Billerica, MA), or AcroWell
96-well 0.45-µm BioTrace filter plates (Pall, East Hills,NY). Cells were subjected to PK
digestion and denaturation with guanidiniumthiocyanate (3 M in 10 mM Tris-HCl, pH 8).
PrPSc-producing cells were detected by Elispot analysis using anti-PrP mAb 6H4,
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followed by AP-conjugated secondary anti-mouse IgG and developed with nitro-blue
tetrazolium chloride/ 5-bromo-4-chloro-3'-indolyphosphate p-toluidine salt (NBT/BCIP).
Images were scanned with CTL ELISPOT equipment, and spot numbers were determined
using ImmunoSpot3 software (Cellular Technology Ltd, Shaker Heights, OH). Statistical
analyses were performed using GraphPad Prism 5.0 for Mac OS X software (San Diego
California USA, www.graphpad.com).
Transduction of Cells Expressing lox-P Flanked PrPC With Adeno-Cre-recombinase
Viral Vector: Cells were plated in 6-well tissue culture plates (BD Falcon, Franklin
Lakes, NJ) and grown to confluence. Cells were washed 2x with PBS, trypsinized (200µl)
and placed into 37°C + 5 % CO2 incubator for 5 min. Cell were resuspended in 1.0 mL
serum free DMEM. One of the 6 wells was used as the representative for counting. The
cells from this well were saved as time point 0 prior to Adeno-Cre-GFP viral transduction
(Vector Biolabs, Philadelphia, PA) at multiplicity of infection (MOI) of 15. Adeno-CreGFP virus was suspended in Opti-MEM for a total of 0.6 ml per plate. Regular growth
media (DMEM + 10% FBS + 1% P/S) was aspirated and diluted Ad-Cre virus (MOI 15)
in 0.1 ml serum-free medium per well was added. The transduction reaction was
incubated for 90 minutes in a 37°C + 5 % CO2 incubator with occasional rocking (every
20 to 30 min). At completion of the incubation 2ml DMEM media with 2.0 % serum was
added. Cell lysates were collected at designated time points (12h, 24h, 36h, 48h and 72h).
Lysates were analyzed by Western blotting
Flow Cytometry: Single-cell suspensions of RK13 cells were generated by incubating the
cells in PBS/4 mM EDTA at 37 °C for 15 min. Cells were washed in FACS buffer (PBS,
2 % heat-inactivated FBS), incubated for 10 min on ice in 100 µl primary antibody diluted
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in FACS buffer (SAF-32 anti-PrP; 4 µg ml−1, Cayman Chemical, Cat. No. 189720, Ann
Arbor, MI), washed in FACS buffer, incubated for 10 min on ice in 100 µl FITCconjugated secondary antibody diluted in FACS buffer (anti-mouse–FITC at 1: 200) and
washed in FACS buffer; twenty µl propidium iodide (50 µg /ml) was added before
analysis.
Representational Difference Analysis (RDA): mRNA isolation out of the RK13-MoPrP
cells was accomplished using the Invitrogen Dynabeads mRNA Direct Kit. The basis of
this kit is to simplify purification of total mRNA using oligo(dT)25 residues that have
been covalently coupled to the surface of Dynabeads. The Dynabeads are uniform, super
paramagnetic beads, stable in the pH range of 4-13. Physical characteristics of beads are
as follows; diameter 2.8 µm ± 0.2 µm (C.V. max 5%); Surface area: 3-7 m2/g; Density:
Approx. 1.6 g/cm3 ; Magnetic mass susceptibility: 120±25×10-6m3/kg. RK13-MoPrP
cells grown to 90% confluence in 10-cm cell culture dishes were washed three times with
5.0 ml of cold (4°C) phosphate-buffered saline (PBS, Gibco). Upon the completion of
washing the cells, 1.0 ml of Trypsin EDTA (Gibco) was added and placed for 5 min in
37°C + 5.0% CO2 incubator to allow cells to detach from the surface. Detached cells
were gently resuspended in PBS and pelleted in 4°C, 250xg refrigerated centrifuge for 5
min. The supernatant was decanted and the cell pellet was gently resuspended in 5.0 ml
of PBS. The cell pellet is resuspended in 1.25 ml of Lysis/Binding buffer (100mM TrisHCl (pH 7.5), 500 mM LiCl, 10 mM EDTA (pH 8.0), 1 % LiDS, 5 mM dithiothritol
(DTT)) and pipetted several times to obtain full resuspension. Cellular DNA was sheared
by passing lysate 3-5x through a 21-gauge needle in 2.0 ml syringe on ice. Dynabeads
Oligo(dT)25 was thoroughly resuspended and 250 µl was transferred to 1.5 ml RNase
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free microcentrifuge tube. The tubes were placed onto a DynaMag magnet for 30 sec
until the Dynabead suspension was clear. The beads were washed in an equal volume of
lysis/binding buffer and removed using the magnet. Cell lysate was added to the prepared
Dynabeads, completely resuspended and incubated with continuous mixing for 5 min at
room temperature. The lysate/bead mixture was placed on the magnet and incubated for 2
min, until the solution became clear. The supernatant was removed and the beads are
washed twice with 1.5 ml Washing Buffer A (10 mM Tris-HCl (pH 7.5), 0.15 M LiCl, 1
mM EDTA, 0.1 % LiDS) at room temperature. The magnet was used in between steps to
separate phases. The beads were washed twice with 1.5 ml Wash Buffer B(10 mM TrisHCl (pH 7.5), 0.15 M LiCl, 1 mM EDTA). Finally, the beads were washed once in 5x
First-strand Reaction Buffer (Invitrogen, cat #11917-010).
RDA Double-Stranded cDNA Synthesis: Double stranded cDNA for the RDA was
synthesized using the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen, Cat
no.# 11917-010). Bead-primed mRNA and 9 µl of DEPC-treated H2O was heated to 70°
C for 10 min and quickly chilled on ice. The samples were briefly centrifuged and 4 µl of
5X First-strand reaction Buffer, 2ul 0.1M DTT and 1ul 10mM dNTP mix were added.
Samples were briefly vortexed and centrifuged. The tubes were placed at 45°C for two
min. Three µl of Superscript II Reverse transcriptase was added, mixed and incubated at
45°C for 1 h. The reaction was stopped by transfer to ice. Second strand cDNA synthesis
was completed by adding 91µl DEPC-H2O, 30 µl 5X second-strand reaction buffer, 3 µl
10mM dNTP mix, 1 µl E.coli DNA ligase (10U/µl), 4 µl E.coli DNA Polymerase I (10U/
µl), and 1 µl E.coli RNase H (2U/ µl) in the respective order. This was mixed and
incubated for 2h at 16°C. Two µl (10 units) of T4 DNA Polymerase were added,
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followed by further incubation for 5 min. The tubes were placed on ice and 10 µl of 0.5
M EDTA was added. Samples were cleaned and purified by addition of 160 µl phenol:
chloroform: isoamyl alcohol (25:24:1), and centrifuged at room temperature for 5 min at
14,000 x g. One hundred and forty µl of the top aqueous phase was placed into a new 1.5
ml tube. Seventy µl of 7.5 M NH4OAc was added followed by 0.5 ml of ice-cold
absolute ethanol. The samples were mixed and centrifuged for 20 min at 14,000 x g at
room temperature. The supernatant was removed and the pellet was washed in 0.5 ml of
ice-cold 70 % ethanol and centrifuged for 2 min at 14,000 x g at room temperature. The
cDNA pellet was dried at 37°C for 10 min and resuspended in DEPC-H2O.
Representational Difference Analysis (RDA): The RDA described in these methods is
adapted from the following (Lisitsyn Iu 1992; Lisitsyn, Rosenberg et al. 1993; Lisitsyn,
Leach et al. 1994). All procedures utilize RNase/DNase free water. Primers were
synthesized by Integrated DNA Technologies Inc. The primers were de-salted and HPLC
purified. All primers were resuspended in water at 62pmol/ µl concentration.
RDA Primers:
Representation:
24-mer: R-Bgl24 – 5’-AGCACTCTCCAGCCTCTCACCGCA-3’
12-mer: R-Bgl12 – 5’- GATCTGCGGTGA-3’
Odd cycle:
24-mer: O-Bgl24 – 5’-ACCGACGTCGACTATCCATGAACA-3’
12-mer: O-Bgl12 – 5’-GATCTGTTCATG-3’
Even cycle:
24-mer: E-Bgl24 – 5’-AGGCAACTGTGCTATCCGAGGGAA-3’
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12-mer: E-Bgl12 – 5’-GATCTTCCCTCG-3’
Preparation of amplicons and representation: Tester and driver double-stranded (ds)
cDNA (5 µg) synthesized from RK13 sensitive and resistant cells, clone 7 and clone 78
respectively, were digested using 10 U DpnII restriction enzyme per microgram of ds
cDNA (New England Biolabs (NEB)) in a total volume of 400 µl per reaction. The
digested tester and driver samples were extracted and purified using 1 volume of phenol
(400 µl) followed by 1 volume of phenol: chloroform: isoamyl alcohol (400 µl). Ethanol
precipitation was performed using 1/10 volume 3M Sodium Acetate (pH 5.2), 2.5 volume
100% ice-cold ethanol, and 20 µg glycogen and centrifuged at 4°C for 20 min. The pellet
was washed once with 70% ethanol and air dried. The pellet was suspended was done
using TE buffer (10mM Tris-Cl, pH 8.0, 1mM EDTA, pH 8.0) at a concentration of 0.1
µg/µl.
Ligation Of Adapters Onto Tester And Driver ds-cDNA: In 30 µl volume, a mixture of 2
µl H2O, 3 µl 10x Ligase buffer (NEB), 7.5 µl 12-mer R-primer, 7.5 µl 24-mer R-primer,
and 10 µl (1µg) ds-cDNA tester/driver digest was established in a PCR tube. The tubes
were placed in a thermo cycler at 55°C with gradual temperature decrease to 4°C over 1
h. One µl of 400 U/ µl T4 DNA ligase (NEB) was added, gently mixed and incubated for
16 hours at 14°C. Samples were then transferred to 1.5ml DNase/RNase free microfuge
tubes and resuspended with 970ul of TE buffer (1 ng/µl ds-cDNA).
PCR-Amplification Of Driver And Tester Amplicons: A master mix was set up based on
the following PCR reaction; 280 µl water, 40 µl 10x Taq Polymerase buffer (NEB), 32 µl
dNTP chase solution (4 mM (each) dGTP, dATP, dTTP, dCTP), 8 µl 24-mer R-primer.
Generally, two tester and twelve driver reactions were established. Forty µl of adapter
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ligated DNA was added per reaction. The mix was held at 72°C in a thermal cycler for
two min. Three µl of 5 U/µl Taq DNA polymerase was added to each reaction prior to
thermo cycling initiation. PCR parameters were as follows; step 1: 5 min incubation at
72°C, step 2: 20 cycles of 1 min denaturation at 95°C followed by 3 min extension at
72°C, and step 3: final step of 10 minute extension at 72°C. Upon completion, all
samples were combined respectively and extracted as previously described. Amplicons
are precipitated using 1 volume of isopropanol with 20 µg glycogen followed by two
70% ethanol washes. Driver and tester amplicons were resuspended in TE buffer at 0.2
to 0.4 µg/µl concentration.
Linker Removal: One hundred and fifty µg of driver and 15 µg of tester DNA was
digested using 10 U Bgl (NEB) restriction endonuclease in a 400 µl total volume. The
samples was extracted and purified using ethanol as previously described and
resuspended in 125 µl TE buffer. Concentration was measured in comparison with
lambda DNA (NEB) standards on a 2% agarose gel.

Adapter Change On Tester Amplicons: Five µg of tester amplicon was loaded on a 1%
agarose gel and electrophoresed to separate DNA in the range from 150 base pair (bp) to
1500bp. Within the described range using a clean and sterile razor blade, two full slits
were made in the gel and a 24-mm GF/C glass microfiber filter and a 6,000- to 8,000MWCO dialysis tubing are inserted using blunt ended forceps. Electrophoresis was
resumed until the DNA had migrated past the filter/dialysis inserts. A collection
apparatus was setup by puncturing a hole in the bottom of a 0.5 ml PCR tube with an 18gage needle and placed into a 1.5 ml microfuge tube. The filter/dialysis samples were
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placed into the apparatus and spun at 8,000 rpm at room temperature for 5 min. The PCR
tubes with filter/dialysis were discarded and the samples were resuspended in 400 µl
water. The amplicons were extracted and purified, dissolved in 30 µl TE buffer, and the
concentration was determined. One µg of tester amplicon DNA was ligated with the Oprimer set following the same protocol as described above. Upon extraction and clean up,
the pellet was resuspended at 10 ng/µl concentration in TE.
Subtractive/kinetic enrichment:
Tester: Driver ratio
Round 1: 1:50, Round 2: 1:500, Round 3: 1:1000
Eighty µl driver amplicon digest (0.5 µg/µl) and 80 µl tester amplicon digest (10 µg/µl)
DNA were combined and mixed. Followed by extraction with 160 µl phenol: chloroform:
isoamyl alcohol. Ethanol precipitation with ammonium acetate; 30 µl of 10 M
ammonium acetate, 300 µl ice-cold 100% ethanol, 1 µl glycogen (20µg), for 10 min,
centrifuged at 13,000 rpm for 20 min. The pellet was washed with 1.0 ml 70% ethanol
and air dried. Four µl of 3 X EE hybridization buffer (30 mM 4-(2-hydroxethyl)-1piperazinepropanesulfonic acid (EPPS). pH 8.0, 3 mM EDTA) was added to pellet,
resuspended and incubated at 37°C for 5 min, followed by 2 min of vortexing and a short
centrifugation at maximum speed to collect sample. In a PCR tube, the resuspended
samples were mixed with 1 µl of 5 M NaCl (preheated to 95°C). The mixture was
incubated for 1 min at 95°C and centrifuged, followed by the addition of 35 µl mineral oil
to overlay the samples. The tubes were incubated for an additional 4 min at 95°C for,
followed by a 30 h incubation at 67°C to hybridize complementary strands.
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Selective Amplification: Mineral oil was removed and the samples were gradually
diluted to 0.1µg/ µl through the sequential addition of 8 µl of 5 µg/ µl glycogen in TE, 23
µl TE, and 364 µl TE mixing and vortexing between each step. The adapter ends were
filled in by mixing 275 µl water, 40 µl 10x PCR buffer (NEB) and 32 µl dNTP chase
solution with 40 µl of diluted hybridized DNA and incubated at 72°C. Three µl of Taq
DNA polymerase (NEB) was added with an additional 5 min incubation at 72°C. Ten µl
of 24-mer O-primers was added and the complete mixture was amplified using the
following parameters; step 1: 10 cycles of 1 min denaturation at 95°C followed by 3 min
extension at 72°C, step 2; final extension at 72°C for 10 min. The samples were
extracted, and isopropanol precipitated, and the pellet was dissolved in 40 µl water.
Single stranded templates were digested using Mung bean nuclease (MBN, NEB); 14 µl
water, 4 µl 10x MBN buffer, 20 µl amplified difference product and 2 µl 10 U/ µl Mung
bean nuclease were mixed and incubated at 30°C for 30 min. One hundred and sixty µl of
50 mM Tris-Cl, pH 8.9 was added to each sample and incubated at 98°C for 5 min to
inactivate the MBN. A PCR mixture as described in the initial tester/driver amplification
step was set up using the 24-mer O-primer and 40 µl of MBN treated difference product.
The addition of Taq polymerase and thermal cycling steps are as described in the initial
PCR setup.
Adapter Change On The Difference Product:

PCR samples were extracted and

isopropanol precipitated. Pellets were dissolved in 80 µl TE and the concentration
determined. Five µg of difference product was digested using BglII restriction
endonuclease in 200 µl total volume. Samples were brought to 400 µl total volume,
phenol/chloroform extracted and ethanol precipitated. The DNA pellet was resuspended

	
  

85	
  

at 0.1 µg/µl in TE. One µg of DNA solution was ligated to E-primer set in a 30 µl
volume. The ligated product was diluted to 1.25 ng/µl in TE.
Subsequent Subtraction/Kinetic Enrichment: The difference products were enriched in
subsequent subtraction rounds following the described protocol with a change in ratio of
tester: driver concentrations.
Cloning RDA Products And Sequencing: Following 3 rounds of RDA enrichment, the
difference product was run out on a 1% agarose gel. Observed bands were excised and
purified with the Promega Wizard SV gel and PCR clean up system kit (Catalog #
A9280). Excised bands were dissolved in membrane binding solution (4.5 M guanidine
isothiocyanate, 0.5 M potassium acetate (pH 5.0) and incubated at 65°C for 10 min.
Dissolved samples were transferred to the SV Minicolumn, held for 1 min prior to
centrifugation at 16,000 x g. The columns were washed with Membrane Wash Solution
(10 mM potassium acetate (pH 5.0), 80% ethanol, 16.7 µM EDTA (pH 8.0)) twice.
Samples were eluted from the columns with nuclease free water and collected in a 1.5 ml
microcentrifuge tubes. Eluted RDA difference product was ligated into the pGEM-T
vector (Promega, Madison, WI). Ligation was setup accordingly; 5 µl 2x Rapid Ligation
Buffer, T4 DNA ligase, 1 µl pGEM-T vector (50 ng), 2 µl RDA product, 1 µl T4 DNA
Ligase and 1 µl water. The mixture was incubated at room temperature for 1 h.
Transformation Of pGEM-T Ligated Difference Product: Two µl of ligated product
was added to 50 µl of competent XL10 bacterial cells, on ice. The cells were kept on ice
for 30 min. Heat shock was done at 42°C for 45 sec and immediately transferred to ice
for an additional 2 min. Two hundred and fifty µl of LB (10g Tryptone, 5g Yeast extract,
10g NaCl for 1 liter production) was added to each transformation tube and incubated for
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1 h shaking at 37°C. One hundred µl of transformed product was spread on to
LB/ampicillin (100µg/ml) agar plates and incubated overnight at 37°C. Colonies were
individually picked and grown in 3ml LB/ampicillin (100ug/ml) medium. Each identified
and expanded clone was subsequently purified by alkaline lysis plasmid isolation and
silica column purification using the Qiagen plasmid mini prep kit (cat.no. 19064).
DNA Sequencing Of Cloned RDA Plasmids: Purified clones were sequenced using the
Beckman Coulter Ceq 8000 DNA Sequencer and The GenomeLab™ DTCS Quick Start
Kit (cat.no. 608120). Sequencing reactions were setup as follows; 9 µl dH2O, 1 µl
pGEM-T-RDA product plasmid were mixed in 0.2 ml thin wall tubes and incubated in
96°C for 1 min. Samples were collected by quick centrifugation, chilled on ice and 2 µl
of T7 forward primer (1.6 µM) and 8 µl DTCS Quick Start Master mix were added.
Thermal cycling conditions were as follows; 30 cycles of: 96°C for 20 sec, 50°C for 20
sec and 60°C for 4 min; samples were held at 4°C. For ethanol precipitation; 5 µl of stop
solution is applied to each sample (2 µl 3M Sodium Acetate (pH 5.2), 2 µl 100 mM Na2EDTA (pH 8.0) 1 µl glycogen (20 mg/ml). Sixty µl of cold 95% ethanol was added and
immediately spun at 14,000 rpm at 4°C for 15 min. Pellets were washed twice with 200
µl 70% ethanol followed by 5 min centrifugation at 14,000 rpm at 4°C. Pellets were air
dried and resuspended in 40 µl Sample Loading Solution (DTCS kit). Resuspended
samples were loaded on to sequencing 96-well plate (P/N 609801) and placed into the
Beckman Coulter Ceq 8000 DNA Sequencer. Consumables placed into the sequencer
were;
- GenomeLab DNA Separation Capillary Array 33cm x 75um (P/N 608087)
- GenomeLab Separation Gel LPA-1 (P/N 609010 10mL for CEQ 8000; P/N
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391438 20 ml for CEQ 8800)
- GenomeLab Sequencing Separation Buffer (P/N 608012)
- Sample Microtiter Plates (P/N 609801)
- 96 Well Plates for sequencing buffer (P/N 609844)
Sequenced data were analyzed using CEQ8000 Genetic Analysis System software, and
nucleotide blasted against all known sequences in the National Center for Biotechnology
Information Data Base (NCBI).
Microarray Studies:
The format of the microarray chip is designated as a 4x44K system, which essentially
contains four distinct arrays on a single chip with 43,803 rabbit probes represented per
array (http://www.genomics.agilent.com). To reduce technical variance, all of the RNA
samples were treated, reverse transcribed, Cy-3 labeled and hybridized simultaneously.
The data acquisition and feature extraction was performed using the Agilent’s microarray
scanner and software.
RNA Isolation: RNA was isolated using the Qiagen RNeasy mini kit (cat. No. 74124).
Six RK13-DeerPrP (RKD) sensitive and six resistant clones were grown to 90%
confluence on a 10cm cell culture plates. Cells were washed twice with PBS and
trypsinized to detach them from the plates. The cells were resuspended in 9 ml of PBS
and pelleted at 300 x g for 5 min at 4°C. The pellets were washed twice more with PBS.
Pellets were then dissolved and lysed with RLT buffer (RNeasy kit). The lysates were
passed through a blunt 20-gauge needle 5 times. One volume of 70% ethanol was added
and mixed by pipetting. Samples were then transferred to the RNeasy spin column and
centrifuged at 14,000 rpm for 30 sec. Seven hundred µl of RW1 buffer was added to each
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column and centrifuged. The columns were then washed twice with 500 µl of RPE buffer
and centrifuged once for 15 sec and the second time for 2 min at 14,000 rpm. The RNA
was eluted with 50 µl RNase-free water and by placing the columns into new nuclease
free 1.5 ml microcentrifuge tubes.
Total RNA Integrity Analysis: The integrity of the isolated RNA was measured using the
Agilent’s 2100 Bioanalyzer (p/n G2938A) and the RNA 6000 Nano Assay Kit (p/n 50671511). Parts required and used in this experiment were: Chip priming station (p/n 50654401), 16-pin bayonet electrode cartridge (p/n 5065-4413) and the IKA- Vortex mixer
(model MS2-S8). RNA was quantified using the NanoDrop ND-1000 UV-VIS
Spectrophotometer (Thermo Scientific).

One-Color (Cy3) Labeling RNA: Agilent one-color spike in master mix (p/n 5188-5282)
was

developed

based

on

Agilent’s

protocol

(http://www.chem.agilent.com/Library/usermanuals/Public/5188-5977.pdf), two hundred
ng of total RNA (1.5 µl) was used in the labeling reaction. Two µl of diluted Spike in mix
was added. Low input quick amp labeling kit, one color (p/n 5190-2305) was used. T7
primer (1.8 µl) was added and denatured at 65°C for 10 min followed by a 5 min
incubation on ice. cDNA master mix ((4.7 µl) 2 µl 5x First Strand buffer, 1 µl 0.1 M
DTT, 0.5 µl 10 mM dNTP mix, 1.2 µl Affinity Script RNase Block Mix) was added per
reaction and incubated at 40°C for 2 h followed by 15 min incubation at 70°C. Samples
were transferred and held on ice. Six µl of transcription mix (0.75 µl water, 3.2 µl 5X
transcription buffer, 0.6 µl 0.1 M DTT, 1 µl NTP mix, 0.21 µl T7 RNA Polymerase
blend, 0.24 µl Cyanine 3-CTP) was added per reaction and incubated at 40°C for 2 h. The
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labeled cRNA was purified using Qiagen RNeasy mini spin columns. Eighty-four µl
nuclease free water was added to each reaction, 350 µl of Buffer RLT (cat. no. 79216)
was added and mixed followed by 25 µl 100% ethanol. The total volume was transferred
to the RNeasy spin column and centrifuged at 13,000 rpm for 30 sec at 4°C. The columns
were washed twice with 500 µl buffer RPE (cat. No. 1018013). The cRNA was eluted
with 30 µl nuclease free water. cRNA quantification was performed using the microarray
measurement tab within the NanoDrop ND-1000 UV-VIS Spectrophotometer. The
following measurements were recorded: Cyanine 3 dye concentration (pmol/µl), RNA
absorbance (260nm/280nm), cRNA concentration (ng/µl). cRNA yield (µg) was
determined as follows: ((concentration of cRNA) x 30 µl (elution volume))/1000
Cyanine 3 incorporation was calculated: ((concentration of Cy3)/(concentration of
cRNA))x 1000 = pmol Cy3 per µg cRNA.
Hybridization: Agilent’s Gene Expression Hybridization Kit (p/n 5188-5242) was used.
Blocking agent (10x) (p/n 5188-5281) was prepared by the addition of 500 µl nuclease
free water and mixing. Fragmentation mix was prepared in a 55 µl total volume; 1.65 µg
Cy3 labeled cRNA, 11 µl 10X blocking agent, 2.2 µl 25X fragmentation buffer, nuclease
free water brought to 52.8 µl. Samples were incubated at 60°C for 30 min and cooled on
ice for one min. The fragmentation reaction was stopped with the addition of 55ul 2X
GEx Hybridization Buffer HI-RPM and mixing, being careful not to introduce bubbles
into the solution. Samples were centrifuged for one min at room temperature 13,000 rpm.
100 µl of hybridization sample was applied to the loaded Agilent SureHyb chamber
assembly (cat.No. G2534A)/gasket (p/n G2534-60011) and gently placed with the Rabbit
Gene Expression Microarray, 4x44K array (cat. No. G2519F-020908). The complete
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hybridization assembly was placed into the hybridization rotator (p/n G2530-60029) and
transferred to the hybridization oven (p/n G2545A) set to 65°C. The hybridization was
set up to run for 17 hours. The arrays were washed with GE Wash Buffer 1 for one min
at room temperature, and a second wash with pre-warmed (37°C) GE Wash Buffer 2 for
one min (Gene Expression Wash Buffer Kit p/n 5188-5327). Each slide was scanned
using the Agilent Microarray Scanner (p/n G2565BA). Agilent Feature Extraction (FE)
Software was used to extract scanned data from each chip.
Microarray Data Analysis:
JMP Genomics Software: JMP Genomics was utilized for manipulation of extracted raw
microarray data, statistical analysis, and hierarchical data clustering to ascertain gene
significance of microarray data. Total overview of this software can be found at:
http://www.jmp.com/software/genomics/index.shtml
The Database for Annotation, Visualization and Integrated Discovery (DAVID):
National Institute of Allergy and Infectious Disease (NIAID) bioinformatic database used
for functional enrichment of identified genes. This database was used to identify
biological themes and processes by uploading the microarray gene lists deemed
statistically significant by the t-test, p-value of 0.05, and a fold cutoff set to 1.5.
DAVID website address: http://david.abcc.ncifcrf.gov
Protein Analysis Through Evolutionary Relationships (PANTHER): Gene Ontology
Reference Genome Project - http://www.pantherdb.org/ PANTHER classification
database is supported by the National Institute of General Medical Sciences and
maintained by the Thomas lab at the University of Southern California. The database
provides functional comparison and classification of up loaded genes using published
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scientific experimental evidence and evolutionary relationships to predict function in the
absence of direct experimental evidence. Classifications are based according to:
Additional Bioinformatic Websites and Databases Used For Data Analysis:
Literature Search: PubMed - http://www.ncbi.nlm.nih.gov/pubmed
Image Analysis: ImageJ - http://rsb.info.nih.gov/ij/index.html
Gene Sequence Identity, Homology, Protein Sequence Analysis, Secondary Structure
Prediction and Subcellular Localization:
ENTREZ Cross-Database Search - http://www.ncbi.nlm.nih.gov/sites/gquery
NCBI BLAST- http://blast.ncbi.nlm.nih.gov/Blast.cgi
ENSEMBL Genome Browser - http://uswest.ensembl.org/index.html
GeneCards Database - http://www.genecards.org
Universal Protein Resource (UniProt) - http://www.uniprot.org
Protein Data Bank (PDB) - http://www.pdb.org/pdb/home/home.do
SIB Bioinformatics Resource Portal (ExPASy) - http://expasy.org
- YASPIN (Hidden Neural Network) secondary structure prediction
- http://www.ibi.vu.nl/programs/yaspinwww
Center For Biological Sequence Analysis (CBS) - http://www.cbs.dtu.dk/services
TargetP (predicts the subcellular location of eukaryotic proteins)
ProtFun (Prediction of cellular role, enzyme class and Gene Ontology category)
MiniMotif Miner - http://mnm.engr.uconn.edu/MNM/SMSSearchServlet
Protein Structure Classification - http://www.cathdb.info
Copyright © Vadim Khaychuk 2012
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Chapter 3
Characterization of Prion Strains in Cell Culture Systems

Introduction
The molecular characterization of prion strain properties challenging. It is the
proteinaceous nature of prions that distinguishes them from viruses, bacteria and other
known disease causing agents. This “protein only” molecular composition of prions
utilizes atypical methods to replicate that differ from the standard dogma of molecular
biology (Fig. 1.3). The absence of nucleic acids is central to the prion strain classification
challenge. Evidence suggests that prion strain diversity relies on conformational
differences PrPSc can acquire (Chapter 1, Section I) (Telling, Parchi et al. 1996;
Wadsworth, Hill et al. 1999). In addition to these conformational differences, the
structural homology between PrPC and PrPSc is also a crucial determinant of replication,
which underlies the fundamental concept of the prion species barrier (Fig. 3.1) (Scott,
Groth et al. 1993; Telling, Scott et al. 1994; Collinge, Palmer et al. 1995; Telling, Scott et
al. 1995). It is the combination of these findings that dictates the conformational selection
hypothesis for prion strain selection and diversity (Collinge 1999; Collinge and Clarke
2007).
Prion Species Barrier: The parameters controlling interspecies prion transmission is not
completely understood. The prion species barrier is influenced by the host’s PrPC primary
structure homology to the PrPSc infectious agent (Fig. 3.1A-B) (Scott, Foster et al. 1989;
Telling, Scott et al. 1995). The prion species barrier may not be absolute, since partial
interspecies transmission have been demonstrated in experimental animals, subsequently
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leading to total barrier abrogation upon serial transmission (Scott, Foster et al. 1989;
Bessen and Marsh 1992; Bruce, Will et al. 1997; Baron, Bencsik et al. 2007; Agrimi,
Nonno et al. 2008; Sandberg, Al-Doujaily et al. 2010). The transmission of BSE to
humans in the form of vCJD is another example of a partial species barrier (Bruce, Will
et al. 1997; Collinge 1999; Scott, Will et al. 1999). Understanding the molecular
determinants of prion species barriers, and factors that regulate interspecies transmission
are crucial for disease prevention in humans and other animals.
PrPC Interference Effect: The interference of endogenously expressed mouse PrPC to
production of human PrPSc in Tg(HuPrP)FVB mice co-expressing mouse and human PrP
was discovered during transmission of human prions to these mice (Fig. 3.1C) (Telling,
Scott et al. 1995). Earlier studies using Tg mice co-expressing hamster and mouse PrPC
did not exhibit similar interfering effects, since there mice inoculated with hamster prions
succumbed to disease (Scott, Foster et al. 1989). Although the differences in
susceptibility for heterologous prions between these studies remains to be fully explained,
it is hypothesized that primary structure homology between mouse in hamster PrPC is
closer than that of mouse in human PrPC.
Heterologous PrPSc In Cell Culture: Methods used to characterize strains include
incubation time in animals, clinical signs at the onset of disease, and neuropathological
profiling of PrPSc (Bruce and Dickinson 1979; Bruce, McBride et al. 1989).
Biochemically, strains maybe characterized by analyzing their glycoform ratios of PrPSc,
protease sensitivity of PrPSc, migration of PrPSc in SDS-PAGE, and conformational
stability of PrPSc following treatment with denaturing agents.
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Current methods used for CWD prion analysis consists of bioassays and/or in
vitro PMCA conversion assays (Green, Castilla et al. 2008). Developing robust cellculture models will provide additional insights into CWD prions at the cellular level. The
studies described in this chapter aim to characterize and enhance in vitro cell culture
models for prion strain analysis. Upon prion challenge, we attempt to isolate cells with
capability to chronically sustain CWD. The prion strains used for these analyses are
designated in table 3.1. The cells that were utilized include the rabbit kidney epithelial
cells (RK13), mouse Neuroblastoma N2a cells and the human embryonic kidney 293
cells. Besides identifying cells capable of interspecies prion replication, these cell culture
model studies recapitulated the prion species barrier and PrPC interference effects
previously demonstrated using transgenic animal models (Scott, Groth et al. 1993;
Telling, Scott et al. 1995).
The neuroblastoma (N2a) cell line replicates experimentally adapted RML
mouse-scrapie prions (Race, Fadness et al. 1987; Butler, Scott et al. 1988). Detailed
characterization revealed that a subset of cells within the total culture efficiently replicate
prions (<2%) (Race, Fadness et al. 1987; Race, Caughey et al. 1988; Bosque and Prusiner
2000). Clonal selection of N2a cells sensitive to prion replication enhanced PrPSc
production by 80-90% (Race, Caughey et al. 1988). Through clonal selection and
transgenesis of the N2a cells, we aimed to create cells that are sensitive towards natural
prion isolates.
RK13 cells do not express endogenous rabbit PrPC, therefore making them the in
vitro cell culture model analogous to the well-established PrPC knock out (Prnp0/0) mouse
(Büeler, Fischer et al. 1992; Büeler, Aguzzi et al. 1993). The absence of endogenous PrPC
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in these cells can be applied towards genetic modulation and infectivity analyses using
heterologous PrP’s. The replication of naturally derived prion isolates without adaptation
in mice was achieved using the RK13 cells (Vilette, Andreoletti et al. 2001). Genetic
modulation of the RK13 cells to express ovine PrPC resulted in chronic propagation of
scrapie directly derived from sheep (Vilette, Andreoletti et al. 2001).
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Figure 3.1 The prion species barrier and PrP interference. (A) Inoculation of wild
type FVB mice with human prions does not cause disease, demonstrating a prion species
barrier between mouse and human. (B) Expression of human PrP (HuPrP) on a Prnp0/0
background, replicates the heterologous human prions and recapitulates disease. Thus,
expression of human PrP in Tg mice abrogates the species barrier between the two
species. (C) Co-expression of human and mouse PrP does not facilitate human prion
replication, demonstrating interference by the endogenously expressed mouse PrPC.
(Telling, Scott et al. 1995)
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Figure 3.1 The prion species barrier and PrP interference.
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RESULTS
Section I: Prion Species Barriers, Interference and the Attempt to Propagate
Chronic Wasting Disease (CWD) in Cell Culture

N2a Cells Recapitulate The Prion Species Barrier And Demonstrate The PrP
Interference Effect
N2a cells were single-cell cloned using limited dilution. Individual clones were
infected with mouse-adapted RML scrapie prions and PrPSc accumulation was assessed
(Chapter 4, Fig. 4.2B). N2a sub-clone #2 exhibited high sensitivity for RML replication.
The uninfected counterpart of this clone was selected for the subsequent transfection with
deer and elk PrPC.

Transfection of the eukaryotic expression vector (pIRESpuro)

genetically engineered to express elk or mule deer PrPC resulted in stable expression of
these proteins in the N2a clone (Fig. 3.2). Expression of cervid specific PrPC was
determined using the 9E9 monoclonal antibody (mAb). The 9E9 mAb was developed and
epitope mapped within our lab (unpublished, Telling lab). Figure 3.2 exhibits 9E9 mAb
specific recognition of elk and mule deer PrPC but not the endogenously expressed mouse
PrPC in the un-transfected N2a sub-clone #2. Actin expression is used as a control for
total protein (Fig. 3.2).
To determine N2a cell susceptibility to CWD, we infected elk and deer expressing
cells with CWD isolates (Table 3.1). Each isolate used in the study was bioassayed and
sub-passaged in transgenic mice expressing cervid PrPC (Tg(deerPrP)1536+/- and
Tg(elkPrP)5037+/-) (Fig. 3.3). The cell-lift assay was used to rapidly detect production of
PrPSc. This assay is ~150-fold more sensitive for identifying prion infected cells than
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standard cell lysate analysis by western immuno blotting (Bosque and Prusiner 2000).
Figures 3.3A-F represents scanned x-ray film images obtained from the cell-lifting assay.
The positive and negative controls for the experiments are shown in figures 3.3C
and 3.3F. N2a cells were either mock infected with PBS (negative control) or infected
with RML prions (positive control). N2a cells co-expressing elk or deer PrPC were also
infected with RML. The sharp dark signal exhibited by the RML infected cells (positive
controls) depicts the normal signal intensity of PrPSc replicating cells (Fig. 3.3C and
3.3F). The mock-infected negative controls demonstrated complete absence of PK
positive material, confirming the uncontaminated purity of the parental N2a cell line (Fig.
3.3 C, F). RML infected cells showed robust production of PrPSc, confirming the highly
sensitive phenotype of the parental sub-clone. Of interest, co-expression of cervid PrPC
did not alter the sensitivity to RML prion replication (Fig. 3.3 C, F).
The heightened sensitivity of these cells for RML prions indicates that the cellular
machinery for replication are present and operational. We therefore hypothesized that
these cofactors would facilitate CWD replication in the cervid PrPC over-expressing cells.
N2a cells expressing mule deer (N2aD-PrP) or elk PrPC (N2aE-PrP) were infected with
0.2% (w/v) CWD brain homogenates obtained from Tg(deerPrP)1536+/- (Fig. 3.3A and
3.3D) or Tg(elkPrP)5037+/- (Fig. 3.3B and 3.3F) infected mice (Table 3.1). N2aD-PrP
cells failed to replicate CWD prions (Table 3.1). The lack of PK resistant PrPSc, as
analyzed by the cell-lifting assay, confirmed these findings (Fig. 3.3A-B). N2aE-PrP cells
also exhibited resistance towards CWD prions. These cells did not demonstrate PrPSc
conversion after CWD infection with isolates passaged in Tg(deerPrP)1536+/- mice (Fig.
3.3D). Select CWD isolates derived from Tg(elkPrP)5037+/- mice showed a weakly
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positive PrPSc signal in N2aE-PrP cells (Fig. 3.3E). These CWD isolates include 73784,
CWD pool, 012-09442, and 012-02212, which were originally derived from diseased elk
(Table 3.1). The PrPSc positive N2aE-PrP cells were expanded for further analysis. Total
cell lysates were processed for western blotting. The results revealed no detectable PrPSc
after PK digestion within the expanded cell populations (Fig. 3.3G). N2aE-PrP cells
demonstrate CWD resistance similar to N2aD-PrP. We conclude that N2aE-PrP and
N2aD-PrP cells are resistant to CWD infection and that clonal selection was not
sufficient to render N2a cells susceptible to CWD (Fig. 3.3). The data gathered using
these cells recapitulate the originally described in vivo observations that demonstrate the
prion species barrier using transgenic mice (Telling, Scott et al. 1995). Similar to mice,
the murine cell line readily replicates mouse-adapted prions, irrespective of the presence
of over-expressed heterologous PrPC protein. Conversely, over-expression of the
heterologous PrPC is not sufficient to replicate prions that are homologous to that species.
Our data indicate that the endogenous mouse PrPC hinders the replication of heterologous
CWD prions by CerPrPC.
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Figure 3.2 Stable expression of cervid PrPC in N2a cells. N2a cells were transfected
with pIRESpuro-elk PrPC/-mule deer PrPC using lipid-based methods. Transfected cells
were grown in selection media and assessed for cervid PrPC expression by western
blotting. The cervid specific 9E9 mAb (Telling et al., unpublished) was used to detect
cervid PrPC. Actin expression is used for total protein control (Pan-Actin mAb-5, Lab
Vision Corporation, Fremont, CA).
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Figure 3.2 Stable expression of cervid PrPC in N2a cells.
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Table 3.1 Prion strains used for cell culture infectivity analysis.
Prion Strain
Origin
Host Species Adapted
Source
Chronic Wasting Disease (CWD)
D10
Colorado
Mule
Tg(deerPrP)1536+/- & Tg(elkPrP)5037+/deer
mice
D92
Colorado
Mule
Tg(deerPrP)1536+/- & Tg(elkPrP)5037+/deer
mice
73784-7
Wyoming Elk
Tg(deerPrP)1536+/- & Tg(elkPrP)5037+/mice
CWD Pool
Colorado
Mule
Tg(deerPrP)1536+/- & Tg(elkPrP)5037+/Deer
mice
012-09442
Colorado
Elk
Tg(deerPrP)1536+/- & Tg(elkPrP)5037+/mice
BALA-01
Canada
Elk
Tg(deerPrP)1536+/- & Tg(elkPrP)5037+/mice
001-403022
Colorado
Elk
Tg(deerPrP)1536+/- & Tg(elkPrP)5037+/mice
BALA-04
Canada
Elk
Tg(deerPrP)1536+/- & Tg(elkPrP)5037+/mice
001-44720
Colorado
Elk
Tg(deerPrP)1536+/- & Tg(elkPrP)5037+/mice
012-02212
Colorado
Elk
Tg(deerPrP)1536+/- & Tg(elkPrP)5037+/mice
Hamster-Adapted Transmissible Mink Encephalopathy (TME)
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Figure 3.3. Mouse N2a cells expressing cervid PrPC are not permissive to CWD
prions. N2a cells expressing deer PrPC were infected with 0.2% (w/v) natural CWD
isolates (D10, D92, 7378-47, CWD pool, 012-09441, BALA01, 001-40322, BALA04,
001-44720, 012-02212) adapted to (A) Tg1536+/- mice expressing deer PrPC or (B)
Tg5037+/- mice expressing elk PrPC, and assessed for infectivity after three passages in 6well cell culture plates by cell lifting assay. On third passage, cells were grown to
confluence on NUNC cell culture cover slips (25mm diameter, Cat. No. 174985). The
cells were directly transferred to cold lysis buffer soaked nitrocellulose membranes. The
membrane was treated with PK (5 µg/ml), denatured with 3M guanidine isothiocynate,
immunoprobed with 9E9 mAb (A,B,D,E,G) or 6H4 mAb (C, F) and signal visualized
with X-ray film. (C,F) Cell lift assay control samples demonstrated lack of prion
contamination (mock infected with PBS) and N2a sensitivity to mouse adapted RML
prions. The N2a cells expressing Elk PrPC were infected with 0.2% (w/v) natural CWD
isolates (D10, D92, 7378-47, CWD Pool, o12-09441, BALA01, 001-40322, BALA04,
001-44720, 012-02212) adapted to (D) Tg1536+/- mice expressing deer PrPC or (E)
Tg5037+/- mice expressing elk PrPC. G. PrPSc positive cells within the N2a-ElkPrPC cells
were expanded, sub-passaged and screened for PK resistant material by Western blotting
using the 9E9 mAb. PK +/- designates digested samples (+) or un-digested (-). RKE cells
are RK13 cells expressing elk-PrPC which maintain chronic CWD infectivity (described
in Fig. 2.4).
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Figure 3.3. Mouse N2a cells expressing cervid PrPC are not permissive to CWD
prions
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Breaking the Prion Species Barrier: RK13 Cells (RKE21+) Expressing Elk PrPC
Replicate Natural CWD Prions
To enhance their propensity to replicate prions, we genetically engineered RK13
cells to stably co-express HIV-1 Gag protein concurrently with PrPC. The basis for the
addition of HIV-1 Gag came from earlier published data providing evidence of positive
enhancement for scrapie prion infectivity upon retroviral infection (Leblanc, Baas et al.
2004; Leblanc, Alais et al. 2006). The molecular mechanisms that govern retroviral
enhancements of PrPSc replication remain to be defined. The following CWD replication
studies with genetically modulated RK13 cells were conducted in cooperation with Dr.
Jifeng Bian (Bian, Napier et al. 2010).
Two separate cell line were created that over-express elk PrPC. The two stably
transfected cell lines were designated as RKE (expressing elk PrPC only) and RKE-Gag
(co-expressing elk PrPC and HIV-1 Gag) (Fig. 3.4). The CWD elk isolate designated 01209442 (Table 3.1), was used to infect and serially passage both cell lines. CerPrPSc
accumulation was assessed by PK treatment and subsequent western blotting and/or cell
lift assay (Fig. 3.4A-B). RKE cells showed diminishing amounts of CerPrPSc replication
by passage five, which was lost completely by passage seven, shown by the left western
blot in figure 3.4A. Conversely, the RKE-Gag cells continued to accumulate and replicate
CerPrPSc for over 67 passages (Fig. 3.4A). Direct comparison of cervid PrPSc replication
by western blotting and cell lifting suggests that there is an approximate ~2 fold increase
of CerPrPSc in the RKE-Gag cells (Fig. 3.4B). These results suggest that HIV-1 Gag is
modulating the cells to efficiently replicate prions. The CWD chronically infected RKEGag cell line is referred to as Elk21+.
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Elk21+ cells were cured of CWD prions by treatment with DS-500, a method that
has previously been described in use for other cell lines (Ladogana, Casaccia et al. 1992;
Caughey and Raymond 1993). The cured cells are referred to as Elk21-. These Elk21cells remained CerPrPSc negative for the remaining passages. Cured Elk21- cells
demonstrated sensitivity to CWD replication upon reinfection (Fig. 3.4I).
After 58 passages Elk21+ cells were further cloned by limited dilution. The
process of cell cloning generated 3 CerPrPSc positive clones and 11 negative clones. Rechallenging negative cloned cells with CWD prions resulted in 10 of the 11 clones being
re-infected (Fig. 3.4I).
Strain stability in cell culture was determined by bioassay. Cell extracts from
chronically infected Elk21+ cells passaged twenty-five consecutive rounds were used to
confirm strain stability of the CWD 012-09442 isolate. CWD infected cell extracts from
Elk21+ were ic injected into Tg(elkPrP)5037+/- mice. The natural elk CWD isolate 01209442 was used as a positive control. Elk21+ cell extract injected mice developed prion
disease with a mean incubation time of 112±1 days, while the natural isolate produced
disease with a mean incubation time of 126±2 days (Fig. 3.4C). Negative controls for the
bioassay included uninfected RKE-Gag cell extract, Elk21-, and Elk21 subclones 3 and 9
(Fig. 3.4C). The cured cell extract controls of the bioassay confirmed the dextran sulfate500 treatment cured cells of prions infectivity.
Cell extract preparations used in the bioassay were normalized for total protein
equivalents by the bicinchronic acid (BCA) protein assay (Thermo Fischer-Scientific,
Rockford, IL). Western blot analysis revealed that the glycosylation and electrophoretic
migration patterns between Elk21+ cell lysate and Tg(elkPrP)5037+/- brain homogenate
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differed (Fig. 3.4D). Histopathological analysis of brain sections from mice inoculated
with Elk21+ cell extract demonstrated diffuse and granular deposition of CerPrPSc (Fig.
3.4E-F), which is similar to previously published reports (Angers, Seward et al. 2009).
The negative control, RKE-Gag cell extract injected mice displayed a disease free
histopathological profile (Fig. 3.4G-H).
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Figure 3.4 Characterization of CWD replication in RK13 cells. A. RK13 cells
expressing Elk-PrPC (RKE) did not sustain CWD infectivity (Elk isolate 012-09442) as
compared to the RKE cells co-expressing HIV-1 Gag (Elk21+), which subsequently
became chronically infected. B. Enhanced Cervid PrPSc replication was demonstrated in
Elk21+ cells by both Western blotting and cell lifting, HIV-1 Gag expression indicates a
~2 fold increase in PrPSc. C. After 25 passages, the Elk21+ cells were bioassayed in
Tg5037+/- mice expressing elk PrP. The Elk21+ cell extract is represented by filled
circles, Elk CWD 012-09442 in Tg5037 are filled squares, uninfected RKE-Gag cells are
open circles, cured Elk21- cells with DS-500 treatment after 13 passages (open triangles)
and after 30 passages (filled triangles), Elk21 subclone 3 are open diamonds and subclone
9 are filled squares. D. Western blot representing CerPrP (100µg and 50µg total protein),
CerPrPSc (200µg, 100µg, and 50µg total protein) generated in Elk21+ cells and Tg5037
mice inoculated with Elk21+ cell extract. E-H. Representation of CerPrPSc deposition in
the hippocampus (E,G) and the thalamus (F,H) of Tg5037 mice that were inoculated
with Elk21+ extract (E,F) or RKE-Gag (G,H) uninfected control. I. The susceptibility to
CWD prions (isolate 012-09442), upon reinfection to individual clonal cells derived from
the cured Elk21+ cells (clone 3, clone 9 and Elk21-) was assessed by western blotting. For
each analyzed cell line, the first two lanes represent mock infection with PBS treatment
and the second two lanes represent infection through exposure to CWD brain
homogenate. Molecular mass markers represent 37, 25 and 20 kDa, top to bottom.
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Figure 3.4 Characterization of CWD replication in the RK13 cell culture system.
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The sensitivity of Elk21+ cell to CWD prions facilitated the development of an in
vitro cell assay for prion titer determination, which call the cervid prion cell assay
(CPCA). Similar to the commonly used viral plaque assay for viral titer determination
(Dulbecco and Vogt 1953), the CPCA calculates PrPSc accumulation on an individual cell
basis using a dilution range of the PrPSc inoculum. The CPCA methodology is adapted
from earlier described scrapie cell assay (SCA) that is used to calculate mouse-adapted
scrapie prion titers with highly susceptible N2a clones (Klohn, Stoltze et al. 2003; Mahal,
Demczyk et al. 2008). The major limitation of the SCA is the inability to use natural
prion isolates, therefore making the CPCA a unique assay for its utility in calculating
natural CWD isolates without the murine adaptation prerequisite (Klohn, Stoltze et al.
2003; Bian, Napier et al. 2010).
The basis of the assay is to infect cells with serially diluted increments of
infectious prion material, in a 96-well format. The cells are passaged for three
consecutive rounds. At confluence of the third passage, the cells are counted and
transferred to a 96 well, 0.45µm filter-ELISPOT plate (Millipore, Billerica, MA) where
they are fixed to the plate membrane. These plates are then PK digested and treated with
guanidinium thiocyanate (GITC) denaturation, followed by an enzyme linked immunesorbent assay-like (ELISA) developing procedure. The plates are scanned and quantified
using the CTL-ELISPOT plate reader and the ImmunoSpot3 software (Cellular
Technology, Ltd, Shaker Heights, OH). Figure 3.5A illustrates a representative read out
of positive and negative wells upon final development.
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The dose response relationship in Elk21+ cells to CWD prions was determined
using elk CWD prions titrated in transgenic mice (Browning, Mason et al. 2004; Angers,
Seward et al. 2009). Infected Elk21+ cells were assessed for titer infectivity at the dilution
range of 10-2 to 10-5 (Fig. 3.5B-C). The double logarithmic plots in figure 3.5B,
demonstrates a linear response to the dilutions ranging from 10-3 to 10-4.4. Positive cell
count, representing CerPrPSc-producing cells, is reflective of prion titers. Furthermore, an
increased dose-response for CWD passaged in the Tg(elkPrP)5037+/- versus the CWD
passaged in Tg(deerPrP)1536+/-, signify higher titers in the former samples. Different
CWD isolates were used to infect Elk21+ cells to determine and compare CPCA prion
titers to previously acquired bioassay data (Fig. 3.5C). In our calculations, we estimate
that 100 µl of 10-2.5 dilution of elk CWD pool yields 300 spots in the well of an ELISPOT
plate, which is the reference point used to determine the response index in the SCA
(Mahal, Baker et al. 2007). This calculated reference point corresponds to 106.0 CPCA
units/g. The titers calculated using the CPCA with various elk CWD inocula provided
values of 106.3, 106.3 and 106.6 units/g of brain (Fig. 3.5C). The CPCA titration data was
less than one log difference compared to the previously published bioassay titers
(Browning, Mason et al. 2004; Angers, Seward et al. 2009). Consequently the CPCA is a
viable in vitro alternative to the bioassay for calculating prion infectivity titers, which
could reduce animal use and costs associated with these studies.
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Figure 3.5 Quantification of CWD infectivity using the RKE cell line in a Cervid
Prion Cell Assay (CPCA). A. Representation of developed wells in the Millipore
ELISPOT plates of the CPCA. B. Demonstration of the double logarithmic plot of spot
number versus brain homogenate dilution. CPCA using the Elk21- cells has a linear
response to pooled elk CWD brain homogenate (open circles) and CWD passaged in Tg
mice (filled circles). Data representative of 6 separate experiments. C. Plots of PrPSc
positive cells as a function of log dilution of CWD prion inocula. The numerical counts
of positive cells reflect the prion titer. Three-hundred counted spots is the point used to
determine the response index which corresponds to 106.0 CPCA units/g brain.
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Figure 3.5 Quantification of CWD infectivity using the RKE cell line in a Cervid
Prion Cell Assay (CPCA).
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Heterologous PrPC Expression On a PrP-null Background Does Not Guarantee Prion
Sensitivity: HEK293A Cells Resist CWD Replication
The human embryonic kidney-293 cells (HEK293A) were derived from the
transformation of normal human embryonic kidney cells and are a commonly used cell
line for various molecular analyses (Graham, Smiley et al. 1977). Similar to the RK13
cells, we found that HEK293A cells do not express detectable levels of endogenous PrPC
(Fig. 3.6A) (Ramljak, Asif et al. 2008). Therefore, we hypothesized that the introduction
and over-expression of a heterologous PrPC on a PrP-null background would permit
prion. We also reasoned that attaining chronic CWD infectivity with 293 cells could aid
in the identification of human-specific cellular components involved in interspecies
transmission. Consequently, the HEK293A cells could provide an in vitro model to
ascertain the zoonotic potential of CWD.
Stably transfected 293 cells were created with using the pIRESpuro-deer PrPC
open reading frame (ORF) expression vector. Stable expression of deer PrPC in 293 cells
was assessed using western immuno-blotting with mAb 9E9 (Fig. 3.6A). HEK293ADeer-PrPC cells were infected with the deer CWD D92 isolate (Table 3.1). The cells were
infected using the standard 0.2% (w/v) CWD mixture and serially passaged four times
prior to PrPSc assessment. Collected cell lysates were PK treated and electrophoretically
separated on a 12%-SDS-PAGE. HEK293A-Deer-PrPC cells did not produce detectable
PrPSc implicating resistance towards prion replication (Fig. 3.6B). In addition,
HEK293A-Deer-PrPC cells were shown to be resistant to other CWD and 293 cells
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expressing Mouse PrPC were also found to be resistant to mouse RML prions (data not
shown).
Section Summary: Three distinct cell lines were used to characterize and generate in vitro
prion cell models. The N2a cell line has been well characterized for its ability to replicate
mouse-adapted scrapie prions (Table 1.2). Through clonal selection of cells sensitive to
prion replication, we reasoned that genetic modulation to introduce cervid-PrPC could
permit the replication of heterologous CWD-CerPrPSc. However, N2a cells remained
resistant to CWD prions, while maintaining their sensitivity for RML prions. Our results
indicate that the molecular basis for this resistance maybe an interference effect by mouse
PrP on CWD prion conversion of CerPrPC, as observed in Tg mouse models (Fig. 3.1)
(Telling, Scott et al. 1995).
RK13 cells permitted replication of CWD prions after modifications to express
elk-PrPC. The absence of endogenous PrPC in RK13 cells allows over-expression of
species-specific PrPC similar to Tg mice on a Prnp0/0 background. In addition to elk-PrPC,
introduction of HIV-1 Gag was shown to enhance PrPSc replication. In this way, we
created a cell line chronically infected with CWD prions, called Elk21+ cells (Bian,
Napier et al. 2010). CWD prion production in Elk21+ cells was confirmed by bioassay in
Tg mice.
Finally, the lack of endogenously expressed PrPC in the HEK293 cells was not
sufficient to facilitate CWD prion replication upon stable expression of cervid PrPC,
indicating that PrPC expression is not the only determining factor for cells to replicate
foreign prions. Our results suggest that sensitivity of cells to prions is co-dependent on
PrPC expression and endogenously expressed factors.

	
  

117	
  

Figure 3.6 Stable expression of cervid PrPC and assessment of CWD replication in
HEK 293A Cells. A. HEK 293A cells were stably transfected with the pIRESpuro-Deer
PrPC ORF expression vector. B. HEK293A cells were infected with CWD deer isolate
D92 and passaged for four consecutive rounds. PrPSc replication in HEK293A-DeerPrPC
cells was assessed following PK digestion, SDS-PAGE separation and Western blotting.
Monoclonal antibody 9E9 was used to probe Western blot for PK resistant material. PK
+/- nomenclature designates digested samples (+) or un-digested (-).
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Figure 3.6 Stable expression of cervid PrPC and assessment of CWD replication in
HEK 293A Cells.
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Section II: Replication of Biologically Cloned Hyper (HY) and Drowsy (DY)
Hamster-Adapted TME Prion Strains in Cell Culture
Transmissible mink encephalopathy (TME) prion strains, Hyper (HY) and
Drowsy (DY) were derived from ranch-raised mink in Stetsonville, Wisconsin and subpassaged in Syrian golden hamsters. These prion strains have been well described and
biologically cloned (Bessen and Marsh 1992; Bessen and Marsh 1992). These two prion
strains differ in disease incubation times, histopathological deposition of PrPSc,
behavioral phenotypes (HY –highly active, hyper, DY-lethargic, slow) and biochemically
(protease sensitivity, glycoform migration patterning) (Bessen and Marsh 1992). In
accordance with in vivo data, HY prions have rapid replication kinetics as compared to
DY, yielding high titers (Bessen and Marsh 1992). The end stage titers of HY and DY,
were 109.5 LD50/g and 107.4 LD50/g, respectively (Bessen and Marsh 1992). We used the
RK13 cells to create an in vitro model to study the molecular characteristics that define
HY and DY.
Expression Of Hamster PrPC In RK13 And N2a Cells: Genomic DNA extracted from
Syrian golden hamster (SHa) brain tissue was used to isolate, sequence and clone the SHa
PrP ORF into the pIRESpuro expression vector. RK13 cells and N2a cells were stably
transfected, and bulk populations expressing SHaPrPC were created (Fig. 3.7A).
Monoclonal antibody 3F4 was used to detect SHaPrPC expression. In addition, sitedirected mutagenesis was used to generate the L42 epitope (W144Y) within the SHaPrP
ORF. The specific epitope for L42 occurs in human, cattle, sheep, goat, dog, cat, mink,
rabbit and guinea pig PrP, but not hamster, mouse or rat PrP (Vorberg, Buschmann et al.
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1999). By generating this epitope in the SHaPrP ORF, we aimed to measure de novo
prion replication in cell cultures (Fig. 3.7A).
To assess susceptibility to HY and DY, RK13-SHaPrP cells were infected with
0.2% (w/v) HY and DY Syrian golden hamsters. RK13-SHaPrP cells were permissive for
HY replication, but not the DY strain (Fig. 3.7A). Of interest, the electrophoretic
migration patterns of CerPrPSc in Elk21+ cells (Fig. 3.4) and HY-PrPSc differ when
compared to CWD- or HY-PrPSc derived from brain homogenates (Fig. 3.7B). The HYand DY- from infected hamster brains were used as positive controls on Western blots
(Fig. 3.7B) (Bessen and Marsh 1992).
Continuous passage of HY-infected RK13-SHaPrP cells resulted in the loss of PK
resistant PrPSc in later passages. The capacity of RK13-SHaPrP cells to replicate HYprions was confirmed using the cell-lifting assay (Fig. 3.8B). Repeated infectivity
experiments using these prion strains produced consistent results. HY PrPSc consistently
became undetectable between the seventh and ninth passage, while DY infected cells
remained PrPSc free throughout the studies (Fig. 3.7B & 3.8B). These cell culture studies
demonstrate differences in susceptibility of RK13-SHaPrP cells to HY and DY strains.
N2a cells expressing SHa-PrPC were also infected with HY and DY prions.
Unlike RK13 cells, the N2a cells did not replicate HY or DY prions (Fig. 3.7C and 3.8A).
Although signal can be seen in PK+ lanes of the infected cells in figure 3.7C, incomplete
protease digestion is the likely cause of this signal. The more sensitive cell-lifting assay
confirms the lack of PrPSc in N2a SHa-PrP cells (Fig. 3.8A). In contrast, N2a SHa-PrP
cells were capable of replicating RML prions (Fig. 3.8A). Using mAb 6H4, we show
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robust accumulation of PrPSc in RML-infected N2aSHa-PrP cells, but not RK13SHa-PrP
cells (Fig. 3.7D & 3.8B).
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Figure 3.7 Characterization of HY and DY prion replication in cell culture. A. Stable
expression of Syrian hamster PrPC (SHa-PrPC, Accession number K02234.1) in RK13
and N2a cells. Both cell lines were transfected with the pIRESpuro-SHa-PrPC expression
vector (Clonetech Laboratories, Inc) and verified using the hamster/human PrPC specific
mAb 3F4 (Covance, Cat. No. SIG-39600). Actin expression is used for total protein
control (Pan-Actin mAb-5, Lab Vision Corporation, Fremont, CA). Bulk selected (B)
RK13 cells and (C) N2a cells expressing SHa-PrPC were infected with 0.2%(w/v) HY
and/or DY brain homogenate. Accumulation of PrPSc was assessed after three passages
by Western blotting using mAb 3F4. D. RK13 and N2a cells expressing SHa-PrPC were
infected with 0.2% (w/v) mouse adapted RML scrapie brain homogenate and passaged
three consecutive rounds: PrPSc was detected by Western blotting using mAb 6H4. The
L42 designation in the figures represents the cell line expressing SHa-PrPC with a site
directed mutation at the 144 amino acid residue position (W144Y).
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Figure 3.7 Characterization of HY and DY prion replication in cell culture.
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Figure 3.8 Characterization of HY and DY prion replication by cell-lifting assay. (A)
N2a-SHaPrPC/ N2a-SHaPrPC-L42 and (B) RK13SHaPrPC were infected with 0.2%(w/v)
HY, DY prions, or mouse adapted RML prions and assessed for infectivity after three
passages in 6-well cell culture plates by cell lifting assay. On third passage, cells were
grown to confluence on cell culture cover slips. The cells were directly transferred to cold
lysis buffer soaked nitrocellulose membrane. The membrane was treated with PK
(5µg/ml), denatured with 3M-guanidine isothiocyanate, immunoprobed for the
accumulation of PrPSc with mAb 3F4 or mAb 6H4 antibodies(Bosque and Prusiner
2000)(Bosque and Prusiner 2000)(Bosque and Prusiner 2000)(Bosque and Prusiner
2000)(Bosque and Prusiner 2000)(Bosque and Prusiner 2000). Dotted lines represent the
boundaries of the coverslip.
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Figure 3.8 Characterization of HY and DY prion replication by cell-lifting assay.
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Production and Characterization of RK13 Cells Co-Expressing SHa-PrPC & HIV-1 Gag
RK13SHa-PrP cells were transfected with HIV-1 Gag. After selection of stable
HIV-1 gag expression, cells were infected with 0.2% (w/v) HY or DY infected brain
homogenates and passaged for three rounds. At third passages the bulk-infected cell
population was single-cell cloned by limited dilution. Individual clones were identified
and consolidated to seven, 96-well cell culture plates, creating a total population of 672
clones (Fig. 3.9A). Of these 672 clones, 23 clones (3.4%) infected with HY exhibited a
positive signal for PrPSc, while all 672 clones from the DY infection remained PrPSc
negative (Fig. 3.9A).
A modified-scrapie cell assay was used to rapidly determine and identify PrPSc
positive clones (Fig. 3.9B). Confluent clones grown in the 96-well cell culture plates
were counted and 20,000 cells were transferred to the 96 well, 0.45µm filter-ELISPOT
plates. Unlike the CPCA or the SCA (Mahal, Demczyk et al. 2008; Bian, Napier et al.
2010), this approach does not utilize log dilutions of infectious material. Equal amounts
of the infectious agent were used (0.2% w/v HY or DY brain homogenate).
All 23 PrPSc positive clones infected with HY prions were expanded by serial
passage to larger culture conditions for assessment of PrPSc production. Western
immuno-blotting was used in subsequent analyses. At fifth passage, 8 out of 23 (35%)
RK13SHaPrPC-HY infected clones lost detectable PrPSc (Fig 3.9C top blots). By the tenth
passage, none of the clones exhibited detectable PK resistant PrPSc (Fig 3.9C, middle
blots). We continued to passage the 23 RK13SHaPrPC-HY clones for 10 more passages,
but PrPSc remained absent in all 23 clones after the 20th passage (Fig. 3.9C, lower blots).
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We hypothesized the eventual loss of HY-PrPSc in the 23 RK13 SHa-PrPC-Gag
clones was due to reduced expression of HIV-1 Gag. Expression of HIV-1 Gag was
assessed for each clone through Western blotting using the p24 mAb (MAB880-A;
Chemicon, Cat. No. 9876543). While expression of HIV-1 Gag varied between clones, it
did not correlate with HY-PrPSc replication (Fig. 3.9D).
Section Summary: The results from this section show the versatility of RK13 cells to
support replication of various prions from different species. Engineering of the RK13
cells to express hamster PrPC permitted replication of HY- but not DY- prions, thus
providing the means to differentiate these strains cell culture techniques. Our data
indicate that cloning is a crucial step for identifying individual cells expressing the
appropriate cellular co-factors for prion replication.
N2a cells demonstrate a similar resistant phenotype towards HY and DY as
described in the CWD infection studies (Chapter 3, section I). In addition, the coexpression of hamster PrPC in N2a-SHaPrP cells did not hinder the replication of mouseadapted RML prions. In this respect, these results differ from the behavior of Tg mice
expressing SHa and mouse PrP, which are capable of replicating SH prions (Scott, Foster
et al. 1989).
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Figure 3.9 Transient replication of HY prions in RK13Gag-SHaPrP cells. A. Singlecell RK13 clones co-expressing SHa-PrPC and HIV-1 Gag, infected with 0.2% (w/v) HY
or DY prions, assayed by a modified Scrapie cell assay. B. Wells representing PrPSc
positive wells (clones) selected for further expansion and continuous passage. C. RK13SHaPrPC cells positively identified for HY replication by the SCA were expanded and
serially passaged. The clones replicated HY for ten passages post infection. Immunoblots
were assessed using mAb 3F4. D. Expression of HIV-1 Gag was assessed for each clone
along with actin expression for total protein control. A total of 23 PrPRes positive clones
were identified. Upon expansion of these clones, some lost PrPSc. Ten of the 23 clones
analyzed are represented.
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Figure 3.9 Transient replication of HY prions in RK13Gag-SHaPrP cells.
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Discussion

To summarize our findings: (i) Expression of cervid PrPC in human 293 and N2a
cells was not sufficient to sustain CWD replication. (ii) N2a cells co-expressing cervid
PrPC remained susceptible to mouse-adapted RML scrapie prions. (iii) RK13 cells
engineered to express elk PrPC (RKE-cells) transiently replicated CWD prions. (iv) RKE
cells (Elk21+) were enhanced to sustain CWD prion replication co-expression of HIV-1
Gag and cloning. (v) Expression of SHa PrPC and subsequent infection HY and DY
prions in RK13 cells resulted in the transient replication of HY but not DY prions. (vi)
N2a cells expressing SHa-PrPC did not replicate HY or DY prions but replicated mouseadapted scrapie RML prions.
Prion Replication and The Prion Species Barrier In Cell Culture: All analyzed cells in
these studies ectopically expressed heterologous PrPC. The stable over-expression of PrPC
did not necessarily confer sensitivity to prions, even within cells that are known for their
prion replication capabilities. Previously published data support the notion that PrPC
expression alone is not sufficient for effective prion replication (Graham, Smiley et al.
1977; Telling, Scott et al. 1995; Raeber, Sailer et al. 1999; Bosque and Prusiner 2000). In
vivo data implies that the efficiency of PrPSc replication is strongly influenced by its
structural homology to PrPC, which is the underlying basis for the prion species barrier
(Fig. 3.1) (Telling, Scott et al. 1995). RK13 cells expressing Elk PrPC sustained CWD
prion replication, following the addition of HIV-1 Gag (Fig. 3.4). RK13 cells expressing
SHa-PrPC were susceptible to HY-prions (Fig. 3.9), thus abrogating another species
barrier in cell culture. Both the N2a and the RK13 cells have previously been shown to
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efficiently replicate prions (Race, Fadness et al. 1987; Vilette, Andreoletti et al. 2001).
Expression of endogenous PrPC is the marked difference between N2a and RK13 cells,
which is present in the former and undetectable in the latter. This absence of endogenous
PrPC in RK13 cells and their ability to propagate prions from different species produces a
system that is analogous to the Tg-mouse model (Fig. 3.1) (Telling, Scott et al. 1995).
However, ectopic expression of PrPC on a null background does not guarantee
susceptibility to prions, which was established with the HEK293A cells inability to
replicate CWD (Fig. 3.6)
Endogenous PrP Interference In Cell Culture: In addition to the structural homology
prerequisites of the PrP molecules, the presence of two different (species) PrPC proteins
could sometimes impose an interfering effect on PrPSc replication (Scott, Foster et al.
1989; Telling, Scott et al. 1995). The selection of an N2a clonal population that is highly
sensitive to mouse-adapted RML does not guarantee replication of prion strains derived
from other species. Similar to the Tg-mice data (Telling, Scott et al. 1995), overexpression of cervid- or hamster- PrPC in the presence of endogenous mouse PrPC does
not permit the replication of prions that are structurally homologous to the over-expressed
transgene, indicating that endogenous PrPC is interfering in the conversion process. More
importantly, the interfering effect is unidirectional because cells over-expressing the
heterologous PrPC transgene continue to maintain full susceptibility for RML, which
depends on conversion of mouse PrPC to PrPSc (Fig. 3.3 and Fig. 3.7). Selection of N2a
cells that lack endogenous PrPC expression, was shown to enable CWD prion replication
upon ectopic cervid PrPC expression, thus further supporting the PrP interfering effect
(Pulford, Reim et al. 2010).

	
  

132	
  

A species-specific molecule, termed protein X, is hypothesized to act as cofactor
that selectively binds and chaperones the PrPC-PrPSc conversion (Fig. 1.4) (Telling, Scott
et al. 1995). Thus, protein X’s preferential binding for endogenous PrPC could effectively
sequester it from interacting with the heterologous PrPC-PrPSc conversion process,
consequently making the cells resistant (Fig. 3.3 and Fig. 3.7). Though hamster prion
infectivity studies using Tg-mice co-expressing both murine- and hamster-PrPC
efficiently replicated PrPSc and succumbed to prion disease (Scott, Foster et al. 1989),
N2a-SHa-PrPC cells did not recapitulate these observations (Fig. 3.7 and Fig. 3.9). One
possible explanation for these discrepancies is the difference in hamster prion strain used
in previous work (Sc237 comparable to HY and DY here). Also, PrP interference was not
a factor in these studies because hamster-PrP expressing mice on wt-background did
replicate hamster PrPSc (Scott, Foster et al. 1989). The mechanisms governing these
observations are not fully understood but were hypothesized to be related by close
homology of murine and hamster PrPC sequence.
Ectopic Expression of PrPC is Not Sufficient for PrPSc Conversion: In transgenic mice,
the inactivation of the endogenous Prnp gene with subsequent introduction of a
heterologous PrPC abrogates the prion species barrier (Telling, Scott et al. 1995).
Furthermore, an inverse relationship exists between the expression level of PrPC and
incubation time of prion disease in mice (Westaway, Mirenda et al. 1991). While PrPC is
absolutely necessary for prion replication (Büeler, Aguzzi et al. 1993), the ectopic
expression of PrPC in certain tissues/cells of Prnp0/0 mice is not sufficient to sustain PrPSc
(Raeber, Sailer et al. 1999). Likewise, cell culture data exhibit discernable variances
towards PrPSc replication that is unrelated to endogenous PrPC expression levels (Race,
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Caughey et al. 1988; Bosque and Prusiner 2000). Besides the PrP requirement, this data
collectively implies that additional cofactors are involved in the prion replication process.
Both RK13 and HEK293A cells lack endogenous PrPC expression, but only one of these
cells has the ability to replicate the prions tested here (Fig. 3.4 and Fig. 3.6). Ectopic
over-expression of cervid-PrPC did not facilitate conversion of CerPrPSc in HEK293. In
fact, the HEK293A cells demonstrated complete resistance towards CWD and RML
prion replication. The RK13 cells do replicate CWD prions but only after clonal selection
and the effect of HIV-1-Gag. In addition to CWD prion replication, we show here that
RK13 cells also replicate hamster prions (HY), which suggests that the cellular factors
are universally applicable to the PrPSc replication process.
Enhancement of PrPSc Replication by HIV-1 Gag: The retroviral element, HIV-1 Gag
enhanced the susceptibility of RK13 cells to CWD infection (Bian, Napier et al. 2010).
Earlier studies have shown that retroviral infection of cells enhanced scrapie infectivity
and extracellular release of PrPSc by the accelerated formation of Gag-recruited detergent
resistant microdomain (DRM)/lipid raft vesicles within the endosomal trafficking
compartments (Leblanc, Alais et al. 2006). Coincidentally, PrPC traffics and co-localizes
to the same cellular compartments that the retrovirus uses for assembly and release (Fig.
1.2) (Shyng, Moulder et al. 1995; Vey, Pilkuhn et al. 1996; Ott 1997; Cimarelli and
Darlix 2002; Demirov and Freed 2004; Fevrier, Vilette et al. 2004; Pelchen-Matthews,
Raposo et al. 2004).
The Gag-polyprotein primary function is to direct viral-particle assembly and
budding release using a non-lytic pathway, keeping the host cell viable for continuous
viral production (Demirov and Freed 2004). This polyprotein consists of four structural
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components that become part of the mature virus. These components consist of matrix
protein (MA), capsid (CA), nucleocapsid (NC) and p6 (Gottlinger 2001). Each
component has a distinct role in the assembly process. The matrix protein (MA) is a
guided target for the plasma membrane, while the CA manages the protein-protein
interactions of the assembly process (Gottlinger 2001). The role of NC is to guide and
couple the newly generated RNA to the assembling virus (Gottlinger 2001). These three
components are shared among all identified retroviruses, while p6 is a unique C-terminus
domain found only in primate retrovirus (HIV-1) (Demirov and Freed 2004). The p6
domain’s core function is to recruit cellular proteins to assist the budding and release of
the newly formed virus (Yu, Matsuda et al. 1995). In addition to the recruitment process
of cellular proteins, the p6 domain is vital for releasing the budding virus from the cell
surface (Gottlinger, Dorfman et al. 1991). The exact mechanism that p6 uses to achieve
this process is not fully understood but the highly conserved sequence motifs of p6
domain indicate a close functional connection to the ubiquitin proteasome system (UPS)
(Patnaik, Chau et al. 2000; Schubert, Ott et al. 2000; Strack, Calistri et al. 2000). The
components of Gag are activated by proteolytic cleavage of the polyprotein in the late
stages of viral assembly and collectively function by recruiting cellular factors,
modulating the intracellular trafficking mechanisms and distorting the plasma membrane
(Demirov and Freed 2004), all of which are implicated in the PrPC-PrPSc conversion
process (Caughey, Raymond et al. 1991; Borchelt, Taraboulos et al. 1992; Taraboulos,
Raeber et al. 1992; Shyng, Heuser et al. 1994; Peters, Mironov et al. 2003; Fevrier,
Vilette et al. 2004; Sarnataro, Caputo et al. 2009; Taylor, Whitehouse et al. 2009; Solis,
Malaga-Trillo et al. 2010; Goold, Rabbanian et al. 2011).
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Thus, HIV-1 Gag’s enhancement of PrPSc replication could be a multifaceted
process involving several cellular mechanisms/pathways. At the cell surface, the
distortion of the plasma membrane (PM) by Gag could accelerate PrPSc conversion by
modulating the physical surface area of contact for PrPC-PrPSc. Recent reports have
suggested that conversion of PrPSc predominantly occurs at the cell-surface and very
rapidly, within one minute of exposure (Goold, Rabbanian et al. 2011). Besides PM
modulation, the release of empty buds/vesicles mediated by Gag could accelerate
dispersion of newly formed PrPSc to uninfected neighboring cells by exocytosis
(Campbell, Crowe et al. 2001; Fevrier, Vilette et al. 2004; Pelchen-Matthews, Raposo et
al. 2004). Furthermore, because PrPSc conversion can also occur intracellularly, it is
probable that Gag partakes within those sites of conversion as well (Borchelt, Taraboulos
et al. 1992; Shyng, Huber et al. 1993; Shyng, Heuser et al. 1994; Vey, Pilkuhn et al.
1996; Beranger, Mange et al. 2002; Peters, Mironov et al. 2003; Vella, Sharples et al.
2007). Of potential interest to the PrPSc conversion process is the role of the p6 domain.
In addition to potentially being the direct PrP interacting protein during the vesicle
recruitment and formation process, this domain also modulates proteasome degradation
pathways (Patnaik, Chau et al. 2000; Schubert, Ott et al. 2000; Strack, Calistri et al.
2000). This interaction of p6 and the UPS could indirectly skew the protein homeostasis
machinery in favor of the PrPC-PrPSc misfolding process.
The deregulation of UPS from correcting conformationally misfolded proteins by
p6 could enhance PrPSc formation by several mechanisms. During normal biogenesis of
PrPC, misfolded PrP protein is delivered to the proteasome system for refolding or
degradation (Ma and Lindquist 2001; Yedidia, Horonchik et al. 2001). The induction of
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ER-stress and proteasomal dysfunction causes the cell to accumulate and aggregate PrP
molecules (Ma, Wollmann et al. 2002). It has been shown that ER stress and proteasomal
inhibition leads to the accelerated accumulation of PrPSc (Nunziante, Ackermann et al.
2011). Therefore, p6’s hijacking of the UPS could produce a scenario where, in addition
to the introduction of exogenous PrPSc from an infectious inoculum source, the cell is
also accumulating its own, spontaneously generated aggregated-PrP molecules. Of course
this would be a rare event, which would explain why clonal selection is so crucial for
identification of cells that become chronically infected with CWD prions. Conversely,
preoccupying the UPS could also simply distract the cellular protein aggregation defense
mechanisms to give PrPSc free range on all available PrPC substrate without interference.
These Gag enhancement mechanisms have not been experimentally addressed, but could
differ based on the prion strain used in the infection analysis. An example demonstrating
the difference would be the RK13-SHaPrPC-Gag cells inability to chronically replicate
HY prions.
Concluding Remarks: The development of these cell culture models facilitates prion
infectivity analysis in more depth. Many questions in prion biology remain unanswered.
Molecular prion strain properties are difficult to characterize using complex organisms
such as mice. Thus, analysis of prion infectivity at the cellular level reduces this
complexity and allows characterization of PrPSc replication in better detail. Furthermore,
besides identifying the mechanisms that dictate PrPSc replication, cell culture models will
help pinpoint cofactors that contribute to this process. Of the three cell lines described in
this chapter, RK13 cells show promise as a universal cell model for PrPC-PrPSc
conversion studies. The ability of these cells to replicate prions from different sources can
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be used to generate cell based screening assays, elucidate cellular differences between
strains and identify cofactors responsible for the permissiveness to convert PrPC to PrPSc.
It is clear from our work, and previous studies that sensitivity towards prions clonally
varies between clones from the same parent cell. In the subsequent portion of this thesis,
the phenotypic differences that dictate cellular permissiveness to prion replication begin
to be addressed using genomic transcriptional analysis approaches.
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Chapter 4
Identification Of Host Factors That Confer Susceptibility to Prions

Introduction
Prion Replication In Vivo: The proposal of a proteinaceous infectious agent that
replicates without nucleic acids (Alper, Cramp et al. 1967; Griffith 1967) was
substantiated with the identification of PrPSc and its normally expressed isoform, PrPC
(Fig. 1.3) (McKinley, Bolton et al. 1983; Oesch, Westaway et al. 1985; Barry, Kent et al.
1986; Basler, Oesch et al. 1986). Strong evidence to support the notion that
conformational conversion of PrPC to PrPSc causes prion disease was provided with the
creation of Prnp0/0 knockout mice (Büeler, Fischer et al. 1992). Mice lacking PrPC did not
generate PrPSc and were resistant to prion disease (Büeler, Aguzzi et al. 1993). In
addition, Prnp0/0 knockout mice did not exhibit any obvious developmental or behavioral
abnormalities (Büeler, Fischer et al. 1992). The ablation of the gene and lack of gross
phenotypic abnormalities in the Prnp0/0 knockout mice indicated that (i) PrPC is not an
embryonic lethal gene and (ii) PrPC loss-of-function is not the cause of neuronal death in
prion diseases (Büeler, Fischer et al. 1992). In contrast, over expression of this PrP in
mice accelerates prion replication (Westaway, Mirenda et al. 1991). Finally, ectopic
expression of species specific PrPC on the Prnp0/0 background permitted numerous
studies that improved our understanding of prion species barriers, replication kinetics in
vivo, PrPSc tissue distribution/tropism and neurological deficits (Telling, Scott et al. 1995;
Telling, Haga et al. 1996; Bruce, Will et al. 1997; Asante, Linehan et al. 2002; Browning,
Mason et al. 2004; Tamguney, Giles et al. 2006; Green, Castilla et al. 2008; Angers,
Seward et al. 2009; Angers, Kang et al. 2010). However, while animal models tell us that
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PrPC is required for disease, identification of additional cofactors that are involved in this
process is more challenging. Furthermore, not all tissues/cells derived from Prnp0/0 mice
have the ability to replicate prions upon ectopic expression of PrPC, additional proof
towards cofactor requirements (Raeber, Sailer et al. 1999).
Prion Replication In Vitro: Expression of PrPC is not sufficient to sustain chronic prion
infectivity in cell culture without additional, unidentified factors (Bosque and Prusiner
2000; Courageot, Daude et al. 2008; Lawson 2008; Bian, Napier et al. 2010). N2a cells,
which are known to replicate mouse-adapted RML prions, vary in their susceptibility,
regardless of expressed PrP levels (Bosque and Prusiner 2000). Studies characterizing
N2a infectivity have demonstrated that only 1 out 144 or roughly 0.7% cells sustain
chronic infectivity (Race, Fadness et al. 1987; Race, Caughey et al. 1988). This strongly
implies that cellular permissiveness to prion replication is co-dependent on unidentified
host factors for catalytic transformation of PrPC into PrPSc to occur.
We hypothesize that ectopic clones of RK13 cells would vary in susceptibility to
prion infection, and that susceptibility and resistant clones would vary in levels of
expression of required genes.
Transcriptional analysis to elucidate host factors involved in prion replication:
Identifying clonally distinct phenotypes (susceptible/resistant towards prion replication)
amongst RK13 cells permits molecular level investigations to elucidate transcriptional
differences that confer these phenotypes. We utilized two transcription-profiling
approaches to elucidate these phenotypic differences, namely the representational
difference analysis (RDA), and full genome microarray transcription scanning. RDA is a
subtractive hybridization based method that provides insights into the transcriptional
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differences between clonal populations. On the other hand, microarray analyses provide a
global perspective of transcriptional differences between the sensitive and resistant
clones. Both approaches are subsequently described in greater detail.
Transcription Profiling Using Subtractive Hybridization Methods: Representational
Difference Analysis (RDA): In an attempt to identify specific transcriptional differences
between sensitive and resistant clones, the first approach we used was the RDA (Vinnik
and Lisitsyn 1993; Lisitsyn, Leach et al. 1994). The benefit of using this approach is its
unbiased ability to identify unique transcripts without specific or known primers to
initiate the search. The technique becomes advantageous when applied towards the RK13
system and its poorly annotated rabbit genome. RDA is a PCR based technique that uses
subtractive hybridization to remove homologous transcripts shared between two DNA
sources, referred to as “tester” and “driver” DNA. Total RNA is purified from two
compared populations and mRNA is sub-purified for reverse transcription to cDNA.
Generally, the “driver” DNA is supplied at various ratios in excess of the “tester” DNA to
remove as many homologous transcripts as possible, leaving only the non-homologous
transcripts for identification. By using this technique we aimed to identify and
characterize unique transcripts in sensitive and resistant RK13 sub-clones.
Transcription Analysis Using DNA Microarray Technology: DNA microarrays, also
known as DNA chips or gene chips, are essentially a large collection of oligonucleotide
probes that have been attached to a solid surface. The attached oligonucleotide probes
vary in length, which depends on target DNA source to be hybridized. Moreover, the
probes used for the chips represent different aspects of genetic information from a target
organism. This experimental design for the microarray chip can target expression level
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variations, detect single nucleotide polymorphisms (SNP’s), genotype and identify
mutations in specific tissue sources (Churchill 2002; Oleksiak, Churchill et al. 2002). The
microarray’s sizeable probe capacity facilitates high-throughput investigations (Churchill
2002).
The primary principle of microarray technology is based on the hybridization of a
fluorescently labeled target sample (cDNA, cRNA) to probe immobilized oligonucleotide
sequences. The typical microarray experiments begin with RNA isolation from target
tissue/cell source. The RNA is than quantified and analyzed for purity. Pure RNA is
reverse transcribed and fluorescently labeled by sequential enzymatic reactions to
produce microarray hybridizing nucleic acids for detection. The target sample is
hybridized to the chips and put through stringency washes to remove poorly hybridized
samples. Finally, a scanner is used to read the chips and quantitatively calculate the total
strength of the hybridized signal intensity.
There are several challenges associated with the microarray methodology and the
bioinformatic analysis of the data. These challenges come up for consideration prior to-,
during- and post- experiments. They include: the biological complexity of the
experimental design and the statistical significance that has to be attained to gain valid
conclusions; standardization of the protocol for consistency of data acquisition; statistical
analysis of the large data sets, which include normalization methods to remove
background noise and identification of statistical significance; accuracy and precision of
the hybridized probe, and the gene it matches; lastly, the handling and distribution of
data, which is a major bottleneck for microarray experimentation due to a lack of
standardized bioinformatic platforms and extremely large data sets that require immense
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storage capacity and significant computing power (Simon 2009; Kim, Zakharkin et al.
2010).
Prion Disease Transcription Profiling: Initial transcription profiling of prion diseases
utilized subtractive cloning of single stranded cDNA libraries derived from scrapieinfected mouse and/or hamster brains. These studies identified three specific transcripts
that were present in abundance, the transcripts identified were the glial fibrillary acidic
protein, metallothionein II, and the B chain of α-crystallin (Wietgrefe, Zupancic et al.
1985; Duguid, Rohwer et al. 1988). The follow up studies using a similar approach
confirmed the original findings and in addition, identified transferrin and sulfated
glycoprotein-2 (clusterin) (Duguid, Bohmont et al. 1989). Subsequently, differential gene
expression of transferrin, sulfated glycoprotein-2, glial fibrillary acidic protein and
metallothionein were also detected in hippocampal regions of Alzheimer’s disease (AD)
and Pick disease (PD2) (Duguid, Bohmont et al. 1989), thus linking these genes with
other known neurodegenerative diseases (Duguid, Bohmont et al. 1989). The search for
specific genes associated with neurodegeneration during the progression of prion disease
continued with an improved technique of the time called the “mRNA differential display”
method. This technique helped identify five more genes missed by previous analyses that
include cathepsin S, the C1q B-chain of complement, apolipoprotein D, and scrapieresponsive genes ScRG-1 and ScRG-2 (Dandoy-Dron, Guillo et al. 1998).
Improvement in gene expression technology expanded and improved the studies
searching for gene-specific changes associated with prion diseases. A high-throughput
analysis using cDNA microarray chips identified 158 differentially expressed genes in
the CNS of prion-infected mice (Booth, Bowman et al. 2004). These microarrays
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facilitated analysis of gene expression changes throughout the progression of the disease
that include early, middle (preclinical) and late (clinical) stage time points. The gradual
gene expression data collected over the described stages of disease link biological
processes with progression of neurodegeneration on a transcriptional level (Booth,
Bowman et al. 2004). Similar studies using these profiling techniques reported additional
genes that were associated with inflammation and stress response (Brown, Webb et al.
2004; Riemer, Neidhold et al. 2004; Xiang, Windl et al. 2004). Expression analysis of
prion infected but preclinical (170 days post infection (dpi)) mouse hippocampus
revealed 78 novel genes to be differentially expressed, specific that region of the brain
(Brown, Rebus et al. 2005). These novel genes were reported to associate with
perturbation of ER, up regulation of glycosylation enzymes, chaperones, protein
trafficking and cellular degradation machinery.
In addition to the newly identified genes that associate with preclinical phase of
prion disease in mice, the stringent mathematical conditions (fold change >1.5 and pvalue < 0.01) applied towards microarray data set signal processing confirmed
differential expression of genes that have been reported in previous studies (Brown,
Rebus et al. 2005). These findings therefore validate transcription profiling as a viable
technique to monitor molecular changes during prion pathogenesis (Duguid, Rohwer et
al. 1988; Dandoy-Dron, Guillo et al. 1998; Booth, Bowman et al. 2004; Brown, Webb et
al. 2004).
A recent study compared gene expression differences from mice infected with
three different mouse-adapted scrapie prion strains (ME7, 22L & RML), therefore taking
a global perspective of molecular events that occur in prion diseases (Skinner, Abbassi et
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al. 2006). The results from those studies revealed a total of 400 genes differentially
regulated during the symptomatic (clinical) stage and 22 genes during the preclinical
stage, averaged out between all three prion strains. Significant differences of gene
expression were reported within each prion strain as well (Skinner, Abbassi et al. 2006).
These expression profiling studies were expanded for natural prion diseases, which
include gene expression analysis in cattle post BSE infection (Khaniya, Almeida et al.
2009; Almeida, Basu et al. 2011; Panelli, Strozzi et al. 2011), natural scrapie in sheep
(Filali, Martin-Burriel et al. 2011; Gossner, Foster et al. 2011), and human CJD (Baker,
Martin et al. 2002; Sugaya, Nakamura et al. 2002; Baker and Manuelidis 2003; Xiang,
Windl et al. 2005; Mead, Poulter et al. 2009; Medina, Hatherall et al. 2009).
In vitro experiments analyzing the transcriptional response to prion infection have
thus far produced sub-optimal results that lack the consistency in vivo data exhibited
(Doh-ura, Perryman et al. 1995; Satoh and Yamamura 2004; Greenwood, Horsch et al.
2005; Julius, Hutter et al. 2008). Initial cell culture experiments analyzing gene
expression differences between infected (ScN2a) and un-infected N2a cells utilized
cDNA library subtractive-hybridization techniques as described for the in vivo studies
(Doh-ura, Perryman et al. 1995). Five specific genes with altered mRNA expression were
identified in the ScN2a cells that included: chromogranin B, intracisternal-A particle
envelope, ornithine decarboxylase antizyme, heat shock protein 70 and one gene not
previously described (Doh-ura, Perryman et al. 1995). The identified transcripts were
present in both cell types (ScN2a & N2a) and did not indicate a unique association with
scrapie infection of the cells.
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A different approach was used on cells that do not express endogenous PrPC. To
assess the effect ectopic expression of PrP has on a non-PrP expressing cell, HEK293
cells were genetically modified to express PrP and then transcriptionally profiled (Satoh
and Yamamura 2004). Microarray screen revealed 33 genes to be differentially expressed
after PrP over-expression. These genes were linked with various neuronal functions that
might be associated with undefined PrPC-mediated neurodegeneration mechanisms
(Satoh and Yamamura 2004).
Large-scale gene expression analysis to identify differences between infected and
uninfected neuroblastoma cells (ScN2a/N2a) and hypothalamic neuronal cells (GT1)
revealed inconclusive results that were based on transcriptional variation of infected and
uninfected cells derived from different neuronal sources (Greenwood, Horsch et al.
2005). Likewise, the absence of a universal transcriptional response to persistent prion
infection within three murine cell lines led to the conclusion that prion infection does not
induce transcriptional alterations in an in vitro setting, which implicate that genes that
render the cells susceptible to prion replication are present prior to exposure (Julius,
Hutter et al. 2008). Collectively, these studies examined differential gene expression that
compared differences before and after prion infection and the effect PrPC imposed on
cells that do not normally express this gene (Doh-ura, Perryman et al. 1995; Satoh and
Yamamura 2004; Greenwood, Horsch et al. 2005; Julius, Hutter et al. 2008). A
mechanistic perspective towards prion replication and endogenous gene expression to
identify cofactors was not considered.
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In our study, we compare clonal cells derived from a common parental cell, that
phenotypically differ in the susceptibility to replicating prions. Our primary aims are to
identify genetic variance that distinguish these phenotypes.

RESULTS

Section I: Identification and Characterization of Susceptible/Resistant RK13 Clones
Expressing Murine PrPC (RKM)
RKM Clonal Selection: We stably transfected RK13 cells with an expression vector
containing the murine PrPC ORF, using the pIRESpuro expression vector. Individual
clones were generated by limited dilution cloning. Seventy-eight single cell RK13
(RKM) clones were identified. Clonal populations were expanded and passaged onto 10cm cell culture plates. PrPC expression in the RKM clones was assessed by Western
immuno-blotting using mAb 6H4 (Fig. 4.1A). RKM clones exhibited differential
expression and processing of PrPC (Fig. 4.1A). PrPC protein levels were evaluated by
densitometry analysis (Fig. 4.1E), using ImageJ image analysis software (Abramoff
2004). The intensity of each protein band on the Western blot was measured and recorded
(Table 4.1).
The variation of PrPC expression is represented in figure 4.1E.

To address

whether PrPC expression levels correlated with prion infectivity in cell culture, the cloned
RKM cells were infected with mouse-adapted RML scrapie prions.
RKM/N2a Clone Infection With RML Scrapie:
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The RKM’s tolerance toward prion replication was assessed using the cell-lift
assay and mSCA (described in chapter 3). Individual RKM clones were infected with
0.2% (w/v) mouse-adapted RML scrapie diseased-BH in a 48-well cell culture format.
The cells were passaged for three consecutive rounds, and analyzed for PK resistant PrPSc
by the cell-lifting assay. The RKM clones exhibited various levels of cellular
permissiveness to prion replication, ranging from robust infectivity to complete resistance
(Fig. 4.1B and Fig. 4.1F). Of the 78 RKM clones infected with RML, 8 (10%) were
resistant, 15 (19%) were partially resistant (show weak signal), 18 (23%) were
moderately sensitive, and were 37 (47%) are highly sensitive (Fig. 4.1B). PK resistant
signals from the cell lifting membranes were evaluated using densitometry analysis,
which is graphically and numerically presented in figure 4.1F and table 4.1.
Limited dilution cloning was used to identify 14 N2a single-cell clones, which
were subject to similar experimental approaches used on the RKM cell. The RML
infected N2a (ScN2a) clones were segregated based on susceptibility: 4 (29%)
completely resistant sub-clones, 5 (36%) partially resistant sub-clones and 5 (36%) highly
susceptible sub-clones (Fig. 4.1C). The dotted lines in figures 4.1B and 4.1C were added
to represent the location of individual clones that demonstrated resistance towards PrPSc
replication, exhibited by the absence PK resistant material.
The mSCA was used to confirm the cell lifting data and semi-quantify the results.
The 78 RKM clones were infected with 0.2% RML using the mSCA format (described in
chapter 3) and passaged three consecutive rounds in a 96-well cell culture plate post
infection. These RML-infected cells were transferred (20,000 total cells) to the 96-well
ELISPOT plate and developed. Figure 4.1D represents the individual well readout using
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the mSCA, while figure 4.1G graphically demonstrates the susceptibility of cells to RML
based on the averaged spot counts. The positive control used for the mSCA were RKM
cells chronically infected with RML and designated with a plus sign (+) in Fig. 4.1D. The
negative control was RK13 cells transfected with an empty expression vector referred to
as RKV and designated by a negative sign (-) in Fig. 4.2C. The clones were infected in
triplicate to establish an average spot count (Fig. 4.1D). Quantitation of PrPSc production
using the mSCA was determined by counting individual spots from each well, which is
presented by a numerical value directly above the well (Table 4.1). The averaged
numerical data of the mSCA and of the cell lifting densitometry data was statistically
applied to ascertain correlation between PrPC expression level and clonal susceptibility to
replicating RML prions.
PrPC expression levels did not correlate with prion susceptibility in the RKM cell
culture model. RKM clones 41 and 47 do not express PrPC and have no detectable levels
of PrPSc (Figs. 4.1A-B, 4.1E-G)(Table 4.1), while RKM clones 8 and 18 express low
levels of PrPC and exhibit moderate production of PrPSc (Figs. 4.1A-B, 4.1E-G). RKM
clones 1, 5, 61, 76 and 78 exhibit robust expression of PrPC by Western blot, however
they did not accumulate PrPSc (Fig. 4.1A and 4.1B) (Table 4.1).
The coefficient of determination (R2) was assessed using linear regression to
calculate the correlation between PrPC expression and PrPSc positive clones (Fig. 4.1H
and Fig. 4.1I). Comparing the correlation between the evaluated densities of PrPC (Fig.
4.1A) and PrPSc (Fig. 4.1B) resulted in a R2 value of 0.01317 (Fig. 4.1H), which strongly
suggests the absence of a relationship between cellular PrP expression levels and
susceptibility for sustaining chronic prion infectivity. The RKM clone sensitivity by cell
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lifting assay (Fig. 4.1B) was confirmed using the mSCA (Fig. 4.1D, exemplary
representation of the assay). Specifically, RKM clones 7, 18, 19, 35, 36, 37, 38, 43, 51,
52, 60, 62, 65, 68 and 75 reveal increased RML susceptibility, while RKM clones 5, 8,
41, 47, 69 and 78 remained mostly PrPSc negative (Fig. 4.1B & 4.1D). The correlation
comparison of PrPC expression to mSCA averaged PrPSc-positive cell counts generated
the R2 value of 0.003517 (Fig. 4.1I). Collectively, our data suggests that PrPC expression
levels in the RKM clones do not dictate cellular susceptibility for RML, and although
PrPC expression is required for infectivity, supplementary host factors are also involved
in the PrPSc replication process.
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Figure 4.1 RKM clonal variability towards PrPC expression and RML susceptibility.
A. 78 clones were identified through limited dilution single-cell cloning. PrPC expression
was assessed by western blotting using mAb 6H4. Actin expression in the lower panel
represents total protein control. Single cell (B) RKM subclones and (C) N2a subclones
were infected with 0.2% (w/v) mouse-adapted RML scrapie prions diseased mouse brain
homogenate (BH), and assayed for prion susceptibility in 24-well cell culture plates by
the cell lifting assay. The cells were grown to confluence on cell culture cover slips.
Confluent cells were transferred to cold lysis buffer soaked nitrocellulose membrane. The
membrane was treated with PK (5µg/ml), denatured with 3M guanidine isothiocyanate,
immunoprobed mAb 6H4. The dark circles represent PK resistant material. D.
Representation of the semi-quantitative modified scrapie cell assay to assess prion
replication in the RKM subclones (examples include clones 1,7,8,9,18,19 &20). RKV
(vector only) and chronically infected RKM cells represent the negative (-) and positive
controls (+), respectively. The clones were seeded to 96-well cell culture plates (20,000
cells/well) and infected with 0.2% (w/v) mouse-adapted RML scrapie prions. On third
passage after infection, the cells were trypsinized and counted. Twenty thousand cells
were transferred to the 96-well ELISPOT filter plates. The plates were treated with PK
(5µg/ml), denatured with 3M guanidine isothiocyanate, immunoprobed with mAb 6H4
primary and an Alkaline-Phophatase (AP)-conjugated anti-mouse secondary antibody.
The combination of NBT (nitro-blue tetrazolium chloride) and BCIP (5-bromo-4-chloro3'-indolyphosphate p-toluidine salt) was used to detect PrPSc positive cells. Each 96-well
plate was scanned using the CTL-ImmunoSpot plate reader and quantification of positive
signal was achieved with the ImmunoSpot Software. (E-F). Western blot PrPC expression
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levels (E) and PK resistant PrPSc from cell lifting membranes (F) were quantified using
the ImageJ analysis software package. The y-axis represents the densitometric value
subtracted from the background of the scanned membrane. The densitometry values used
for the bar graphs are listed in Table 4.1. The x-axis represents the 78 RKM clones in
order from left to right (1…78). PrPC expression does not correlate with susceptibility
towards replicating RML prions. Linear regression was used to calculate the coefficient
of determination (R2) between PrPC expression (x-axis) to (H) cell-lifting PK resistant
PrPSc (y-axis) and (I) modified scrapie cell assay PrPSc-spot counts from infected clones
(y-axis). GraphPad Prism Software was used to graph data points (Table 4.1) and
calculate R2.
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Figure 4.1 RKM clonal variability towards PrPC expression and RML susceptibility.
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Table 4.1 Summary of RML prion replication amongst cloned RKM cells using
three distinct assays for assessment (Abramoff 2004)
RKM$
clone

	
  

PrPC

PK+$
Cell$
Li0

PK+$
SCA

RKM$
clone

PrPC

PK+$
Cell$Li0

PK+$
SCA

RKM$
clone

PrPC

PK+$Cell$
Li0

PK+$
SCA

1

1.2E+07 0.0E+00 150.67

31

6.8E+06 1.3E+05 14.67

61

4.4E+06 9.8E+02

2

8.2E+06 7.7E+04

32

5.6E+06 1.4E+06 45.67

62

5.3E+06 1.5E+06 801.67

3

1.0E+07 4.2E+05 66.5

33

4.3E+06 1.3E+06 112.33

63

7.1E+06 1.4E+05 41.67

4

1.2E+07 5.9E+05 27.16

34

4.1E+06 1.9E+05

64

9.6E+06 1.2E+06 58.67

5

9.3E+06 5.8E+03

35

5.0E+06 1.2E+06 177.33

65

5.6E+06 1.7E+06 326.67

6

1.2E+07 7.6E+05 122.5

36

3.5E+06 1.5E+06 229

66

1.3E+07 1.4E+06 71.67

7

8.6E+06 1.3E+06 706.83

37

8.8E+06 1.3E+06 473

67

1.9E+06 8.3E+05 81.67

8

0.0E+00 8.5E+04

38

2.8E+06 1.4E+06 195.66

68

9.9E+06 1.7E+06

358

9

9.6E+06 7.1E+05 17.83

39

9.2E+06 1.2E+06 125.66

69

0.0E+00 1.3E+02

0

10

6.0E+06 1.2E+06 43.5

40

7.1E+06 1.3E+06 28.33

70

9.1E+06 1.7E+06 52.67

11

3.8E+06 1.2E+06 27.17

41

0.0E+00 5.7E+03 5.33

71

9.7E+06 1.6E+06

12

9.8E+06 1.3E+06 142.83

42

8.6E+06 5.6E+05 105

72

2.7E+06 1.1E+06 8.67

13
14

4.4E+06 2.5E+05 9.83
1.1E+07 1.3E+06 394.5

43
44

9.0E+06 1.3E+06 591.66
9.0E+06 8.3E+05 104.66

73
74

3.1E+05 6.1E+05 475.67
2.9E+06 1.2E+06 65.34

15

9.7E+06 3.9E+05 47.83

45

7.6E+06 1.4E+06 62.33

75

6.5E+06 1.6E+06 802.67

16

6.8E+06 1.2E+06 51.5

46

1.1E+07 1.2E+06 59.33

76

9.3E+06 1.1E+03

17

1.2E+07 1.1E+06 10.5

47

0.0E+00 8.9E+03

77

6.8E+06 7.1E+05 19.67

18

2.5E+06 1.5E+06 972.5

48

6.6E+06 5.7E+04 47.66

78

5.1E+06 3.0E+03

19

7.9E+06 1.4E+06 956.83

49

9.6E+06 5.3E+05 79.33

20

1.0E+07 8.1E+04

50

5.9E+06 1.3E+05 55.33

21

1.0E+07 1.1E+06 16.83

51

4.6E+06 1.5E+06 366.33

22

1.1E+07 1.0E+06 16.83

52

8.4E+06 1.4E+06 241

23

8.5E+06 1.9E+05 23.83

53

8.2E+06 1.3E+06 224.33

24

8.8E+06 1.3E+06 89.67

54

4.9E+06 1.4E+05 83.66

25

8.3E+06 1.8E+05

55

8.0E+06 6.7E+05

70

26

4.6E+06 7.5E+05 5.16

56

6.9E+06 9.2E+05

74

27

8.0E+06 4.9E+04 7.16

57

4.6E+06 4.5E+05 17.66

28

5.9E+06 1.4E+06 69.16

58

6.2E+06 4.5E+04 47.33

29

1.2E+07 4.6E+04 0.16

59

9.7E+06 1.3E+06 110.33

30

8.1E+06 4.5E+04 11.16

60

7.2E+06 1.5E+06 386.66

5

6.5

2.5

3.5

0
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To ascertain chronic replication of RML prions, certain RKM clones were chosen
for expansion and continuous passage. RKM clones 7, 14, 18, 19 and 43 were chosen for
their sensitivity and RKM clones 29, 34, 61 and 78 were selected for their resistance to
RML. Each clone was passaged 20 times and assessed for sustained production of PK
resistant PrPSc. The RML sensitive clones (7, 14, 18, 19 and 43) chronically sustained a
steady state of PK resistant PrPSc, whereas the resistant RKM clones (29, 34, 61 and 78)
exhibited no detectable PK resistant PrPSc (Fig. 4.2A).
To address whether the sensitive/resistant phenotypes of cells reflect differences
in cell surface presentation of PrPC, two clones with similar PrPC expression levels and
distinct prion susceptibility (sensitive/resistant) were selected for cell surface presentation
comparison analysis. The two RKM clones selected for the study were clone 7 (RML
sensitive) and clone 78 (RML resistant) (Figs. 4.1 and 4.2A). Surface expression of PrPC
was analyzed in both clones by flow cytometry. The mAb SAF-32 targeted to the
octapeptide-repeat region located at the N-terminus of the PrPC (Fig. 1.1A) was utilized
for this purpose. The flow cytometric data reveal no differences in cell surface expression
of PrPC between the two clones (Fig. 4.2B).
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Figure 4.2 Accumulation of PK-resistant PrP and PrPC surface expression in RML
susceptible and resistant RKM clones. A. RML sensitive (7, 14, 18, 19, & 43) and
resistant (29, 34, 61 & 78) clones cell lysates were PK digested and analyzed by Western
immuno blotting after 20 passages. RKV (vector only) and chronically infected RKM
cells represent the negative (-) and positive controls (+), respectively. PrPSc was detected
using mAb 6H4. B. PrPC cell surface expression was assessed in RML sensitive (RKM
clone 7, green line) and resistant (RKM clone 78, red line) and compared to the non-PrPC
expressing RK13 control (blue line) by flow cytometry. The SAF-32 mAb was used for
cell surface detection of PrPC. The y- and x-axis of the histogram represents the cellular
counts and the mean fluorescent intensity (MFI) of PrPC, respectively. (C) Subsequent
RML-susceptibility analyses of uninfected RKM clones (7 & 78) revealed RKM-78
(Resistant) ability to replicate low-levels of PK resistant PrPSc. The Western blot
represents cell lysate analysis after 12 passage rounds. PrP was detected using mAb 6H4.
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Figure 4.2 Accumulation of PK-resistant PrP and PrPC surface expression in RML
susceptible and resistant RKM clones.
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Transcriptional Profiling By RDA: RKM clones 7 and 78 were utilized as the
representative clones for transcriptional profiling by RDA. The two clones were
subjected to three successive rounds of subtractive hybridization and amplification. The
stringency of hybridization was increased with each round (Fig. 4.3). The final enriched
PCR products of RKM 7 and RKM 78 were separated using 2% agarose DNA gel
electrophoresis (Fig. 4.3).

Distinct PCR bands were identified for both subtractive

reactions and exhibited specific migration patterns in the range of 150 bp - 400 bp (Fig.
4.3). These DNA bands were carefully excised, purified and cloned into the pGEM-T
vector. The cloned products were transformed into competent bacterial cells and grown
on antibiotic selective agar plates. A total of 98 individual colonies were picked between
the two clonal RDA products. Plasmids were purified from these colonies and
subsequently sequenced to identify specific transcripts. A total of eight unique nonhomologous transcripts were recognized between the susceptible and resistant clones
(Table’s 4.2 and 4.3).
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Figure 4.3 RDA for the identification of differentially expressed genes in RKM
subclones. The 2% agarose gels represent sequential subtractive hybridization coupled to
PCR-mediated enrichment for differentially expressed transcripts in susceptible (RKM7)
and resistant (RKM78) clones. Representation of two nearly identical DNA pools is
generated in round 1, followed by subtractive/kinetic enrichment for distinct difference
product in rounds 2 and 3. For each round, lane (A) represents RKM 7 (susceptible) clone
as the tester (cDNA limited) cDNA amplifying non-homologous sequences unique to that
cell that is subtracted by RKM 78 (resistant) clone driver (cDNA added in access). Lane
(B) is the subtractive/kinetic enrichment in reverse order of (A). The tester:driver
stringency ratios were increased for each subtractive round as follows: Round 1: 1:50,
Round 2: 1:500, Round 3: 1:1000
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Figure 4.3 RDA for the identification of differentially expressed genes in RKM
subclones.
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RDA Identified Transcripts From RKM Clone 7 (Sensitive): Four specific transcripts
were identified in RKM clone 7 by RDA profiling. Three of these four transcripts are
either hypothetical and/or conserved hypothetical sequences. Thus, they completely lack
functional data to support their existence. The criteria used by the National Center for
Biotechnology Information (NCBI) to categorizes identified sequences as hypothetical
proteins are based on one of two factors. The protein is deemed hypothetical if its
sequence is homologous to genes of unknown function in the NCB database and/or no
known homologs exist (Sivashankari and Shanmughavel 2006). All three proteins were
derived from the Oryctolagus cuniculus (rabbit) genomic sequences annotated using the
gene prediction method, GNOMON and supported by EST evidence. The GNOMON
gene prediction method is used to predict and annotate genes from poorly unannotated
genomes. A complete overview of GNOMON and the NCBI eukaryotic gene prediction
tool

is

available

on

the

NCBI

website

(http://www.ncbi.nlm.nih.gov/projects/genome/guide/gnomon.shtml).
The hypothetical protein with accession number XM_002722317 has not been
characterized (Table 4.2). The NCBI nucleotide database search indicates that this
predicted protein is 343 amino acids in length and has an approximate molecular weight
of 37-kDa (Table 4.3). This novel protein has orthologs throughout mammalian species
but has not been functionally analyzed in any of them. The Homo sapiens (human)
ortholog is 351 amino acids long and belongs to the uncharacterized protein family 0692
(UPF0692). The Universal Protein Resource (UniProt) database analysis of this protein
indicates that it exists at the protein level (subsection of protein attributes descriptor), is
found on human chromosome 19, has three potential splice variants and is

	
  

162	
  

posttranslationally modified with the attachment of a phosphate at a serine residue in the
c-terminus of the peptide (316 aa, phosphorylated) (Gerhard, Wagner et al. 2004;
Grimwood, Gordon et al. 2004; Ota, Suzuki et al. 2004; Dephoure, Zhou et al. 2008). In
addition to the UniProt data mining, structure and localization prediction analyses were
done using the ExPASy bioinformatic resource portal (http://expasy.org/tools/). TargetP
(http://www.cbs.dtu.dk/services/TargetP/),

a

bioinformatic

tool

used

to

predict

subcellular location of eukaryotic proteins indicates that this protein could localize to the
mitochondria (mitochondrial targeting sequence) and/or vesicles of the secretory
pathways (by signal sequence) (Emanuelsson, Nielsen et al. 2000). YASPIN secondary
structure prediction tool (http://www.ibi.vu.nl/programs/yaspinwww/) predicts that this
hypothetical protein is predominantly coiled due to a proline-rich composition (Lin,
Simossis et al. 2005). In addition to the overall coiled structure, 7 α-helices and 8 βsheets are predicted to span the entire protein (Table 4.3). Thus, although the protein has
not been experimentally analyzed, the predicted attributes (evolutionary conservation,
phosphorylation site, and highly structured) suggest that it has a physiological function
that has yet to be defined. Moreover, as a unique transcript identified in RKM clone 7,
this peptide could be one of the unidentified cofactors that are responsible for the prion
susceptibility phenotype.
The second hypothetical protein recognized by the RDA has the accession
number of XM_002723849 (Table 4.2). Like the above-mentioned hypothetical protein,
this transcript has not been described and has not been shown to exist at the protein level.
Additional bioinformatic database searches indicate that all data collected in regards to
this protein is predicted and preliminary (Di Palma F. 2009). If this protein does exist, it
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would be 533aa (488aa predicted) in length and have an approximate mass of 54.3-kDa
(Table 4.3) (UniProtKB sequence analysis, http://www.uniprot.org/uniprot/G1TFK2).
TargetP analysis indicates that this protein would localize to the mitochondria
(Emanuelsson, Nielsen et al. 2000). YASPIN secondary structure prediction analysis
indicates that this protein is predominantly unstructured but does have one short α-helix
domain (~6aa) at the N-terminus and two short β-sheet domains (13aa and 4aa) at the Cterminus (Lin, Simossis et al. 2005). Furthermore, NCBI BLASTp analysis reveals that
the C-terminus of this novel protein is homologous (7% of total protein) to a human
integral membrane transporter protein with an accession number of CAB81951. This
protein is also categorized as hypothetical but has more descriptors that indicate its
primary function is involved with anti-apoptotic signaling (Liu 2000).
The third predicted transcript identified by RDA is categorized as a conserved
hypothetical protein, meaning that its sequence is homologous to proteins that already
have designated biological function. This protein is identified in the NCBI database by
the accession number of XM_002723594 (Table 4.2) and is predicted to function as a
signal transducer with kinase activity (http://www.ncbi.nlm.nih.gov/protein/291414786).
UniProt analysis extrapolates this protein to have serine/threonine kinase activity, signal
transducing activity and ATP binding affinity (http://www.uniprot.org/uniprot/G1TSK1).
This hypothetical protein is large, it spans for 1,295aa and has molecular weight of 139.7kDa (Table 4.3)(Di Palma F. 2009). The protein is predicted to have the PAS domain that
contains serine/threonine kinase activity. PAS domains are evolutionary conserved
signaling domains found in proteins which tend to function by associating with specific
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cofactors (Ponting and Aravind 1997). Structurally, this protein is predicted to have 25
α-helices and 37 β-sheets (Lin, Simossis et al. 2005).
The fourth unique transcript identified by the RDA in the RKM 7 susceptible
clone is the rabbit MT-2 processed gene for metallothionein (accession number
X07791.1). Described as a pseudogene without associated function, the transcript belongs
to the family of low molecular weight (7 kDa), heavy metal-binding proteins with high
cysteine content (Table 4.2). Metallothionein proteins generally localize to the Golgi and
are assumed to confer protection against oxidative stress regulating metal homeostasis in
the cell (Blindauer and Leszczyszyn 2010).
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Table 4.2 Transcripts identified by RDA in the prion susceptible RKM 7 clone
Accession #
Susceptible RKM 7
Function

	
  

XM_002723849 hypothetical protein
LOC100353326

Not characterized, novel protein.
Partially homologous to an integral membrane
transporter protein [Homo sapiens]. Associated
with anti-apoptosis signaling

XM_002723594 PAS domain containing
serine/threonine kinase
(LOC100338542),
mRNA

PAS domains regulate the function of many
intracellular signaling pathways in response to
both extrinsic and intrinsic stimuli

XM_002722317 hypothetical protein
LOC100338446

Not characterized, novel protein

X07791.1

Pseudogene, family of low molecular weight,
heavy metal-binding proteins characterized by a
high cysteine content

Rabbit MT-2 processed
gene for metallothionein
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Table 4.3 Bioinformatic Prediction and Analysis Of RDA Identified Hypothetical
Proteins
LOC100338446 –
XM_002722317

LOC100338542 –
XM_002723594

A

B

Predicted
Structure

LOC100353326 –
XM_002723849

No
Predicted
Structure

XM_002722317

XM_002723594

XM_002723849

Predicted
Residues

1-113aa, 114-222aa

(A)1-114, (B)47-131,
132-321, 322-364

NA

Size (AA/
kDa)

343aa/37-kDa

1,295aa/139.7-kDa

533aa/54.3-kDa

Functional
Category

Biosynthesis of
Cofactors/
Translation

Purines/Pyrimidines,
Biosynthesis of
Cofactors, Central
Intermediary
Metabolism

Translation

EnzymeClass

Enzyme-Lyase

Enzyme-Ligase/
Hydrolase

Non-enzyme

Gene
Ontology

Transcription/
Growth Factor

Structural Protein,
Transcription
Regulation, Growth
Factor

TranscriptionRegulation

Secondary
Structure
Prediction

(7) α-helix, (8) βsheet

(25) α-helix, (37) βsheet

Unstructured

Domains

Extracellular,
Tyrosine-ProteinKinase Receptorlike, Titin-like,
IGSF-like
Fibronectin-like,
Tenascin-X,
Filamin-like

PAS, MAPK-like,
Protein Kinase,
Tyrosine-ProteinKinase-Fyn, Serine/
Threonine protein
kinase

No Predicted Domains

Notable
Motif

Binds EVH1(WH1),
WW(PRP40
&Fe65), SH3,
Endothiapepsin,
Rhodopsin, Protein
Modification
Targets,
Phosphorylation
Sites

Binds NAD,NADP,
FAD, Cullin, Ubiquitin,
SH3, Rhodopsin,
Ankrin B, eIF4E,
Protein Modification
Targets,
Phosphorylation Sites

Binds ATP, NADP,
DNA Proteolysis by
Furin, Modification
Signals
(Phosphorylation,
Trafficking to ER,
Endocytosis) Protein
Binding

*Databases employed for analysis: Minimotif Miner 3.0, ProtFun 2.2, CATH v3.4,
YASPIN, BLAST (Lin, Simossis et al. 2005; Balla, Thapar et al. 2006; Di Palma F.
2009; Rajasekaran, Balla et al. 2009; Mi, Merlin et al. 2012)
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RDA Identified Transcripts From RKM Clone 78 (Resistant): Similarly to RKM clone 7,
RDA transcription profiling of RKM clone 78 (resistant) identified four unique
transcripts (Table 4.4). These transcripts were unrelated to the transcripts identified in
RKM clone 7. The transcripts unique to RKM clone 78 have enzymatic functions, which
are associated with protein degradation, chaperone protein folding and endogenous
retroviral elements.
A transcript homologous to the rabbit endogenous retrovirus H (RERV-H)
(accession number AF480925) was identified using RDA in RKM clone 78. PCR
screening of human tissue led to the identification of RERV-H, considered to be a novel
human retrovirus (Griffiths, Venables et al. 1997). Subsequent cloning studies revealed
the correct origin of RERV-H to originate from European rabbits (Griffiths, Voisset et al.
2002). This endogenous retrovirus is genome encoded and maintains highly conserved
ORF for the gag, pro and pol retroviral elements (Griffiths, Voisset et al. 2002).
Although functional characterization is still absent for this endogenous retrovirus, in vitro
analysis has revealed that the RERV-H viral protease (PR, pro ORF) is active if
recombinantly generated (Voisset, Myers et al. 2003).

Retroviral proteases are

functionally classified in the aspartic protease enzyme family (Wlodawer and Gustchina
2000), and have been identified in a wide range of living organisms (Davies 1990; Hill
and Phylip 1997).
The chaperonin-containing TCP-1 subunit gamma (CCT3), a transcript identified
in RKM clone 78, belongs to the molecular chaperone complex called the TCP1 ring
(TRiC) (Table 4.4). The predominant function of this chaperonin is to facilitate actin and
tubulin folding (Kubota, Hynes et al. 1994). This 60kDa protein is an evolutionary
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conserved member of a heat shock/chaperonin family with strong relation to Hsp60
(Kubota, Hynes et al. 1995). The CCT complex has been shown to promote activation of
the anaphase-promoting complex (APC/C) by directly interacting with cell-division cycle
protein 20 (Cdc20), a regulator of cell division (Camasses, Bogdanova et al. 2003). The
direct interaction of CCT with Cdc20 positively regulates cell division, causing the cell
cycle to progress (Camasses, Bogdanova et al. 2003).
The plasma alpha-1-antiprotease S-1 protein (accession number D16104.1) and
mannose-binding protein associated serine protease-3 (MASP-1/3) (accession number
XM_002716369.1) were two proteins identified in RKM clone 78 and associated with
enzyme regulatory activity. Plasma alpha-1-antiproteases are glycoproteins that inhibit
serine proteases, which include trypsin, chymotrypsin, elastase and plasmin (Travis and
Salvesen 1983; Potempa, Watorek et al. 1986). Unlike other plasma alpha-1antiproteases, the rabbit alpha-1-antiprotease S-1 has been characterized to protect trypsin
from inactivation by other protease inhibitors (Saito and Sinohara 1993). While, MASP1/3 is a serine protease that is involved in the lectin pathway activation complex of
complement (Stover, Lynch et al. 2003). The function of this protease has not been
determined but the related MASP-1 has been determined to cleave C3 and C2, while
MASP-2 cleaves C4 and C2 complement components to produce the C3 convertase,
C4BC2B (Matsushita, Thiel et al. 2000). Complement is an indispensable constituent of
the innate immune response. Furthermore, complement activation has been demonstrated
to facilitate prion infection in vivo (Klein, Kaeser et al. 2001) with a converse effect upon
depletion (Mabbott, Bruce et al. 2001).
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Section Summary: RK13 cells expressing mouse PrPC were individually cloned from a
bulk selected cell culture population. The individual clones were assessed for PrPC
expression level and susceptibility to replicating RML scrapie prions (Fig. 4.1). Although
required, the variability of PrPC expression amongst clonally selected RKM cells was the
only determining factor for prion susceptibility (Fig. 4.1), and there was no correlation
between PrPC expression levels and PrPSc accumulation (Fig. 4.1). Several RKM clones
were isolated that conferred the susceptible or resistant phenotype for RML prions (Fig.
4.2). These clones were continuously passaged to determine their ability to sustain
chronic infectivity. PrPC cell-surface presentation was assessed in individual clones
bestowing the RML sensitive or resistant phenotypes (Fig. 4.2), but no difference in PrPC
surface presentation was observed. We applied RDA assay to assess transcriptional
differences between these clones. A total of eight unique transcripts were identified
between the sensitive and resistant clones (Tables 4.2 & 4.4). In the midst of the RDA
analysis, it was discovered that RKM-78 (resistant clone) had the ability to replicate lowlevels of PK resistant PrPSc (Fig. 4.2C).
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Table 4.4 Transcripts identified by RDA in the prion resistant RKM 78 clone

	
  

Accession
#

Resistant RKM 78

Function

AF480925

rabbit endogenous retrovirus H

Contains Functional gag, pro & pol

XM_00271
5377

chaperonin-containing TCP-1 subunit molecular chaperone called TCP1 ring complex
gamma (CCT3) mRNA
(TRiC) plays a role in actin and tubulin folding

D16104.1

mRNA for plasma alpha-1antiproteinase S-1, complete cds

Protects Trypsin from inactivation

XM_00271
6369.1

mannose-binding protein
associated serine protease-3
(MASP-1/3), mRNA

Serine protease involved in complement
activation
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Section II: The Identification of CWD Susceptible and Resistant RK13-Deer PrPC
(RKD) Clones
Isolation And Characterization Of Sensitive And Resistant Clones: RKD clonal cells were
generated using the multi-step stable transfection process to co-express deer PrPC and
HIV-1 Gag (Fig. 4.4A). CWD sensitivity of clones was determined. RKD cells were
cloned by limited dilution and infected with 0.2% (w/v) CWD isolate 012-09442
passaged through Tg(deerPrP)1536+/- mice (Table 3.1). RKD6 clone demonstrated
susceptibility to CWD but could not sustain chronic replication of CWD prions. RKD6
cells were re-transfected with HIV-1 Gag , and the resulting RKD6-Gag cells were reinfected with CWD isolate 012-09442 and cloned by limited dilution. This resulted in the
isolation of the 5E9 clonal cell line, which chronically replicates CWD prions (Fig.
4.4A). Subsequently, the 5E9 RKD clone was cured of CWD prions by single cell
cloning, which enabled the identification of sub-clones that were either resistant or
susceptible to CWD prions (Fig. 4.4A). A total of 20 5E9 sub-clones were identified
using this procedure (10 susceptible and 10 resistant). Of those 20, 12 5E9 RKD subclones (6 sensitive and 6 resistant) were chosen for subsequent confirmation of
susceptibility and microarray transcriptional profiling.
Confirmation of Susceptibility In RKD Subclones: Confirmation of CWD prion
susceptibility was a prerequisite to transcriptional profiling. Twelve clones were reinfected with CWD prions and passaged three rounds. At passage three, Western blotting
was used to assess PrPSc accumulation. Six chosen 5E9 RKD-resistant (RKD-R) clones
remained free of PK resistant CerPrPSc material (Fig. 4.4B, left blot), while the sensitive
5E9 RKD cells (RKD-S) reconfirmed their ability to accumulate PK resistant CerPrPSc
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(Fig. 4.4B, right blot). Equal amount of total protein was used throughout the experiment
(Fig. 4.1B & C). PrP density measurements showed similar amount of PrPC expression
among the twelve RKD clones with only RKD-S cells replicating CWD prions.
The twelve CWD prion infected 5E9 RKD clones were continuously passaged to
monitor prion replication in later passages. At the 12th passage, the sub-clones were rescreened for PK resistant CerPrPSc accumulation by Western blotting (Fig. 4.4C). RKD-R
cells remained CerPrPSc negative, (Fig. 4.4C, left blot). However, RKD-S3 and RKD-S6
sub-clones became CerPrPSc negative by the 12th passage (Fig. 4.4C, right blot), raising
the possibility for a cellular phenotype that supports incomplete expression of the
necessary host factors required for CWD prion susceptibility (Fig. 4.4C).
Microarray Transcription Profiling: Previous data suggests there is no change in
differential gene expression in cell cultures pre- and post- prion exposure (Julius, Hutter
et al. 2008), indicating that endogenous prion host factors are always present. Total RNA
was isolated from RKD sub-clones prior CWD prion re-infection. Microarray analysis
was not initiated until the susceptibility phenotypes were reconfirmed. Isolated RNA was
reversed transcribed, Cy-3 labeled, and hybridized to microarray chips for gene
expression analysis, after CWD prion susceptibility confirmation.
Statistical Analysis of Microarray Data: The rabbit 4x44K chip used in these studies is
shown in figure 4.5A. Acquired expression data from RKD clonal cells was Log2
transformed and normalized using robust multichip average (RMA) normalization
method (Bolstad, Irizarry et al. 2003; Smyth, Yang et al. 2003; Kerr and Churchill 2007).
Log2 transformation of microarray spot intensities and ratios is a prerequisite to data
normalization processing. The transformation creates independence between intensity
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variation and absolute magnitude of the data set (Smyth, Yang et al. 2003). Taking base 2
log of all spot intensity data from microarray scans completes this transformation.
Normalization of microarray data removes background noise from nonspecific binding of
fluorophores and reduces variances introduced by physical flaws of the printed chips.
These normalization methods produced smoothed gene expression data sets that could be
used in statistical analyses. The smoothed data sets were analyzed for mathematical
stringency to determine significance.
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Figure 4.4 Molecular characterizations of RKD subclones. A. Schematic of molecular
characterization steps used to identify CWD prion susceptible and resistant RKD clonal
cells. Western blot analysis representing RKD-R and RKD-S cells infected with 0.2 %
(w/v) CWD prion brain homogenate, isolate CWD 012-09442 passaged through
Tg1536+/- mice, post (B) 3 and (C) 12 passages. The total protein amount used for
analysis was 15µg for PK(-) lanes and 1000µg for PK(+) lanes. The mAb 9E9 was used
to detect PrP signal. The designation of each clone goes by the letter indicating it’s
phenotype; resistant (R) or sensitive (S), and by a number indicating individual subclones (R1…R6, S1….S6). (D) Western blot PrPC and PK resistant CerPrPSc expression
levels were quantified using the ImageJ analysis software package The y-axis represents
numerical densitometry value subtracted from the background of the scanned membrane.
The x-axis represents the resistant (R) and sensitive (S) RKD clones. Blue bars represent
total PrPC expression without PK treatment. Red bars represent the density of PK+
material CerPrPSc.
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Figure 4.4 Molecular characterizations of RKD subclones.
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Figure 4.4 Molecular characterizations of RKD subclones.
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To increase stringency and remove false positive and false negative data,
restrictions were set to eliminate saturated or near background gene signal intensities.
Statistical stringency was set by two distinct parameters, which were t-test p-values and
fold-cutoff (FC) change. Most stringent of analyses used a t-test p-value of ≤ 0.001 and a
FC of ≥ 2.0 (Fig. 4.5B, Tables 4.5 and 4.6), while the least stringent analysis used t-test
p-value of ≤ 0.05 and a FC of ≥ 1.5. The volcano plot exhibited in figure 4.5B graphically
represents genes that were either above or below the higher stringency threshold. The yaxis of the volcano plot represents t-test p-values, while the horizontal dotted line
spanning the graph represents p-value threshold of 0.001. The line signifies all events
(black dots - genes), which were statistically significant and relevant for further analysis.
The x-axis of the volcano plot represents FC change, signifying the averaged gene probe
intensities of RKD-R gene expression results directly compared to RKD-S gene
expression (Fig. 4.5B). In summary, the higher the signal is above red line in either
direction, the more significant it is to the overall analysis.
A relationship model to predict mathematical correlation between each RKD
clone was established using the principal component analysis (PCA). The PCA is an
orthogonal transformation tool used for investigative data analysis and assist in predictive
model construction (Jolliffe 2002; Peterson 2002). This procedure is purely mathematical
and does not consider biological significance. The differences identified were based of
numerical intensities for each individual probe representing the RKD subclones analyzed.
The data samples were spatially clustered in two dimensions to demonstrate relationship
similarities (Fig. 4.5C). The numbers on the graph represent distinct RKD sub-clones and
the colors represents susceptibility phenotype for CWD prions (RKD-S = Red and RKD-
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R = Blue) (Fig. 4.5C). The PCA data demonstrates distinct clustering of sensitive and
resistant clones (Fig. 4.5C). Spatial distribution of clusters graphically represents
variation of gene expression profiles between each clone. The resistant clones cluster into
three distinct groups to the left quadrants of the PCA1 x-axis and the four sensitive clones
distinctively cluster to the right of the PCA1 x-axis. Thus demarcating a phenotypic
difference between the two groups, albeit two of the sensitive clones (RKD-S 3&4) plot
closer to the resistant clusters (Fig. 4.5C). The PCA graph gives a global glimpse into the
distribution of acquired microarray raw data. Differential distribution of RKD subclones
by PCA is first to suggest the possibility for multiple factors/pathways that are involved
to cause prion susceptibility in RKD subclonal cells. Bioinformatic analysis of
normalized gene intensity data is required to acquire additional detail and significance
associated with the PCA findings.
Cluster analysis is a technique utilized to establish phylogenetic relationships
between evolutionary conserved genes from various species. Hierarchical cluster analysis
algorithm was used to graphically represent RKD normalized microarray data (Fig.
4.5D). The hierarchical cluster data was analyzed by sequentially comparing rows
(genes) from each column (RKM clones) side by side. Hypothesis for experimental
relationship and significance was determined by analyzing both variables. Ten
differential gene clusters were identified using this method (Fig. 4.5D). Gene clustering
data exhibited in figure 4.5D was based on a statistical stringency threshold of p-value ≤
0.05 and FC ≥1.5. This analysis provided a more global perspective on the physiological
conditions occurring in RKD cells.
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Analysis Of Normalized Microarray Data: The hierarchal cluster analysis revealed genes
that were associated with various cellular functions. To derive these associated functions,
genes from each cluster were systematically annotated and database mined. Database
mining revealed specific protein functions associated with endomembrane system
trafficking, proteolysis, protein maintenance, protein biosynthesis, cell division and metal
ion binding. Moreover, these annotated clusters provide insight to target pathways that
could be important prion replication. In particular, the distinct clustering of RKD-S3 and
RKD-S6 demonstrate an interesting reflection of phenotypic variation and instability
(Fig. 4.5D). These two clones were considered susceptible by primary and secondary
CWD prion infection studies but with continuous passages lost detectable PK resistant
CerPrPSc (Fig. 4.4B and Fig. 4.4C). Hierarchal cluster visual analysis of S3 and S6
clearly demonstrates a distinct clustering pattern, which they share with both resistant and
sensitive counterparts (Fig. 4.5D). These findings suggest that clones S3 and S6 represent
a “quasi-“sensitive species that lacks the full repertoire of host factors required for
chronic replication of CWD prions. Subsequent bioinformatic analyses were used to
confirm these microarray data findings.
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Figure 4.5 Microarray statistical data analysis of differential gene expression in 5E9
RKD CWD prion subclones. A. Representative image of the Rabbit Gene expression
4x44k microarray chip B. Statistical volcano plot of significantly expressed genes from
RKD-R cells subtracted from RKD-S cells with stringency thresholds set to a p-value
≤0.001 and FC ≥2.0. The x-axis represents FC and the y-axis represents p-value. The red
line on the plot was set for p-value 0.00, all black dots (genes) above the line were
statistically significant. C. Principal component analysis (PCA) of the 12 RKD clones in
two-dimensional schematic. Red numbers represent RKD-S clones and blue numbers
represent RKD-R clones. The PCA correlates each mathematical component (RKD
Microarray normalized signal intensity) and clusters it in multi-dimensional coordinates
to demonstrate the relationship and internal structure of a complex data set. D. Heat map
of hierarchical gene clustering using the microarray data derived from the 12 RKD
clones. A graphical representation of gene expression similarities. Each column
represents individual RKD clones, labeled at the bottom of the heat map. The rows
represent specific probes (genes). The intensity of red indicates high expression to the
sample mean and the blue low expression. Ten clusters were identified, from top to
bottom.
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Figure 4.5 Microarray statistical data analysis of differential gene expression in 5E9
RKD CWD prion subclones.
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Gene List Development and Annotation: Several gene lists were derived from the
microarray analyses. The gene selection criteria to develop the lists were based on the
following: averaged total gene signal intensities ((R1+R2+R3…R6)/6) for each
individual gene and statistical thresholds (mentioned earlier). A total of 100 differentially
expressed genes were identified using stringent conditions set to t-test p-value ≤ 0.001
and FC of ≥ 2.0 (Table 4.5). RKD-R clones exhibited 32-up and 68-down regulated genes
using this threshold parameter (Table 4.5). This statistical stringency leaves no doubt that
the genes were differentially expressed, therefore making them primary targets for future
validation. These 100 annotated genes are listed in their entirety in tables 4.6 and 4.7.
Reduction of statistical stringency to p-values of ≤ 0.05 and FC of ≥ 1.5 resulted in a
larger gene list used to gain a global perspective of biological processes (Table 4.5). A
total of 1,375 genes were derived using this statistical stringency parameter.
The ongoing rabbit genome-sequencing project made gene annotation of our data
challenging. Manual ortholog data mining using multiple database search engines were
used to derive the described gene lists. Completing the annotation of these lists required
careful extraction and conversion of rabbit gene probes to mouse or human ortholog gene
identification names, and symbols. In addition to identifying functional roles of these
orthologs, the ortholog conversion enabled the use of gene ontology databases to assess
pathway connections and interacting molecules. These databases are currently limited to
human and/or mouse annotations.
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Table 4.5 Summarization of identified and annotated genes lists by microarray
experiments.
Analysis

RKD-R (Resistant) Up
Regulated Genes

RKD-S (Sensitive)
Up Regulated
Genes

Fold Cutoff 2.0
Pval 0.001

32 Genes

68 Genes

Fold Cutoff 1.5
Pval 0.05

664 Genes

711 Genes

FC1.5 Cross
referenced to Prion
Disease Database
(PDDB)

132 Genes

182 Genes

PDDB – The total identified genes from the FC1.5 data subset is cross
referenced to the differentially expressed genes identified from in vivo
studies following RML infection at 6, 10, 14, 18, 20 and 22 weeks post
inoculation.
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Functional Correlation Of Gene Data Using Gene Association/Prediction Databases:
Large-scale analysis of microarray data requires access to genomic databases that
maintain gene annotation with reference to peer-reviewed literature. In addition, these
databases require immense computational power to cross-reference the users gene/probe
names against the validated/annotated genes of the database. The databases applied to our
microarray analysis include the Protein ANalysis Through Evolutionary Relationships
(PANTHER) and the Database for Annotation, Visualization and Integrated Discovery
(DAVID). The PANTHER database functions by applying user’s input gene data and
cross-referencing it through all data published in scientific journals containing
experimental evidence as validating support. Moreover, this database also utilizes
evolutionary relationships to predict function (http://www.pantherdb.org/). This database
has several classification systems that are sub-categorized into the following; Gene
families and subfamilies, Gene ontology classes, PANTHER Protein classes and
Pathways.
The DAVID database provides users with comprehensive mathematical tools that
assist in functional annotation and understand large gene lists derived specifically from
transcription profiling experiments (http://david.abcc.ncifcrf.gov). This database enables
identification of enriched biological themes, gene relationship and simplifies data sets by
removing genes that are redundant. In addition, DAVID also cross-references other
databases for pathway information, rapid literature searches and structural information.
Furthermore, DAVID converts gene identifier between species, a beneficial function to
our study. Although the conversion of identifiers comes with a caveat that assumes the
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genes have previously been annotated, a hurdle to overcome with the poorly annotated
rabbit genome.
Uploading the 1,375 RKD differentially expressed genes into PANTHER
database provided the global perspective into the difference of physiological functions
between sensitive and resistant cells (Fig. 4.6). Extrapolating the data from PANTHER
and DAVID databases establishes biological function associations to analyze by
validation in RKD clones. The summaries of the functions are exhibited by percentages
of total genes compared to biological parameters and constraints established through
respective databases (Fig. 4.6). The molecular functions that associate with differentially
expressed RKD gene predominantly participate in binding activity (33%), catalytic
activity (30%) or could not be classified (34%) by PANTHER (Fig. 4.6A), while cellular
processes were divided between metabolism (39%), cell communication (21%), transport
(29%) and unclassified (29%) (Fig. 4.6B). Pathway predictions using PANTHER has
enabled the identification of 38 differentially expressed genes associating with protein
misfolding diseases such as AD, PD and HD (Fig. 4.6C).
Although simplified, DAVID database analyses provide the most comprehensive
insight into cellular physiological differences between RKD clones (Fig. 4.6D).
Metabolic processes involved with protein maintenance, intracellular trafficking and
plasma membrane delivery of glycosylphosphatidylinisotol (GPI)- anchored proteins
represented RKD-R down regulated genes. RKD-R and RKD-S gene expression profile
have inverse relationship, down-regulated genes in RKD-R were upregulated in RKD-S
cells and vice versa. Hence, protein maintenance processes that were down-regulated in
RKD-R, dominate the expression profile of the RKD-S cells (Fig. 4.6D). Suggesting that
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primary selection of host factors for validation should include protein that regulate
homeostasis, intracellular trafficking and lipid raft PrP co-localized proteins. Our in vitro
data provides support and allows the opportunity to validate these gene expression
interpretations. In contrast, DAVID investigation of RKD-R upregulated genes reveals
the enrichment of cell division and DNA replication processes (Fig. 4.6D). Therefore,
higher rate of cell division in resistant cells generates unfavorable condition for prion
replication. We have not analyzed the rate of cell division between RKD-R and RKD-S
cells.
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Figure 4.6 Bioinformatic analysis of 1,375 RKD-R differentially expressed genes. A.
Graphical representation of molecular function percentage representing the complete
gene list developed through the PANTHER database. B. Clustering percentage of the
differentially expressed genes associated to a cellular process developed through the
PANTHER database. C. PANTHER database pathway prediction clustering graph. Total
of 1168 gene IDs were mapped. Classification specificities are based on published
literature association predictions. D. Graph representing the separation of differentially
expressed genes based on positive/negative expression values to demonstrate clustered
functionality using the DAVID database.
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Figure 4.6 Bioinformatic analysis of the 1,375 RKD-R differentially expressed genes.
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Figure 4.6 Bioinformatic analysis of the 1,375 RKD-R differentially expressed genes.
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Figure 4.6 Bioinformatic analysis of the 1,375 RKD-R differentially expressed genes.
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Section Summary: RKD cells were genetically modified to express Deer PrPC and HIV-1
Gag, similar to ELK21+ cells. Limited dilution cloning was used to derive CWD prion
susceptible and resistant RKD clones (Fig. 4.4A). RKD clonal susceptibility to CWD
prions was the phenotypic basis used to select cells for transcriptional profiling analyses
(Fig. 4.4B). Differential gene expression was assessed using rabbit gene expression
microarray chips (Fig. 4.5A). Twelve clones were transcriptionally profiled using
microarrays. Transcriptional profiling revealed a significant difference in gene expression
between RKD-R and RKD-S clones (Fig. 4.5B,C and D). Continuous passage of CWD
prion infected clones subsequently revealed the loss of PK resistant CerPrPSc material in
RKD-S3 and S6 clones, which also exhibited a unique, and distinguishing gene
expression profile (Fig. 4.4C and Fig. 4.5D). Averaging signal intensities and applying
statistical stringency thresholds led to the development of a dual-parameter based gene
lists (Table 4.5). Global characterization of differentially expressed genes was achieved
using DAVID and PANTHER bioinformatic databases (Fig. 4.6). These analyses of
differentially expressed genes are discussed in the proceeding sections of this thesis.
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Discussion
Section I
PrPC Expression and Clonal Susceptibility Towards PrPSc Replication: Several studies
have demonstrated the primary role of PrPC as the substrate for PrPSc conversion and
prion disease but few have addressed the underlying factors that allow or inhibit
processes at the cellular level. N2a cell culture studies showed that prion susceptibility
was a rare event (~0.7% N2a cells accumulate PrPSc) (Race, Fadness et al. 1987).
Additional prion infectivity experiments using N2a cells identified sub-clonal populations
that exhibit susceptibility variation (Bosque and Prusiner 2000). These findings suggest
that susceptibility in clonal cells does depend on PrPC expression level in cells. In
contrast, in vivo data demonstrates a direct correlation between expression level and
PrPSc accumulation and a inverse relationship for incubation time of disease (Westaway,
Mirenda et al. 1991). The findings from cell culture studies suggest that additional
cofactors are involved to confer cell permissiveness to prion conversion and replication.
Ectopic expression of PrPC in cells cultured from Prnp0/0 mice do not support prion
replication, although ectopic expression of PrPC in Prnp0/0 mice replicate prions and
succumb to disease (Raeber, Sailer et al. 1999). To extend these findings and identify
additional host factors, we chose to use genetically modulated RK13 cells that ectopically
express PrPC.
Our findings suggest that PrPC expression levels do not correlate with cellular
susceptibility to replicating prions (Fig. 4.1 and Fig. 4.4). RKM clonal susceptibility
confirms the absolute requirement of PrPC expression for sustaining prion replication.
RK13 cells replicate prions derived from mice, hamster, ovine and cervid (both elk and
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deer) but vary in efficiency (Vilette, Andreoletti et al. 2001; Bian, Napier et al. 2010).
RKM cells became readily infected with RML prions, while Elk21+ and RKD cells
require supplemental factors and multiple cloning to identify CWD prion permissive cells
(Fig. 4.1, Fig. 4.4 and Chapter 3). This suggests that the efficiency of replicating prions is
stochastically rare, that is phenotypically selected through cloning. Clonal selection for
CWD prion susceptibility was also shown using genetically modulated N2a cells that
ectopically expressed CerPrPC (Pulford, Reim et al. 2010). Our data also shows that
cellular conversion factors required for replicating prions is universally shared in these
cells. Without endogenous PrPC interference, cells may or may not have the
supplementary conversion factors. We also show that these conversion factors were
partially active in subclones but not sufficient to chronically sustain the replicative
process (Fig. 4.4C and Fig. 4.5D). The occurrence of partial susceptibility was
demonstrated by RKD clones S3 and S6 (Fig. 4.4). These clones were deemed CWDprion susceptible at third passage after infection but lost detectable PK resistant CWDCerPrPSc by twelfth passage (Fig. 4.4B and C). The loss of prion infectivity in later
passages with permissive cell lines is not new, but the distinct transcriptional profile
exhibited by these cells revealed a striking difference (Fig. 4.5D). The gene clustering of
these two particular clones showed similarities with both sensitive and resistant RKD
clones, indicating that the cells partially expressed the repertoire of genes that are
required to sustain prion replication but not sufficient enough to maintain it (Fig. 4.4B-C
and Fig. 4.5C-D).
Distinguishing Clonal Variation Through PrPC Cell-Surface Presentation Analysis:
Besides total PrPC expression, intracellular trafficking and surface presentation
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mechanisms may also determine susceptibility in cells. Prion conversion is hypothesized
to predominantly occur on the cell surface (Caughey, Race et al. 1989; Caughey and
Raymond 1991; Caughey, Raymond et al. 1991; Taraboulos, Raeber et al. 1992; Shyng,
Huber et al. 1993; Goold, Rabbanian et al. 2011). Initial pulse-chase labeling experiments
and phosphatidylinositol-specific phospholipase C (PIPLC) treatments were used to
release PrPC from the cell surface (Borchelt, Scott et al. 1990). These studies revealed
that PrPC and PrPSc have differential biogenic stability, and half-life based on their
accessibility for degradation. Moreover, the differences between these molecules
occurred after post-translational modifications (Borchelt, Scott et al. 1990; Stahl,
Borchelt et al. 1990). Topological experiments in ScN2a cells using PIPLC and trypsin
protease suggested that PrPSc was generated from a cell-surface precursor (Caughey and
Raymond 1991). Recently, ectopic expression of epitope-tagged PrP in N2a cells lacking
endogenous PrPC revealed rapid PrPSc conversion mainly occurring at the plasma
membrane (Goold, Rabbanian et al. 2011). We hypothesized that prion susceptibility
differences were caused by inefficient cell-surface presentation of PrPC by resistant cells.
We used flow cytometry to determine the answer to this question, and discovered similar
cell surface presentation of PrPC. Equal expression of total PrP and similar surface
presentation in clonal cells suggests that phenotypic difference is at the transcriptional
level.
The Search For Prion Host Factors Using RDA To Transcriptionally Profile Clonal
Cells: Transcriptional differences between sensitive and resistant RKM clones were
analyzed using RDA. The RDA facilitates the identification of unique transcripts from
two nearly identical cDNA pools without the requirement of an annotated starting point
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in the genome. RDA was used as a pilot experiment to transcriptionally profile RKM
clones. High-throughput molecular tools that are common use for mouse and human
genome analysis were still lacking for the rabbit genome. Hence, prior to making large
investments into customized gene chips and transcriptional sequencing, we aimed at
using experimentally proven and unbiased techniques to identify differences between
prion susceptible and resistant clones. RDA does not require an annotated genome to
perform the subtractive screening, which was the primary limitation with RKM cells.
As a pilot study, one respective clone from each susceptibility phenotype was
selected for analysis. RDA identified transcripts were statistically insignificant (n=1).
Moreover, subsequent prion infectivity results revealed incomplete resistance by RKM
clone 78 (Fig. 4.2C), which led us away from pursuing this approach any further. We
concluded that customized microarray expression analysis was a better experimental
approach to take. The transcripts that were identified by RDA are listed in Tables 4.2 and
4.4. The genes that are encoded by the identified transcripts represent single targets for
elucidating the mechanisms that dictate cellular susceptibility. In addition, three RDA
identified transcripts lack characterization data because they were computationally
predicted. Basic characterization of these hypothetical proteins was completed using
bioinformatic data mining approach (Table 4.3).
Unique Prion Susceptibility Transcripts
Uncharacterized Hypothetical Proteins: Three hypothetical proteins were identified as
ORF’s in the Oryctolagus cuniculus (rabbit) genomic sequences, which was annotated
using the GNOMON gene prediction method and supported by EST evidence (Di Palma
F. 2009). The predicted proteins range in amino acid length (343-1,295aa) and molecular
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weight (~37 – 140-kDa) (Table 4.3). Structural calculation analysis indicates secondary
and tertiary structure formation with functional associations in two of the three proteins
(Table 4.3), while hypothetical protein LOC100353326 appears lack secondary structure.
Roughly 7% of LOC100353326 protein’s amino acid sequence is homologous to a
human integral membrane transporter protein with an accession number of CAB81951.
This integral membrane transporter protein has been associated with anti-apoptotic
functions. Interestingly, several studies have implied PrP to have biological functions
associated with anti-apoptotic activity (Kurschner and Morgan 1995; Chiarini, Freitas et
al. 2002; Zanata, Lopes et al. 2002; Li and Harris 2005). If this hypothetical protein has a
functional role in protecting the cell from apoptosis, than it would be reasonable to
hypothesize that resistance to cellular toxicity of accumulating PrPSc enables survival of
sensitive cells in an otherwise unfavorable condition. Whereas the resistant cell
population lack this anti-apoptotic property and cannot survive PrPSc accumulating
cytotoxicity. In contrast, resistant cells do not die upon prion exposure, suggesting that
toxicity from accumulating PrPSc is exacerbated in cells that are actively replicating the
infectious agent. Therefore, susceptible cell must activate protective mechanisms while
the prion conversion and accumulation of PrPSc is occurring. Enhanced anti-apoptotic
activity in the permissive clone could be one of several cellular phenotypes that enable
prion replication.
LOC100338542 protein (XM_002723594) was the largest of the hypothetical
proteins recognized in the study (Table 4.2 and 4.3). Sequence prediction analysis
revealed a conserved PAS-domain containing serine/threonine kinase activity. The PASdomain containing serine/threonine kinases are evolutionary conserved signaling
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molecules that are activated in response to stimuli (Rutter, Michnoff et al. 2001). Normal
signal detection by PAS-protein domains is through an interaction with an associated
cofactor (Ponting and Aravind 1997). In addition, sensory functions of these PASproteins regulate metabolic homeostasis (Schlafli, Borter et al. 2009). The relative size
and structure of this protein could implicate a very important intracellular function in
RK13 cells that should be characterized (Table 4.3). The predicted signaling capabilities
of this PAS-domain containing protein could be the intracellular PrP interacting molecule
involved in unidentified regulating signaling pathways that control prion replication.
All descriptive records pertaining to hypothetical LOC100338446 protein is
nonexistent in NCBI database. Analyzing this protein with various bioinformatic
prediction programs has revealed several interesting characteristics, which could be used
in future validation studies. The protein, if expressed, would have higher order
conformational structure and maintain a molecular weight of 37-kDa (Table 4.3). It
would have enzymatic activity regulating some form of homeostatic processes. Similar to
LOC100338542, this protein’s interactions with PrP could involve the regulation of
unidentified signaling cascades regulating PrP conversion (protein homeostasis) or
cellular tolerance/survival in response to PrPSc-induced aggregation toxicity.
Unique Prion Resistant Transcripts
Up Regulation Of Proteolytic Enzymes: The sequence encoding endogenous rabbit
retrovirus H (Accession # AF480925) was a product detected in RKM 78 resistant clones
(Table 4.4). These viral remnants from the rabbit genome encode retroviral elements gag,
pro and pol (Griffiths, Voisset et al. 2002). Retroviral element HIV-1 Gag was shown to
enhance prion susceptibility and stabilized chronic infectivity in Elk21+ cells (Bian,
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Napier et al. 2010). In contrast to Elk21+ cells, RKM-78 cells were phenotypically
resistant, suggesting that other retroviral elements could have reverse effects on PrPSc
accumulation. Characterization studies of the rabbit endogenous retrovirus H show that it
encodes a functional protease, referred to as RERV-H protease (Voisset, Myers et al.
2003). The RERV-H protease is an aspartic protease that cleaves the Gag polyprotein
precursor (Voisset, Myers et al. 2003). Other well-characterized eukaryotic aspartic
proteases include pepsin, cathepsins and renins (Szecsi 1992). Proteolytic cleavage and
processing of PrP molecules have been described and associated with normal and
aggregation based toxicity states of the protein (Zhang, Spiess et al. 2003; Luhr,
Nordstrom et al. 2004; Yadavalli, Guttmann et al. 2004; Dron, Moudjou et al. 2010).
These proteases have been described in the context of prion infectivity and resistance.
Cathepsins B and L have been shown to degrade prions in GT1-1 neuronal cells (Luhr,
Nordstrom et al. 2004). It is therefore reasonable to hypothesize that RERV-H could
facilitate resistance within RKM-78 clone using a similar mechanisms.
The mannose-binding protein associated serine protease-3 (MASP-1/3, accession
# XM_002716369.1) is another proteolytic enzyme identified in RKM 78 resistant clone
(Table 4.4). The mannose-binding protein associated serine protease-3 (MASP-1/3) has a
role in complement activation processes (Iwaki, Kanno et al. 2011). Similar to Proteinase
K, MASP-1/3 is a serine protease enzyme that could proteolytically digest PrPC proteins.
Upregulation of this protease in resistant cells could interfere in the conversion process
by actively interfering in formation of the PrPC-PrPSc complex. Rabbit plasma alpha-1antiprotease S-1, another RDA identified transcript (Table 4.4), protects trypsin (serine
protease) from being inactivated by proteolytic inhibitors (Saito and Sinohara 1993). The

	
  

199	
  

abundance of proteolytic enzymes in the resistant clone could signify another cellular
mechanism involved in prion sustainability. This mechanism could involve subcellular
trafficking of PrPC to lysosomal compartments where it undergoes rapid degradation by
these upregulated proteolytic enzymes. Rapid degradation of the primary PrP substrate
for PrPSc conversion results in a cellular phenotype that confers resistance to prion
infectivity. In vivo, these enzymes perform diverse physiological functions but in vitro
upregulation simply results in cellular resistance to prions.
Chaperones and PrPC Folding: The chaperonin-containing TCP-1 subunit gamma
(CCT3, accession # XM_002715377) mRNA identified in RKM 78 clone belongs to the
molecular chaperone family of proteins called TCP1 ring complex (TRiC) which
participate in actin and tubulin folding (Walkley, Demaine et al. 1996). Molecular
chaperones are vital to intracellular protein homeostasis. They modulate correct protein
folding and/or cause misfolded or dysfunctional proteins to be degraded. Chaperone
proteins have previously been implicated with cellular prion replication (Kenward, Hope
et al. 1994; Lindquist, Patino et al. 1995; Kenward, Landon et al. 1996; DebBurman,
Raymond et al. 1997; Shyu, Harn et al. 2002; Allen, Wegrzyn et al. 2005; Tutar, Song et
al. 2006; Lian, Zhang et al. 2007; Loovers, Guinan et al. 2007; Shorter and Lindquist
2008; Guinan and Jones 2009; Wang, Zhou et al. 2011). The distinct expression of this
chaperone transcript in resistant cells suggests for the possibility of a selected pathway
involved in protein processing which, if carefully regulated would cause attenuation of
protein aggregation and toxicity.
Summary: RDA data regarding hypothetical proteins and other recognized proteins were
just brief, hypothesis driven predictions that require extensive validation. It is difficult to
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elaborate further on these proteins this data is statistical insignificant and resistant cells
considered resistant, subsequently replicated RML prions. These were n = 1 analyses that
would require more RDA screens incorporating various combinations of sensitive and
resistant clones. Moreover, additional subtractive hybridization analysis would also be
required of the parental RK13 cell line genetically un-modulated to express foreign
proteins. The application of microarray gene expression profiling to prion sensitive and
resistant clones allowed us to attain statistically confident data that RDA analyses were
unable to do. In addition, this high-throughput method also provided a global perspective
on cellular functions and pathways occurring amongst the two phenotypically distinct cell
populations.
Section II
Gene Annotation And Selection: Microarray gene expression experiments pose a major
challenge after completing the initial data acquisition step. This challenge originates from
vast amounts of data single gene expression experiment generates. Mining acquired data
for meaningful information becomes even more challenging if the expression results of
the microarray do not have an annotated genome to work with. This was a major
challenge we encountered working with the rabbit gene expression microarray chips.
Manual gene annotation was prerequisite to formulating and selecting genes for
discussion and future analysis. This was an extremely time consuming process requiring
the use of multiple databases to cross-reference microarray gene probe identification
numbers with associated Genbank entries, followed by mouse/human ortholog search and
conversion. The mouse/human ortholog genes were subsequently used to compile the
final version of each list and were used as the basis for downstream bioinformatic
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database analyses. Inconsistency in gene nomenclature was another challenge confronted
during this phase of research. The existence of multiple names and symbols for single
genes makes literature cross-referencing very difficult. For example, during the crossreferencing annotation process of gene list formulation, a microarray rabbit probe id
matches a gene in the ensembl genome browser by the name of Ribosomal protein SA
(gene symbol RPSA). This ortholog information was logged and data-entered into the
primary gene list. The issue of multiple gene names reappears when the annotated list is
explored for differentially expressed genes that have associations with prion biology.
RPSA

is

represented

in

the

ensembl

database

with

the

identification

of

ENSMUSG00000032518, which shows that this gene has multiple nomenclature and is
also known as the 67-kDa Laminin Receptor-1 (LAMR1, LAMBR), a protein proposed
as a major interactor of PrP (Rieger, Edenhofer et al. 1997; Gauczynski, Peyrin et al.
2001; Hundt, Peyrin et al. 2001; Gauczynski, Nikles et al. 2006; Nikles, Vana et al. 2008;
Kolodziejczak, Da Costa Dias et al. 2010). Therefore using RPSA gene symbol to scan
the annotated gene would not return results indicating importance and the upregulation of
67-kDa Laminin Receptor-1 amongst clonal cells would be overlooked. In actuality, this
protein was over-expressed in the CWD prion permissive RKD-S cells (Table 4.10). This
issue of multiple gene names/symbols does not emerge when using mouse or human
microarrays because the annotations have been well characterized. The preliminary
selections of genes for future validation analysis were chosen based on mathematical
significance threshold parameters, which enabled us to identify and connect genes in a
hypothesis driven prediction analysis (Tables 4.6 and 4.7). The subsequent discussion of
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predicted genes associated with prion replication stem from these primary selection
criteria.
Cross-Referencing Gene Expression Data To The Prion Disease Databases (PDDB): To
establish a link between the microarray-identified genes and prion disease, we utilized the
Prion Disease Database (PDDB) for comparison analysis. The PDDB retains documented
gene expression profiles from mice of different genetic backgrounds, infected with
different mouse-adapted scrapie strains. This systems approach measured gene
expression of mouse brains pre- and post- prion infection. Expression was measured
using microarray technology over the complete prion disease incubation timeline. The
primary time points analyzed and presented in the PDDB were of 6, 10, 14, 18, 20 and 22
weeks post infection. The 1,375 RKD annotated genes were uploaded and compared into
the PDDB. This scan returned a total of 314 (23%) RKD differentially expressed genes
matching annotated genes within PDDB (Table 4.5). Of these 314 matched genes, 132
were down regulated, while 182 genes were upregulated in RKD-R cells (Table 4.5).
Furthermore, of 314 matched genes, 32 genes (10%) have previous publications
associated with prions. These genes are presented in tables 4.8 and 4.9.
RKD-R Down Regulated/RKD-S Up Regulated Genes And Vice-Versa: Sixty-eight genes
were identified to be significantly down regulated in RKD-R cells (up-regulated in RKDS cells) using t-test p-values of ≤ 0.001 and FC of ≥ 2.0 (Table 4.6). The chosen genes
consequently discussed were selected based on biological relationship to protein
misfolding and associational linkage to PrP based of PDDB cross-reference results. The
biological relationships include pathways hypothesized to regulate intracellular protein
homeostasis, endocytic trafficking and exocytic transport. Cellular mechanism regulating
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metal ion homeostasis and transport were also considered in the rationale for gene
selection. DAVID and PANTHER database analyses also demonstrated a clear
demarcation of gene expression between the sensitive and resistant RKD clones (Fig.
4.6). Therefore gene selection was partially directed with those data in observance.
Cross-reference analysis of genes identified by DAVID database to the high stringency
gene list helped identify several interesting gene targets. We chose to specifically target
autophagy-related 4a protein (Atg4a), eukaryotic translation initiation factor 2-alpha
kinase 2 (eIF2ak2), small heat shock protein 8 (HSPB8), chaperonin containing Tcomplex polypeptide 1, subunit 6A (CCT6a), cyclophilin peptidyl-prolyl isomerase
(Ppil4), Ceruloplasmin (CP), protein C (PROC), alpha-1-Acid glycoprotein (Orm1),
protocadherin-alpha 1 (Pcdha1), and adaptor-related protein complex AP-1, sigma 3
(Ap1S3) (Table 4.6 and 4.7). These genes were used as starting points to subsequently
analyze the larger gene list containing 1,375 genes. The following discussion assembles
and connects the expressed genes to develop a hypothesis driven prediction on the
phenotypic characteristics that mediate cellular susceptibility to prions.
Autophagy: The direct translation of autophagy is “self (auto)-eating (phagy-to eat)”. In
the context of cell biology, autophagy is a catabolic process used by cells during stress
(Yorimitsu and Klionsky 2005). This mechanism can further be subdivided into three
distinct processes, which include macroautophagy, microautophagy and chaperonemediated autophagy (CMA) (Khalfan and Klionsky 2002; Reggiori and Klionsky 2002;
Massey, Kiffin et al. 2004). The mechanisms that dictate the induction of autophagy have
not been fully characterized but the basic process of macro- and micro- autophagy entails
the engulfment of cytosol by newly-formed double membraned structure called the
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autophagosome (Fig. 4.7A) (Horst, Knecht et al. 1999; Klionsky and Ohsumi 1999;
Klionsky 2005). The autophagosomes subsequently fuses with lysosomes at which point
the autophagosome content is degraded by lysosomal enzymes (Fig. 4.7A). CMA
autophagy does not require the formation of autophagosomal structures because the
targeted proteins are directly translocated into lysosomes (Massey, Kiffin et al. 2004).
Approximately ~30 genes (Atg) have been described to be directly linked to autophagy
(Klionsky, Cregg et al. 2003). Autophagy is a tightly regulated process that may be
selective or non-selective, and causes deleterious effects if skewed in either direction
(Komatsu, Ueno et al. 2007). Moreover, autophagy deregulation is linked to protein
aggregation and protein misfolding diseases, making it a primary target mechanism for
our differential gene expression analyses (Anglade, Vyas et al. 1997; Anglade, Vyas et al.
1997; Kegel, Kim et al. 2000; Petersen, Larsen et al. 2001; Goldberg 2003; Yu, Cuervo et
al. 2005).
Protein Homeostasis, Macroautophagy Induction and CerPrPSc Replication: The
aforementioned predictions made by DAVID led us to initiate the search for genes
involved in intracellular protein homeostasis. Autophagy-related 4a protein (Atg4a) and
small heat shock protein 8 (HSPB8) were two genes that instantly stood out as possible
candidates for further investigation. At the time of selection, there was no prior
knowledge of a linking relationship between the two genes and were considered to not be
interdependent. Using HSPB8 as the primer in researching functional association to
protein misfolding, it was discovered that this particular small heat shock protein has a
very unique function that can initiate macroautophagy and/or CMA (Massey, Zhang et al.
2006).
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Chaperone proteins are important modulating factors in protein misfolding
diseases. HSPB8 was discovered to be significantly upregulated in cells permissive to
prion replication (Table 4.6). This protein belongs to the small heat-inducible heat shock
chaperone protein family sharing the highly distinctive α-crystallin domain characteristic
of other proteins in the family (Chowdary, Raman et al. 2004). Several different names
have been used to describe this protein, which include HSPB8, Hsp22, H11 kinase, and
E2IG1. This protein is 196aa in length and has a molecular mass of 21.6 kDa (Hu, Chen
et al. 2007). Like other small-heat shock proteins, HSPB8 is activated by cellular stress
and exhibits protein-folding chaperone activity (Chowdary, Raman et al. 2004).
Moreover, HSPB8 has been shown to specifically interact with kinase proteins, causing it
to become phosphorylated in the process (Benndorf, Sun et al. 2001). In particular,
protein kinase C (PKC), mitogen-activated kinase (MAPK) and eukaryotic translation
initiation factor 2-alpha kinase (eIF2ak) phosphorylate HSPB8, a crucial characteristic to
the proceeding discussion. In addition to these physiological functions, HSPB8 exhibits
association with several protein misfolding diseases that include distal hereditary motor
neuropathy type II (dHMNII), AD, HD and ALS (Fontaine, Sun et al. 2006; Wilhelmus,
Boelens et al. 2006; Crippa, Carra et al. 2010; Crippa, Sau et al. 2010; Kwok, Phadwal et
al. 2011). Protein misfolding and cellular toxicity associated with HSPB8 is directly
linked to the induction of autophagy and containment of protein aggregation (Carra,
Seguin et al. 2008; Carra, Brunsting et al. 2009; Carra, Boncoraglio et al. 2010; Crippa,
Sau et al. 2010). Autophagy pathway induction by HSPB8 requires a co-chaperone
protein called Bcl2-associated athanogene 3 protein (BAG3) (Carra, Seguin et al. 2008).
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The Bcl2-associated athanogene (BAG) protein family are co-chaperones
functionally attributed to regulating protein quality control with heat shock proteins
(Hcs/HSP70) (Takayama and Reed 2001). Three BAG proteins were differentially
expressed between the sensitive and resistant RKD cells (Table 4.10). BAG3 protein, the
co-chaperone of HSPB8 was up regulated in RKD-S cells while BAG2 and BAG6 were
both down regulated (Table 4.10). A molecular link has been made between protein
degradation during the aging process and BAG3 expression (Gamerdinger, Hajieva et al.
2009). During cellular aging, mechanisms that dictate degradation of polyubiquitinated
protein gradually switch from proteasomal pathways to macroautophagic degradation
processes, shown by the gradual shift in expression ratio levels of BAG1 to BAG3
(Gamerdinger, Hajieva et al. 2009). In addition to this ratio change, ubiquitin-binding
proteins involved in the UPS mechanisms together with higher cathepsin activity were
also observed. Interestingly, BAG1 has been described to functionally link Hsc/HSP70 to
the proteasome using a unique ubiquitin-like domain (UBL), a domain that is found in
one other BAG protein, BAG6 (-1.62-FC in RKD-S, Table 4.10) (Luders, Demand et al.
2000). The down regulation of BAG6 in RKD-S cells provide additional evidence to
suggest that the proteasomal mechanisms geared for maintaining proper protein-folding
are skewed to cause malfunction. If BAG6 has UPS-related functions (Luders, Demand et
al. 2000) and BAG3 induces autophagy specially targeted for protein aggregation (Carra,
Seguin et al. 2008), both mechanisms closely related to the prion replication process than
BAG2 must also be a crucial component relating to prion cellular susceptibility. Indeed,
BAG2 functionally inhibits the chaperone-associated ubiquitin ligase CHIP (Arndt,
Daniel et al. 2005). Ubiquitin-ligase CHIP links molecular chaperones to the UPS system
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and is vital to the overall protein folding and degradation process in eukaryotic cells
(Murata, Minami et al. 2001; Esser, Alberti et al. 2004; Shimura, Schwartz et al. 2004;
Esser, Scheffner et al. 2005). Notably, CHIP’s main function is to attach ubiquitinderived signals to chaperone-bound protein clients for one of two reasons; (i) normal
conformational regulation of protein folding (Xu, Marcu et al. 2002; Westhoff, Chapple
et al. 2005) and more importantly (ii) recognizing aggregation-prone proteins for quality
control purposes (Murata, Minami et al. 2001; Shimura, Schwartz et al. 2004). Thus,
RKD-S cells down regulate two proteins (BAG2 and BAG6) that strongly associate with
targeting proteins for proteasomal degradation and up regulate BAG3, which selectively
targets protein degradation by autophagy. Experimental evidence suggests that protein
aggregation is correlated with the presences of both HSPB8 and BAG3, and absent of
other heat shock proteins, indicating preferential specificity towards aggregationmediated stress response (Carra, Seguin et al. 2008; Carra, Brunsting et al. 2009; Carra,
Boncoraglio et al. 2010; Seidel, Vinet et al. 2012)
The formation of HSPB8-BAG3 complex leads to the phosphorylation of
eIF2ak2, which consequently shuts down protein synthesis and initiates autophagy (Fig.
4.7) (Carra, Brunsting et al. 2009). In response to misfolded protein stress, activated
eIF2ak2 reduces the influx of nascent proteins into the ER and stimulates upregulation of
chaperone proteins (Zhanataev, Lisitsyna et al. 2009). Autophagy initiation by eIF2ak2 is
a direct response to misfolded proteins, which include PrPC-PrPSc conversion. Moreover,
proteasomal dysfunction and ER stress enhances the trafficking of prion protein
aggregates, triggering accumulation of PK resistant PrPSc (Nunziante, Ackermann et al.

	
  

208	
  

2011). The aggregation of the Htt-Poly-(Q) protein in HD also activates the eIF2ak2
autophagy response (Peel, Rao et al. 2001).
DAVID bioinformatic gene analysis uncovered a difference in cell growth and
division between the sensitive and resistant RKD cells (Fig. 4.6). The activation of
macroautophagy through HSPB8-BAG3 mediated phosphorylation of eIF2ak could
provide the explanation to the results obtained from DAVID analysis. If RKD-S cells
were preferentially skewed towards eIF2ak-mediated autophagy activation, than the
logical side effect would be complete shutdown of protein translation and growth arrest.
For that reason, microarray gene expression analysis would filter the cell division genes
into the RKD-R group. To extrapolate this beyond the bioinformatic interpretations and
put it into the context of prion replication, transient growth arrest mediated by the
aforesaid protein-folding stress responses also provides the time required to efficiently
convert PrPC to PrPSc. Earlier cell culture studies have indicated that cell division strongly
influences cellular ability to accumulate PrPSc (Ghaemmaghami, Phuan et al. 2007).
Looking back at the annotated gene lists, we discovered that both BAG3 (1.54FC, p-value of ≤ 0.05 and a FC of ≥ 1.5) and eIF2ak2 (2.73-FC, p-value of ≤ 0.001 and a
FC of ≥ 2.0) were upregulated in RKD-S cells (Table 4.6 and 4.10). Interestingly, the
HSPB8-BAG3 complex initiates the autophagy mechanisms along with stress-induced
translational arrest independent from the normal ER stress response other chaperone
proteins utilize for dealing with protein misfolding (Carra, Brunsting et al. 2009). The
chaperone proteins normally associated to protein misfolding response are the 70-kDa
heat shock protein family (HSPA), DNAJ proteins and BAG1 (Cuervo and Dice 1998),
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which coincidentally have been down regulated in RKD-S cells (Table 4.10). Indicating a
mechanistic shift in the protein maintenance processes.
HSP70 proteins have been shown to significantly reduce α-Synuclein (α-Syn)
aggregation, fibril formation and cellular toxicity in both mouse and drosophila PD
models (Klucken, Shin et al. 2004; McLean, Klucken et al. 2004; Auluck, Meulener et al.
2005; Dedmon, Christodoulou et al. 2005; Outeiro and Kazantsev 2008; Outeiro, Putcha
et al. 2008). Heat-shock 70-kDa protein 12A (HSPA12A, 2.09-FC) and heat-shock 70kDa protein 2 (HSPA2, 3.89-FC) were upregulated in RKD-R cells (Table 4.10, Fig. 4.7).
The upregulation of these proteins could be pertinent to the resistance phenotype, which
is based on the described functional characterization studies. Coincidentally, HSPA2
(3.89-FC in RKD-R) is predominantly co-localized to the cell-surface, the primary
location predicted for PrPSc conversion (Goold, Rabbanian et al. 2011), while HSPA12A
is cytoplasmic. Overall, HSPA12A and HSPA2 have not been well characterized,
therefore it is difficult to speculate further on their exact function in RKD-R cells.
Whereas the abovementioned 70-kDa chaperone proteins were down regulated in
RKD-S cells, the reverse was true for the 90-kDa heat shock proteins (HSPB family)
(Fig. 4.7 and Table 4.10). Dual upregulation of HSP90B1 (1.6 FC) and HSP90AB1 (1.53
FC) in RKD-S cells also has applicability towards the mechanisms governing cellular
permissiveness to prion replication (Table 4.10, Fig. 4.7). Blocking HSP90 from
phosphorylating tau in the tauopathy mouse model demonstrated significant reduction of
tau aggregate formation (Dickey, Kamal et al. 2007), suggesting that the presence of
HSP90 proteins could enhance aggregate formation. In addition to enhancing tau
aggregation, HSP90 has also been linked with Rab11a GTPase in recycling and secreting
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aggregated α-Syn from cells (Liu, Zhang et al. 2009). Rab GTPase mediated intracellular
trafficking and recycling of endosomal, lysosomal, and exosomal vesicles also has
relevance to intracellular prion replication (Borchelt, Taraboulos et al. 1992; Fevrier,
Vilette et al. 2004; Marijanovic, Caputo et al. 2009).
Additional chaperone like genes differentially expressed in RKD-S cells were the
chaperonin containing T-complex polypeptide 1, subunit 6A (CCT6a) and subunit 2
(CCT2a) (Table 4.10 and Fig. 4.7B). The chaperonin protein family separates into two
sub-categories, group I and group II. Group I chaperonins are predominantly located in
the mitochondria and group II are cytosolic (Mukherjee, Conway de Macario et al. 2010).
Both CCT proteins belong to the group II chaperonin family. Each subunit of this
complex has an approximate 52-65kDa molecular mass, but becomes 970kDa when
formed into the hetero-oligomeric complex (Schwartz, Kittelberger et al. 2000). The
primary function of this and other family proteins is to assist proper protein folding and
reduce aggregation. Interestingly, an in vivo study analyzing the complete transcription
profile of prion-infected mice revealed that CCT6A is one of few chaperone proteins
upregulated in the time-course of infection (Sorensen, Medina et al. 2008). In addition,
CCT6a and CCT2 have been linked to modulate Htt-mediated polyglutamine expansion,
aggregation and cellular toxicity (Kitamura, Kubota et al. 2006; Tam, Geller et al. 2006;
Teuling, Bourgonje et al. 2011). CCT6a is upregulated, while CCT2 is down regulated in
RKD-S cells. Although, specific roles in prion replication for these proteins have not
been determined.
The initial stages of protein misfolding, CMA mechanism is the dominating
process by which cells clear aggregate-prone proteins (Cuervo and Dice 1998). CMA
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does not rely on autophagosome formation to degrade misfolded proteins, instead
HSP/DNAJ/BAG1 complex forms at the membrane of a lysosome that inadvertently
interacts with the constitutively active HSPA (70-kDa) chaperone to induce selective
protein degradation (Cuervo and Dice 1998). Degradation of misfolded proteins using
CMA mediated autophagy is limited to small aggregates and does not have the capacity
to break down larger protein aggregate structures (microaggregates) (Ravikumar, Duden
et al. 2002). Cellular response to microaggregates is macroautophagy, which HSPB8BAG3 complex activates. Therefore, the acquired microarray data indicates two
divergent mechanisms are occurring within RKD cells. The resistant RKD-R cells are
utilizing the UPS and CMA systems very efficiently to disallow the formation of PrPSc
aggregates. This is implied from the overexpressed HSPA, DNAJ and BAG2&6 proteins
(Table 4.10). While RKD-S cells are actively shutting-down these systems and inducing
macroautophagy in attempt to clear PrPSc replication and dispersion, which is indicated
by the upregulated HSPB8, BAG3, eIF2ak proteins (Table 4.10). Pausing to think about
these scenarios and how they relate to the abovementioned experimental evidence, it
would seem that these processes are reversed. The initiation of macroautophagy is the
exact response a cell would require to efficiently clear large protein aggregates such as
the ones formed by PrPSc aggregates and not the contrary. Macroautophagy studies in AD
have shown that autophagosome vacuoles accumulate in dystrophic neurites in the late
stages of disease and maintain beta-amyloid (Abeta) proteins (Nixon, Wegiel et al. 2005;
Yu, Cuervo et al. 2005). Moreover, targeting mTOR1 (primary inhibitor of autophagy)
with inhibitors such rapamycin increases autophagosome formation and the accumulation
of Abeta-filled autophagic vacuoles (AVs) (Yu, Cuervo et al. 2005). The buildup of
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intracellular Abeta levels in AVs of dystrophic neurites could link autophagy
deregulation with promoting Abeta aggregation in AD patients. Additional reports have
revealed that deregulating the HSPB8-BAG3 autophagy mechanisms significantly
enhances protein aggregation (Carra, Boncoraglio et al. 2010). Thus, it is feasible that the
selected RKD-S clones are deregulating these protein homeostatic processes to efficiently
replicate and sustain PrPSc aggregated molecules. But how would this deregulation allow
prions to accumulate and infect other cells? Macroautophagy exponentially generating
infectious PrPSc seeds is one hypothesis that could explain these observations. Indeed,
others have previously indicated that skewing autophagy is counterproductive and toxic
to cells (Nixon, Wegiel et al. 2005; Yu, Cuervo et al. 2005; Heiseke, Aguib et al. 2010;
Nunziante, Ackermann et al. 2011). The exposure of PrPSc aggregate-fibrils to the
lysosomal enzymes would induce fragmentation of the fibrils to smaller and more
infectious molecules. Previous reports comparing PrPSc fibril size to infectivity have
demonstrated that infectivity and conversion was most efficient with PrP-fibrils 300600kDa in size or approximately 14-28 PrP molecules (Silveira, Raymond et al. 2005).
Additional evidence to support the autophagy-based PrPSc replication scenario is
the upregulation of lysosomal enzyme cathepsin L1 (CTSL, 2.1-FC) in RKD-S cells.
CTSL has previously been associated with various neurodegenerative protein misfolding
diseases, which includes TSE (Diedrich, Minnigan et al. 1991; Kegel, Kim et al. 2000;
Zhang, Spiess et al. 2003; Brown, Webb et al. 2004; Polyakova, Dear et al. 2009). Prion
infectivity studies in N2a cells revealed a significant increase of cathepsins B and L in the
ScN2a infected cells as compared to the uninfected counterparts, consequently leading to
the hypothesis that lysosomal proteases participate and enable intracellular conversion of
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PrPSc (Zhang, Spiess et al. 2003). In vitro experiments that proteolytically cleaved PrP
with Cathepsin S produced N-terminally cleaved protein (PrP94-233) molecule, which
readily converted isoform conformation from α-helix to β-sheet rich (Polyakova, Dear et
al. 2009). Moreover, the β-sheet rich PrP94-233 molecules formed thioflavin-T positive
aggregate species reminiscent of PrP species shown to be highly toxic in mouse models
(Shmerling, Hegyi et al. 1998; Baumann, Tolnay et al. 2007). Recently published data
analyzing endogenous proteolytic cleavage of PrPSc in cell culture and tissue
demonstrated that both cathepsin B and L were the primary enzymes responsible for
cleaving PrPSc (Dron, Moudjou et al. 2010). Notably, this study utilized RK13 cells for
the cell culture portion of the experiments, providing strong support towards the
relevance of CTLS over expression in the RKD-S cells.
Cyclophilin Ppil4 is a peptidyl-prolyl isomerase with attributed function of
catalyzing the interconversion between cis and trans isomers of proline (Fischer, Bang et
al. 1984; Zeng, Zhou et al. 2001). The Ppil4 gene is upregulated in RKD-S cells
determined by high statistical stringency analysis (2.11-FC, Table 4.6). Its selection for
functional validation is based on its proposed functions to behave as a chaperone
involved in cellular maintenance of protein homeostasis (Fischer and Will 1990). Ppil
proteins have been implicated in several signaling pathways but the basic biochemical
function of the Cyclophilin enzyme is not fully understood (Davis, Walker et al. 2010).
Peptidyl-prolyl cis-trans isomerases have previously been described as potential
chaperones to PrPC with associations as a possible factor in GSS (Cohen and Taraboulos
2003). It was experimentally demonstrated that cells treated with Cyclosporin A (CsA),
an inhibitor of cyclophilins, induced accumulation of misfolded PrP in aggresomes
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(Cohen and Taraboulos 2003). Moreover, cyclophilins associated with prion aggregation
to specific cellular compartments designated ‘juxta nuclear quality control compartment’
(JUNQ) and the ‘insoluble protein deposit’ compartment (IPOD) (Ben-Gedalya,
Lyakhovetsky et al. 2011). These cellular compartments were shown to actively recruit
chaperones for quality control purposes. In addition to chaperone activity, human
cyclophilins have also been determined as essential interacting partners for the HIV-1
Gag polyprotein during infection, with a suggested role in the un-coating process (Qi,
Yang et al. 2008; Schaller, Ocwieja et al. 2011). This HIV-1 Gag interacting function of
Ppil4 is especially relevant because all susceptible cell lines described thus far stably coexpress HIV-1 Gag (Elk21+ & RKD). Therefore, Ppil4 could be the endogenously
expressed protein linking HIV-1 Gag with the enhanced susceptibility phenotype
exhibited by both RKD-S and Elk21+ cells.
Autophagy-related 4a protein (Atg4a) is a cysteine protease protein associated
with oxidative stress response and detoxification autophagy pathway (Scherz-Shouval,
Shvets et al. 2007). Atg4a is 398 aa in length and is predominantly a cytoplasmic
protease responsible for intracellular degradation processes (Marino, Uria et al. 2003).
The Atg4a protein is vital for cellular survival under stress conditions, protecting the cell
from entering apoptosis (Ohsumi 2001; Marino, Uria et al. 2003; Codogno and Meijer
2005; Scherz-Shouval, Shvets et al. 2007). Besides the direct link with autophagy and
overexpression in RKD-S cells, the functions within the autophagy pathway this protein
associates with makes it an appropriate to the overall hypothesis driven discussion.
Although autophagy is characterized as non-selective self-degradation mechanism, recent
studies have shown that certain proteins are highly selected for autophagy-mediated
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degradation (Ohsumi and Mizushima 2004; Kim, Rodriguez-Enriquez et al. 2007; Farre,
Manjithaya et al. 2008). In both selective and non-selective autophagy processes, there
exists two ubiquitin-like protein conjugating systems, which are mediated through either
Atg12 or Atg8 proteins (Ohsumi 2001). While Atg12-mediated conjugation is primarily
involved in the formation of a multi-protein (Atg12-Atg5-Atg16) complex that guides
autophagosome membrane formation, Atg8 conjugation facilitates the progression of
non-specific autophagy and vacuole targeted (Vt) autophagy (highly-selective) pathways
(Kirisako, Ichimura et al. 2000; Hutchins and Klionsky 2001). Atg4 is vital to the Atg8conjugating system (Kirisako, Ichimura et al. 2000). As a cysteine protease, Atg4 cleaves
Atg8 from the membrane-lipid complex it is bound to (phosphatidylethanolamine (PE))
(Ichimura, Kirisako et al. 2000). This cleavage event allows Atg8 to sequentially go
through the multi-step conjugating system to form another membrane integral Atg8-PE
complex. Unlike the Atg12 complex, Atg8-PE complex is continuously recycled by a
second Atg4 cleavage event which liberates Atg8 to reform new complexes and
consequently mediate the specificity of the autophagosome formation and size (Kirisako,
Baba et al. 1999). Moreover, Atg8-PE also behaves as a scaffold to enable membrane
expansion for larger vesicle formation. Recent studies have provided evidence indicating
a direct correlation between the levels of Atg8, size and autophagosomal expansion
(Nakatogawa, Ichimura et al. 2007; Xie, Nair et al. 2008; Xie, Nair et al. 2008). Thus,
Atg4 over expression in RKD-S cells helps drive selective autophagy that has the
potential ability for expanding the autophagosomes to accommodate large CerPrPSc
aggregates.
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Recapping the supporting evidence for the hypothesis driven prediction regulating
prion susceptibility: The introduction of CWD prions to RKD-S cells causes the
upregulation of HSPB8 and BAG3, which forms a co-chaperone complex that
phosphorylates eIF2ak (Fig. 4.7B). The activation of eIF2ak causes RKD-S cells to shut
down protein translation and become temporarily growth arrested. Concurrently, the
second mechanism activated by eIF2ak is the induction of macroautophagy (Fig. 4.7A),
which seems to be independent of the UPS and CMA response (Fig 4.7B). This noncanonical response is indicated by the active down regulation of HSPA (70-kDa), DNAJ
and BAG (2 & 6) proteins that are normally involved in the classic UPS response (Table
4.10). Selective autophagy in RKD-S cells mediated by the Atg4’s release of Atg8-PE
complex generates CerPrPSc-fibril filled autophagosomes that seclude the infectious
microaggregates from becoming toxic to the cell. Replication and infectivity of CerPrPScfibrils is ensued when the autophagosome docks and fuses with lysosomes abundantly
filled with Cathepsins and other proteases that are upregulated in RKD-S cells. Instead of
clearing CerPrPSc-fibrils, the matured autophagosome-lysosome complex cleaves
CerPrPSc-fibrils into smaller, more infectious molecules that are subsequently released
intracellularly and/or exocytosed out to infect neighboring cells (Fig 4.7B). Upregulation
of Rab GTPases by RKD-S cells is additional evidence strongly supporting this
hypothesis (Table 4.10, Fig 4.8B). In either case, proteolytic digestion and reduction of
CerPrPSc microaggregates releases the cells from growth arrest, which in turn allows
RKD-S to divide and exponentially replicate CWD prions.
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Figure 4.7 Autophagy and PrPSc Replication. A. Schematic representation of
Macroautophagy

(Autophagy)

induction.

Different

stimuli

induce

intracellular

autophagy, which range from homeostatic organelle/protein maintenance to stress
responses induced by exogenous sources (Infection, Starvation, and Reactive Oxygen
Species (ROS). The multi-step process initiates with cytosolic membrane isolation
collecting and sequestering molecules. This progressive cytosolic membrane forms a
mature autophagosome containing molecules destined for degradation. Molecule
degradation is achieved when the autophagosome docks and fuses with lysosomes,
releasing lysosomal proteolytic enzymes to ensue degradation (Klionsky 2005; Nair and
Klionsky 2005; Reggiori and Klionsky 2005; Yorimitsu and Klionsky 2005; Moreau, Luo
et al. 2010). B. Hypothesis driven schematic using differentially expressed RKD genes to
predict the intracellular mechanisms regulating prion replication. Significant upregulation
of HSPB8, BAG3, eIF2ak, Atg4a (Table 4.6) in the CWD prion permissive RKD-S cells
imply the induction autophagy. HSPB8-BAG3 induce the phosphorylation of eIF2ak,
which subsequently induces the complete shut down of translation and stimulates
autophagy (A non-canonical stimulation irrespective of HSP70 and ubiquitin ligase
activation)

(Carra,

Brunsting

et

al.

2009).

Autophagy

induction

leads

to

activation/deactivation of other chaperone proteins involved in stabilizing protein folding
(Red color genes indicate upregulation (ex. HSPB8), black color (ex. BAG2) indicate
down regulation in RKD-S cells). The continuous stimulation of this process in
combination with cell growth arrest (translational shut down) enables PrPSc infectious
seed production enhancing cellular infectivity(Silveira, Raymond et al. 2005; Heiseke,
Aguib et al. 2010). Full Gene names and functions are described in table 4.10.
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Figure 4.7 Autophagy and PrPSc Replication.
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Table 4.6 Differentially down regulated gene expression in RKD-R cells as
compared to the RKD-S cells. Robust multichip average (RMA) and quantile
normalization methods were used for signal normalization and false-positive signal noise,
respectively. Significance and stringency was set to p-value 0.001 and fold change cutoff
of 2.0, respectively. Abbreviations, Fold Change (FC), Not Associated (NA),
Endoplasmic Reticulum (ER), plasma membrane (PM)
Gene Name
Gene
FC
Cell Process
Component
Symbol (-)
AmilorideAccn2
2.57 Cation transport
PM, synapse
sensitive cation
channel 2
Helicase-like
Hltf
2.06 Chromatin
Nucleus
transcription
modification,
factor
metabolic process
transcription DNA
dependent
Autophagy-related Atg4a
2.78 Autophagy,
Cytoplasm
4A
metabolic transport,
protein transport,
proteolysis
Hepatitis A virus
Hvcr1
2.38 Phagocytosis,
Cell surface,
cellular receptor 1
mycotoxin, nutrient membrane, phagocytic
vesicle
Solute carrier
Slc25a2 3.0
Carnitine shuttle,
Membrane,
family 25 member 0
transport
mitochondrial inner
20
membrane
Interferon gamma Ifngr1
2.52
ER, membrane,
receptor 1
postsynaptic density,
vesicle
F-box protein 32
Fbxo32 3.55 Muscle atrophy
Nucleus
ABI gene family,
Abi3bp 2.91 Extracellular matrix Extracellular
member 3 (NESH)
organization,
matrix/space,
binding protein
positive regulation
interstitial matrix
of cell-substrate
adhesion
RalBP1 associated Reps1
2.04 NA
Coated pit, plasma
Eps domain
membrane
containing protein
F-box protein 30
Fbxo30 2.43 Protein
Cellular component
ubiquitination
(computational
estimation)
T cell receptor
Trav12 2.90 NA
NA
alpha variable
d-1
12d-1
BCL2-associated
Bclaf1 2.01 Positive regulation
Cytoplasm, Nucleolus,
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transcription
factor 1
Peptidyl-prolyl
isomerase
(cyclophilin)-like 4
ADP-ribosylation
factor-like 8B

Ppil4

2.11

Arl8b

2.05

Docking protein 1

Dok1

3.16

Solute carrier
family 6, member
5

Slc6a5

3.46

Discoidin, CUB
and LCCL
domain containing
2
RIKEN cDNA
9030625A04 gene

Dcbld2

3.43

Eukaryotic
translation
initiation factor 2alpha kinase 2

903062 2.31
5A04Ri
k
Eif2ak2 2.73

Crystallin, beta B2 Crybb2
Enoyl Coenzyme
Echdc1
A hydratase
domain containing
1
Protein kinase,
Prkar2a
cAMP dependent
regulatory, type II
alpha

	
  

2.08
2.28

2.63

of Apoptosis

nucleus

Protein folding,
protein peptidylprolyl isomerization
Cell cycle/division,
chromosome
segregation, mitosis

Cellular component,
nucleus

MAPKKK cascade,
Ras protein signal
transduction,
intracellular protein
kinase cascade
Amino acid
transmembrane
transport, glycine
transport
Cell adhesion,
negative regulation
of cell growth

Cytoplasm,
cytoskeleton,
endosome, lysosome,
membrane, midbody,
spindle midzone
Cytoplasm

Integral to membrane,
Membrane
Cell surface, Integral to
plasma membrane

Biological

Cellular component

ER unfolded protein
response,
phosphorylation,
positive regulation
of apoptosis, protein
autophosphorylation,
virus-infected cell
apoptosis
Visual perception
Metabolic

Intracellular, nucleus,
soluble fraction

Phosphorylation,
protein, regulation of
protein kinase
activity

T-tubule, cAMPdependent protein
complex, centrosome,
cytoplasm,
insoluble/soluble
fraction perinuclear
region of cytoplasm,
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NA
Cellular

RIKEN cDNA
1700011H14 gene

	
  

PM
Cellular

2.17

Biological

Relaxin 1

170001
1h14Ri
k
Rln1

21.3
7

EFR3 homolog A

Efr3a

2.07

G-protein signaling,
regulation of NO
mediated signaling
Cell-cell adhesion

FYN binding
protein
Family with
sequence
similarity 110,
member C
Hairy/enhancerof-split related
with YRPW motif
2
Glia maturation
factor, beta
Splicing factor 3b,
subunit 5
Vanin 3

Fyb

3.47

Fam11
0c

2.13

Hey2

2.54

Notch signaling,
negative regulation
of transcription

Gmfb

6.11

NA

Intracellular

Sf3b5

2.00

Vnn3

2.26

RNA
splicing/processing
Nitrogen compound
metabolic process,
Cell adhesion, motor
axon guidance

U12-type spliceosomal
complex, Nucleus
Membrane Anchored,
extracellular space, PM
Axon, External side of
PM, neuronal cell body

Metabolic process,
regulation of
apoptosis, response
to virus
Metabolic

Cytoplasm,
intracellular, nucleus

Nucleus

Intracellular, nucleus

NOT mast cell
activation
Biological

Activated
Alcam
leukocyte cell
adhesion molecule
Interferon induced Ifih1
with helicase C
domain 1

9.85

Ribonuclease,
RNase A family, 1
Myelin
transcription
factor 1-like

Rnase1

9.51

Myt1l

3.40

Adenosine
deaminase, tRNAspecific 2, TAD2
homolog
Nuclear receptor

Adat2

5.13

Cell differentiation,
nervous system
development, DNAdependent
transcriptional
regulation
tRNA processing

Ncoa7

2.53

Cell wall

2.52
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NA
Cornified envelope,
intracellular, Plasma
membrane
Cytoplasm, nucleus
Cellular-component,
cytoplasm,
cytoskeleton,
microtubule
Nucleus

NA

Cellular component

coactivator 7

Ceruloplasmin

Cp

3.23

Adenosine
deaminase

Ada

2.45

PPPDE peptidase
domain containing
Monoacylglycerol
O-acyltransferase
3
Heat shock
protein 8
2'-5'
oligoadenylate
synthetase-like 2
Hypothetical
protein LOC73112

Pppde1

2.19

Mogat3

2.29

Hspb8

4.23

Glycerol metabolic
process, lipid
biosynthetic process
Response to stress

Oasl2

7.24

NA

Cytoplasm,
intracellular, nucleus
Cellular component

311000 2.39
3A17Ri
k
Tnip1
2.07

NA

NA

Glycoprotein
biosynthetic

Cytoplasm, nucleus

2.01

Phosphorylation

Cellular component

6.43

Cytoplasm

TNFAIP3
interacting protein
1
cDNA sequence
BC016
BC016495
495
InterferonIfit1
induced protein
with
tetratricopeptide
repeats 1
Eukaryotic release
factor 3
Sterile alpha motif
domain containing
4B
RAR-related
orphan receptor
alpha

	
  

macromolecule
process, DNAdependent regulation
of transcription
Copper ion
transport, oxidationreduction process,
Cell adhesion,
negative regulation
of apoptosis,
inflammatory
response
NA

Anchored to PM,
extracellular
region/space
Cell junction, cell
surface, cytoplasm,
cytoplasmic vesicle,
extracellular space,
lysosome, membrane,
NA
ER membrane,
membrane

Hbs1l

2.09

Cellular response to;
dsRNA, interferonalpha/beta,
intracellular
transport of viral
proteins in host cell
NA

Samd4
b

2.04

NA

NA

Rora

2.93

cGMP metabolic
process, NO
biosynthesis,
positive regulation
of transcription

Nucleus

223	
  

NA

	
  

Transmembrane
protein 89
Myeloblastosis
oncogene

Tmem8
9
Myb

3.05

Receptor
transporter
protein 3
Family with
sequence
similarity 126,
member B
Eukaryotic
translation
initiation factor
4E member 3
human
immunodeficiency
virus type I
enhancer binding
protein 2
Vanin 2
RAS guanyl
releasing protein 1

Rtp3

3.78

Fam12
6b

3.79

regulation
NA

Integral to membrane

G1/S transition of
mitotic cell cycle,
calcium ion
transport, chromatin
remodeling,
Protein targeting to
membrane

Nucleus

4.41

NA

Intracellular

Eif4e3

2.11

Regulation of
translation

Cytoplasm

Hivep2

2.44

Signal transduction,
DNA dependent
transcription

Intracellular, nucleus,
transcription factor
complex

Vnn2
Rasgrp
1

4.10
3.17

NA
Cell differentiation,
intracellular signal
transduction,
Cell adhesion,
migration,
opsonization, cell
proliferation,
phagocytosis, signal
transduction
NA

NA
Golgi, cytoplasm, ER,
PM

RNA splicing,
positive regulation
of apoptosis
Cellular protein
metabolic process

Nucleus, spliceosomal
complex

cytoplasm

CD47 antigen (Rh- CD47
related antigen,
integrin-associated
signal transducer)

2.02

Androgen-induced Aig1
1
RNA binding
Rbm5
motif protein 5

2.03

Chaperonin
containing Tcp1,
subunit 6a (zeta)
Ring finger
protein 222
Zinc finger
protein 684

CCT6a

2.07

RNF22
2
Znf684

2.42

NA

Membrane

2.05

DNA-dependent
regulation of

Nucleus

2.41
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Extracellular vesicular
Exosome, PM

Integral to membrane

Cytoplasm

CD1e

2.63

Nucleus
accumbens
associated 1, BEN
and BTB (POZ)
domain containing
Tenascin C

Nacc1

2.11

Induction of
apoptosis,

Tnc

2.78

Cell adhesion,
positive regulation
of cell proliferation
and gene expression

2.12

Cell cycle arrest

Cell growth
Cgrrf1
regulator with
ring finger domain

	
  

transcription
Antigen processing
and presentation

T-cell surface
glycoprotein
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Golgi, early/late
endosome, PM,
Lysosomal lumen
Cytoplasm,
intracellular membrane
bound organelle,
nuclear body
Basement membrane,
extracellular
region/space,
proteinaceous
extracellular matrix
NA

Auxiliary Proteins Correlated To Prion Susceptibility: Differentially expressed proteins
that interact with PrP molecules at the cell surface are also important to discuss in the
context of prion susceptibility. Although mentioned already, it is important to reiterate
that PrPC-PrPSc initial interaction and conversion occurs at the cell-surface of the plasma
membrane (Stahl, Borchelt et al. 1987; Goold, Rabbanian et al. 2011; Hooper 2011). It is
crucial to identify and characterize differentially regulated proteins that interact with PrP
in lipid rafts and within intracellular compartments that would involve trafficking to and
from the plasma membrane. In the last section of the introductory chapter is a
comprehensive list of proteins that have been attributed to interact with PrPC and/or PrPSc
(Table 1.3). Using that list as reference, both high and low stringency RKD gene lists
(Table 4.5) were searched for matching proteins from that list (Table 1.3) or share
homologous resemblance to those described proteins. This investigation led to the
discovery of genes that have previously been reported on with association to PrP and
potentially novel genes. The extrapolated genes are listed in table 4.10.
Proteins At The Cell-Surface PrPC-PrPSc Interface
PrP Receptors/Interactors: PrPC is a glycoprotein tethered to the plasma membrane by a
GPI-anchor, which requires interacting proteins for internalization and perhaps signaling
(Stahl, Borchelt et al. 1987; Caughey and Raymond 1991; Stefanova, Horejsi et al. 1991;
Borchelt, Taraboulos et al. 1992; Taraboulos, Raeber et al. 1992; Shyng, Huber et al.
1993; Shyng, Heuser et al. 1994; Vey, Pilkuhn et al. 1996). Gene list analysis has
revealed several proteins previously shown to interact with PrP or co-localize together.
These differentially expressed genes include the 37-kDa/67-kDa laminin receptor 1
(Lamr1), apolipoprotein receptors (LRP1 and LRP3), adhesion molecules protocadherin-
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Alpha 1 (Pcdha1), cadherin 9 (CDH9), activated leukocyte cell adhesion molecule
(ALCAM),

integrins

(ITGB),

glycoproteins

(CD36,

CD47,

ORM1)

and

metalloproteinases (ADAM & MMP’s) (Table 4.10 and Fig. 4.8A).
PrPC-PrPSc Complex Stabilization: The 37-kDa/67-kDa laminin receptor 1 (LAMR1) is
upregulated in RKD-S cells (Table 4.8, 4.10 and Fig. 4.8A). Several studies have linked
direct interaction of LAMR1 with both PrPC and PrPSc, acting as internalization receptor
(Kolodziejczak, Da Costa Dias et al. 2010; Mbazima, Da Costa Dias et al. 2010). The
interaction of PrP with LAMR1 in RKD-S cells could have a multifaceted effect on the
cells, which subsequently enables prion replication to ensue. The first and most obvious
scenario involves the ability of these proteins to physically interact (Gauczynski, Peyrin
et al. 2001). This interaction could stabilize the PrPC-PrPSc complex, which would
possibly require the participation of other adhesion/receptor proteins (LRP, CDH9,
ALCAM) that are also upregulated by RKD-S cells (Fig. 4.8A) (Santuccione, Sytnyk et
al. 2005; Gauczynski, Nikles et al. 2006; Taylor and Hooper 2007; Mbazima, Da Costa
Dias et al. 2010). Although, stabilization of PrPC-PrPSc by these adhesion proteins would
not be sufficient to drive the conversion process forward. Coincidentally, RKD-S cells
also over express metalloproteinases that have been experimentally validated for their
ability to cleave both forms of PrP molecules (Table 4.10, Fig. 4.8A) (Cisse, Sunyach et
al. 2005; Taylor, Parkin et al. 2009). Upregulated ADAM-9 has been shown to indirectly
induce ectodomain PrP shedding through ADAM10, and therefore could influence the
replication process (Cisse, Sunyach et al. 2005). Although, ectodomain shedding process
exhibited by ADAM9-10 does not seem to have a direct effect on regulating prion
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conversion (Taylor, Parkin et al. 2009). Nonetheless, joint interaction between the
described proteins could have the additive effect that is favorable for prion conversion.
In addition, the microarray data indicates that clusterin (CLU) is also upregulated
in RKD-S cells. The clusterin (Clu) gene encodes a secreted chaperone protein that is
attributed with cellular debris clearance, protein aggregation induction and inhibition of
apoptosis (Jones and Jomary 2002; Zhang, Kim et al. 2005; Materia, Cater et al. 2011;
Wyatt, Yerbury et al. 2011). Especially relevant to the discussion is clusterin’s ability to
maintain and stabilize unfolded proteins in a quasi-conformation state without inducing
the protein to refold (Yerbury, Poon et al. 2007). Clusterin’s interaction with cell surface
receptors stimulates internalization and consequent activation of lysosomal degradation
processes (Wyatt and Wilson 2010). This characteristic strongly complements the
aforementioned discussion on autophagy activation and PrPSc replication in RKD-S cells.
In addition, this protein has been associated with AD, severity of disease, pathology and
amyloid plaque formation (DeMattos, O'Dell M et al. 2002; Yerbury, Poon et al. 2007;
Nuutinen, Suuronen et al. 2009; Thambisetty, Simmons et al. 2010; Schrijvers, Koudstaal
et al. 2011; Schurmann, Wiese et al. 2011; Thambisetty, An et al. 2012). Clusterin
exhibits direct interaction with PrP and has previously been linked with reducing the
incubation time of prion disease (Kempster, Collins et al. 2004; Xu, Karnaukhova et al.
2008). Thus, it is feasible to hypothesize that the combinatorial interaction between the
laminin

receptor

(LAMR1),

adhesion

proteins

(ALCAM,

CDH9,

LRP),

metalloproteinases (ADAM 1, 8, 9 & MMP/MME) and extracellular chaperone, clusterin
(CLU), strongly supports the formation of PrPC-PrPSc replicative complex (Fig. 4.8A).
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Laminin receptor’s capacity for internalization collectively with clusterin’s ability
to trigger internalization is the second possible mechanism/process in which RKD-S
maintain prion susceptibility. In this process, we build onto the predicted cell surface
mechanisms. PrPC-PrPSc is stabilized by the cell surface proteins, at which point LAMR1
and CLU act out their secondary functions in the conversion process. These processes
include subcellular internalization and activation of intracellular chaperones through
misfolded stress response mechanisms (Fig. 4.8A-B). Besides internalization, LAMR1
and CLU both exhibit anti-apoptotic survival signaling capacities (Trougakos, Lourda et
al. 2009; Vana, Zuber et al. 2009). Thus, at the interface of prion internalization, LAMR1
and CLU trigger additional survival pathways that keep the cell from entering apoptosis.
These pathways involve genes that have been upregulated in RKD-S cells (Table 4.10).
The genes regulate pathways involved in cellular survival mechanisms, which include
ataxin 7 (ATXN7), tumor necrosis factor receptor subfamily member 1B (TNFRSF1B),
nuclear factor kappa B subunit -2 (NFKB2), and eIF2ak2 (Table 4.10).
In addition, RKD-S cells recruit other proteins to assist in the process. PDDB
cross-referencing enabled the identification of the calcium-dependent, membrane-binding
protein, called Copine (Cpne8) (Table 4.8, 4.10 and Fig. 4.8B). The function of Cpne8
remains to be determined, but inferred to participate in membrane trafficking. Copine
family of proteins are Ca2+-dependent phospholipid-binding proteins involved with
membrane trafficking (Tomsig and Creutz 2002). It is probable that Cpne8, LAMBR1
and PrPC co-localize and form an interaction. The mechanisms of this interaction to assist
PrPSc replication is hard to predict but the upregulation of Cpne8 during the course of
prion disease in mice has been reported indicating some sort of connection between these
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proteins (Lloyd, Maytham et al. 2010). Consequently, RKD-S cells upregulate, what
seems to be the right combination of cell-surface proteins to efficiently stabilize,
chaperone and internalize prion molecules.
Ceruloplasmin (CP), upregulated gene in RKD-S cells is not associated with
protein homeostasis but could be crucial to prion replication. CP is an alpha-2glycoprotein that binds 95% of copper in the human serum (Ortel, Takahashi et al. 1984).
The primary functions of this protein include iron homeostasis and neuronal survival with
profound expression throughout the central nervous system (Klomp, Farhangrazi et al.
1996). Co-localization to lipid rafts and metal ion binding functions similar to PrPC was
the basis for selecting this protein for further analysis (Koschinsky, Chow et al. 1987;
Mukhopadhyay, Attieh et al. 1998). CP has been demonstrated to mediate iron and
manganese oxidation and transfers it to the plasma transferrin (Tfn) protein (Jursa and
Smith 2009), which coincidentally has also been linked to the prion protein
internalization mechanisms (Sunyach, Jen et al. 2003). Furthermore, this glycoprotein has
been linked with other protein misfolding neurodegenerative disorders such as AD, PD
and ALS (Loeffler, LeWitt et al. 1996; Vassiliev, Harris et al. 2005; Squitti, Quattrocchi
et al. 2007; Capo, Arciello et al. 2008; Squitti, Quattrocchi et al. 2008; Texel, Xu et al.
2008; Torsdottir, Kristinsson et al. 2010; McNeill and Chinnery 2011; Olivieri, Conti et
al. 2011). In addition, CP has been shown to interact with serine proteases and
apolipoproteins to induce CP-mediated neuro-aggregation in P19 neuro-embryonic stem
cells (Maltais, Desroches et al. 2003; Ducharme, Maltais et al. 2010). In vitro models
using ROS in conjunction with CP have shown to induce efficient aggregation of α-Syn
(Kim, Choi et al. 2002). This type of activity adds pertinence to the overall phenotype of
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the prion sensitive cell. Collectively, RKD-S cells upregulate ApoE proteins (LRP),
extracellular proteases (ADAM’s & MMP/MME’s, Chymase (CMA1-serine protease))
and extracellular chaperones (CLU) concurrently with CP. We hypothesize that these
upregulated proteins are needed for optimal PrPC-PrPSc conversion (Table 4.10 and Fig.
4.8). Copper chaperone for superoxide dismutase (CCS) is also upregulated by RKD-S
cells (Table 4.10 and Fig 4.8B). This protein shares functional similarity to CP through
regulation of metal ion homeostasis and copper ion transporting (Fig. 4.8B) (Suazo,
Olivares et al. 2008). Co-localization of PrPC, CCS and CP to the cell surface and
cytosolic metal ion transport suggests importance in the global scheme of host
modulations that enhance and/or select specific cells sensitive to prion replication.
The cell-surface protein expression in RKD-R cells somewhat differs. RKD-R
cells upregulate adhesion proteins and metalloproteases that are different from RKD-S
cells (Fig. 4.8A). Unlike RKD-S, RKD-R cells upregulate serine protease enzymes that if
activated have the capability to digest PrPC.

Moreover, other RKD-R expressed

glycoproteins could indirectly inhibit PrPSc replication at the cell-surface interphase
keeping the cells free from internalizing the infectious agent. For example, alpha-1-Acid
glycoprotein (Orm1) is localized to the plasma membrane of RKD-R cells. Orm1 is a 4145-kDa acute phase plasma-glycoprotein that is prevalent during inflammation (Treuheit,
Costello et al. 1992). This protein has been shown to interact with the plasminogen
activator inhibitor-1 protein by stabilizing its function in inhibiting plasminogen
activation (Fournier, Medjoubi et al. 2000; Boncela, Papiewska et al. 2001). This
stabilization of plasminogen activator inhibitor-1 by Orm1 to reduce plasminogen
production is indirectly relevant because plasminogen has been hypothesized to be one of
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the cofactors associated with PrPSc conversion (Fischer, Roeckl et al. 2000; Maissen,
Roeckl et al. 2001; Ryou, Prusiner et al. 2003; Mays and Ryou 2010; Mays, Yeom et al.
2011). Then, overexpression of Orm1 by RKD-R could inadvertently reduce plasminogen
output by the cell, which would destabilize PrPC-PrPSc conversion.
An additional glycoprotein expressed by RKD-R cells that could infer resistance
is protein C (PROC) (Table 4.7 and Fig. 4.8A). PROC is a predominantly inactive serine
protease that is dependent on vitamin K to become active (Clouse and Comp 1986). The
protein is 419 aa long and has several function domains that give it both receptor binding
and proteolytic properties (Mosnier and Griffin 2006). It was first described in the
context of protealytically inactivating blood coagulation factors Va and VIIIa (Mammen,
Thomas et al. 1960), but recently been associated with cytoprotective properties that
include regulatory gene expression functions, anti-inflammatory, anti-apoptotic and
endothelial barrier protective functions (Mosnier, Zlokovic et al. 2007). Cytoprotective
properties are preformed though the interaction with the endothelial protein c receptor
(EPCR) and the protease-activated receptor-1 (PAR-1), causing the activation of
downstream regulatory pathways that modulate cellular response to stress (Mosnier,
Zlokovic et al. 2007). Activated PROC has been established to upregulate expression of
tumor necrosis factor receptor superfamily proteins and bone morphogenic proteins
(Riewald, Petrovan et al. 2002), which are also upregulated in RKD-R cells. Furthermore,
PROC maintains enzymatic protease similar to PK, a proteolytic enzyme used for
digesting PrPC and biochemically detecting PrPSc. Over-expression of PROC could bring
on the unintentional digestion of PrPC substrate prior the PrPSc conformational conversion
step, making the cells phenotypically resistant. Ultimately, the pleiotropic functions of
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PROC make it an attractive target for validation as a potential resistance factor
responsible for inhibiting PrPC-PrPSc conversion.
Protocadherin-Alpha 1 (Pcdha1) is a Ca2+-dependent cell adhesion molecule
upregulated in RKD-R cells (Table 4.7, 4.10 and Fig 4.8A), which is normally expressed
in neurons of the central nervous system (CNS) (Yagi and Takeichi 2000). The
protocadherin gene family is composed of approximately 60 genes (Nollet, Kools et al.
2000; Yagi and Takeichi 2000). Besides cell adhesion functions, differential expression
of protocadherins amongst neurons is hypothesized to provide neuronal identity at the
cell surface. Protocadherins have been demonstrated to undergo proteolytic cleavage by
both metalloproteinases and γ-secretase (Haas, Frank et al. 2005; Hambsch, Grinevich et
al. 2005), enzyme previously linked to protein misfolding diseases (Turner and Nalivaeva
2007; Zhang, Ma et al. 2011). The cadherin proteins concurrently with other cell
adhesion proteins have been implicated as probable interacting partners for PrPC
(Gauczynski, Hundt et al. 2001; Aguzzi, Baumann et al. 2008; Malaga-Trillo, Solis et al.
2009). Ultimately, overexpression of this protein in RKD-R clones could have a
functional implication towards the resistance.
Activation Of Intracellular Transport: The mechanisms of prion trafficking in
relationship to subcellular PrPSc replication have stimulated great interest in current prion
research. Microarray analysis suggests discrete transport mechanisms between RKD-S
and RKD-R cells. RKD-R cells upregulate genes that involve caveolae- and clathrinmediated endocytic transport, whereas RKD-S cells upregulate genes involved in
modulating intracellular vesicle docking, fusion and transport (Table 4.10 and Fig. 4.8B).
These two scenarios depict the conditions that drastically alter membrane topology and
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composition. PrPC has been shown to utilize both clathrin and/or the caveolin mechanism
as vehicles of transport from the surface to the endosomal compartments (Taraboulos,
Raeber et al. 1992; Vey, Pilkuhn et al. 1996; Peters, Mironov et al. 2003; Sunyach, Jen et
al. 2003; Sarnataro, Caputo et al. 2009). RKD-R cells modulate endocytic pathways that
subsequently cause continuous turnover of the plasma membrane. Henceforth, enhanced
turnover of the plasma membrane reduces the interaction kinetics between PrPC and PrPSc
at the cell surface, precluding the occurrence for efficient PrPSc conversion. This is
implied by RKD-R upregulation of caveolin (CAV2, 1.87-FC), flotilins (FLOT1, 2.95FC), clathrin (CLTC, 1.92-FC), sortilin (SORT1, 1.76-FC), sorting Nexin 17 (AP1B,
1.76-FC), adaptor-related protein complex AP-1, sigma 3 (AP1S3, 2.20-FC) and rasassociated protein 15 (RAB15, 2.02-FC). The aforementioned implications of the plasma
membrane as the primary location for PrPSc conversion makes these differentially
expressed genes additional targets for susceptibility assessment (Goold, Rabbanian et al.
2011).
While the plasma membrane is being turned over in RKD-R cells, RKD-S cells
are utilizing intracellular vesicle recycling mechanisms to continuously traffic PrPSc
aggregate-fibrils

to

and

from

autophagosomal/lysosomal

compartments.

It

is

hypothesized that one replicative interphase of PrPSc is within the transporting vesicles
that recycle PrPC-PrPSc molecules from the surface (Caughey and Raymond 1991; Goold,
Rabbanian et al. 2011). This mechanism could than be linked to the abovementioned
autophagy scenario which enable prion replication to proceed. Continuous intracellular
transport of PrPSc molecule to lysosomal degradation compartments induces aggregatefibril fractionation into smaller and more infectious molecules (Table 4.10 and Fig. 4.8B)
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(Silveira, Raymond et al. 2005; Vella, Sharples et al. 2007; Marijanovic, Caputo et al.
2009). The upregulation of RAB (1a, 7, 7a, 7L1, 8b), ADP-ribosylation factors (ARL8B),
Ras-like family (RASL12), aminophospholipid transporters (ATP8B1), Exosome
components (EXOC5), syntaxins (STX1B) and vesicle transport and docking proteins
(VAPA) strongly support the intracellular PrPSc recycling prediction (Table 4.10 and Fig.
4.8B). These genes specifically associate with intracellular vesicle traffic.
Connecting The Dots: The Collective Mechanisms That Make Cells Prion Susceptible:
Numerous cellular mechanisms/pathways must be activated to enable efficient PrPSc
conversion and prion replication. Starting at the cell surface where the initial PrPC-PrPSc
contact is made, we hypothesize the conditional presence of protein groups with distinct
functions to set off PrPSc conversion. These cell surface proteins must include PrPbinding receptors with cytoplasmic domains to enable the internalization of PrPC-PrPSc.
Followed by proteolytic enzymes, which modulate the conversion process, extracellular
chaperones for enhanced stability and metal ion binding proteins for dual function that
include stabilization and membrane translocation (Fig 4.8A). As the conversion proceeds
forward, and becomes internalized, the cell must exponentially increase output of PrPSc
seed. This process is achieved by activating endosome-recycling proteins that induce
continuous formation of vesicles. Simultaneously, the cell also activates a very selective
protein misfolding response that does not require the recruitment of the proteasome
degradation pathways but rather utilizes the already activated lysosomes through
macroautophagy-mediated

mechanisms.

This

non-canonical

autophagy

response

transiently arrests cell growth, creating the ideal cytoplasmic conditions to form PrPSc
aggregate-fibrils. Without cell division taking place, the infectious PrPSc-fibrils grow at
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an exponential rate. The cells survive this cytoplasmic stress using two additional
mechanisms. First, anti-apoptotic pathways are activated by both cell-surface receptors
and intracellular proteins involved in the already activated autophagy pathway. Second,
the autophagosome-lysosome fused compartments break apart the large PrPSc aggregates
into smaller less toxic entities. Coincidentally, these smaller less-cytotoxic PrPSc
aggregate molecules are more inclined to reinitiate PrPC-PrPSc conversion. The break
down of the large aggregate fibrils also releases the cell from growth arrest, allowing it to
divide. Eventual initiation of cell division releases the infectious PrPSc molecules into the
extracellular space, which subsequently causes neighboring cells to also become infected.
Resumed cell division generates additional clones which posses all the proper conversion
factors to enable prion replication and survive. These conclusions are inferred entirely
from comparing published literature on the topics to the acquired gene expression results.
Future validation studies are required to prove or disprove the described hypothesis of
cellular mechanisms that dictate prion susceptibility.
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Figure 4.8 RKD differentially expressed genes targeted for cell-surface presentation
and intracellular transport. A. Schematic representation of differentially expressed
genes that co-localize to the cell surface of RKD cells. Proteins depicted on the left and
labeled in red represent identified genes that were upregulated in PrPSc sensitive RKD-S
cells. Proteins depicted on the right and labeled in black represent identified genes that
were up regulated in PrPSc resistant RKD-R cells. B. Schematic depiction of RKD’s
differentially expressed genes regulating intracellular vesicle transport and recycling. (1)
PrPC-PrPSc interaction at the cell surface initiates the conversion process. (2) Continuous
intracellular transport cycling of PrPC to and from the surface facilitates intracellular
PrPSc conversion. (3) Endocytic delivery of the PrPC-PrPSc complex activates proteinstress response, which consequently induces macroautophagy and chaperone-mediated
autophagy, mechanisms that stabilize and enhance prion conversion. (4) Autophagosome
transporting large PrPSc aggregates dock and fuse with lysosomal vacuoles to initiate
degradation. Large PrPSc-aggresomes are fractured to produce smaller, more infectious
PrPSc molecules. (5) The smaller infectious PrPSc particles are either exocytosed or
become intracellular seeding material.

Red-labeled genes represent upregulation in

RKD-S cells while black-labeled genes represent upregulation in RKD-R cells.
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Figure 4.8 RKD differentially expressed genes targeted for cell-surface presentation
and intracellular transport.
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Table 4.7 Differentially upregulated gene expression in RKD-R cells as compared to
the RKD-S cells. Robust multichip average (RMA) and quantile normalization methods
were used for signal normalization and false-positive signal noise, respectively.
Significance and stringency was set to p-value 0.001 and fold change cutoff of 2.0,
respectively. Abbreviations, Fold Change (FC), Not Associated (NA), Endoplasmic
Reticulum (ER)
Gene Name
Gene
FC
Cell Process
Component
Symbol
(+)
Nucleolar protein
Nom1
2.05
RNA metabolic
Nucleolus
with MIF4G domain
process
1
Sulfatase modifying Sumf2 2.01
NA
ER
factor 2
Orosomucoid 1
Orm1
5.45
Acute-Phase
Extracellular region
response,
regulation of
immune system,
transport
Protein-tyrosine
Tpst1
2.38
Metabolic process Golgi, membrane
sulfotransferase 1
BEN domain
Bend6
2.23
NA
NA
containing 6
ProPomc
4.52
Cell-cell signaling, Cytoplasm,
opiomelanocortinneuropeptide
extracellular region,
alpha
signaling
stored secretory
granule
Plastin-1
Pls1
3.60
NA
Cytoplasm
Single-stranded
Ssbp2
3.23
DNA dependent
Cytoplasm & nucleus
DNA binding
transcriptional
protein 2
regulation
P450 (cytochrome)
Por
2.03
Internal peptidylER, membrane,
oxidoreductase
lysine acetylation, microsome,
negative regulation mitochondrion,
of; apoptosis,
soluble fraction
caspase activity
Procollagen lysine,
Plod2
2.61
OxidationER, Membrane
2-oxoglutarate 5reduction process
dioxygenase 2
Cell cycle regulator 493342 2.77
Cell cycle
NA
Mat89Bb homolog
4B01Ri
k
Protocadherin alpha Pcdha1 2.07
NA
Membrane fraction
1
Centrosomal
Cep72
2.83
Gamma-tubulin
Centrosome,
protein 72
complex
cytoplasm,
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Bone morphogenetic Bmp4
protein 4

3.28

Ankyrin3

Ank3

4.79

Thiopurine
methyltransferase
Guanine nucleotide
binding protein,
gamma 10
Adaptor-related
protein complex AP1, sigma 3
Protein aurora
borealis

Tpmt

2.64

Gng10

9.96

Ap1s3

2.20

672046
3M24R
ik
Lcp1

2.01

Suppressor of
cancer cell invasion

Scai

2.25

HEAT repeat
containing 5A
Tumor necrosis
factor receptor
superfamily,
member 21
Retinoblastoma
binding protein 7

Establishment of
protein
organization,
Metabolic process,
methylation
G-protein coupled
receptor signaling

Cytoplasm,
extracellular region,
membrane bounded
vesicles,
proteinaceous
Basolateral plasma
membrane, synapse
Cytoplasm, soluble
fraction
Heterotrimeric GProtein complex, PM

Endocytosis,
intracellular
protein transport,
Cell cycle

Golgi, coated pits,
cytoplasmic vesicle,
membrane coat
NA
Actin cytoskeleton,
cell junction,
phagocytic cup, PM

Heatr5a 2.12

Actin filament
assembly,
intracellular
protein transport
Negative
regulation of; Rho
protein signal
transduction
NA

Tnfrsf2
1

2.38

Apoptosis, signal
transduction

Axon, cytoplasm,
membrane

Rbbp7

2.02

Ubiquitinconjugating enzyme
E2M

Ube2m

2.15

ESC/E(Z) complex,
NuRD complex,
Nucleus
NA

Protein C

Proc

5.29

DNA replication,
negative regulation
of cell growth,
Positive regulation
of neuron
apoptosis,
ubiquitination
Cellular protein
metabolic process,
peptidyl-glutamic

Lymphocyte
cytosolic protein 1

	
  

localization,
spindle
organization
SMAD protein
transduction,
activation of
MAPKK,

3.46
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Cytoplasm,
membrane, nucleus
NA

Golgi, ER,
extracellular, PM

Parathyroid
hormone 1 receptor

Pthr

Discs, large homolog Dlg2
2

3.16

Membrane protein,
palmitoylated 7

2.24

Mpp7

Zinc finger protein
Zfp397
397
Vascular endothelial Vegfc
growth factor C
Protocadherin 1
Pcdh1

	
  

2.48

2.02
2.86
2.57

acid carboxylation,
Proteolysis
Activation of
Phospholipase C
activity by GPCR
signaling coupled
to IP3 second
messenger
Neuronal ion
channel clustering,
receptor clustering
Positive regulation
of protein complex
assembly
Regulation of
transcription
Cell
differentiation,
Calciumdependent cell-cell
adhesion
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Basolateral, PM

Cytoplasm,
membrane fraction,
neuronal cell body
Adherens junction,
membrane, tight
junction
Nucleus
Extracellular,
membrane
Cell-cell junction,

Table 4.8 Prion Disease Database (PDDB) cross-referenced RKD-R down regulated
genes associated with published prion literature.

Gene Name

	
  

Gene
Symb
ol

Function

40S ribosomal protein
SA/Laminin receptor 1

RPSA/
Lamr1

Cytoplasmic domain, extracellular domain,
laminin binding, laminin receptor,
translation regulator

Clusterin/Apolipoprotein

CLU

Coiled-coil domain, Ku70 protein binding
domain, nuclear localization sequence,
protein binding, signal binding, ubiquitin
protein ligase binding

Aldolase C

ALDO
C

Cytoskeletal protein binding, enzyme,
fructose-bisphosphate aldolase, protein
binding

Complement Factor B

CFB

Alternative-complement-pathway, C3/C5
convertase, peptidase, serine endopeptidase

Ataxin 7

ATXN
7

Chromatin binding, glutamine repeat
domain, nuclear export signal, protein
binding

Eukaryotic translation
initiation Factor 2-Alpha
Kinase 2

EIF2A
K2

Phosphotrensferase, ATP-binding domain,
basic and catalytic domains, coiled-coil
domain, dimerization domain, protein
binding, protein kinase, protein phosphatase
2A, intrinsic regulator, protein
serine/threonine kinase

Copper Chaperone for
Superoxide Dismutase

CCS

Copper ion binding, transporter, enzyme,
protein binding, superoxide dismutase,
copper chaperone, zinc ion binding

Tumor Necrosis Factor
Receptor Subfamily
Member 1B

TNFR
SF1B

Cytoplasmic, cytosolic tail, extracellular and
intracellular domains, pre-ligand assembly
domain, transmembrane receptor, tyrosine
kinase

TATA Box Binding
Protein like Protein 1

TBPL
1

Beta-transducin protein family located at the
pH resistant lipid raft fraction, plasma
membrane

Small Nuclear
Ribonucleoprotein
Polypeptide N

SNRP
N

Protein binding
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V-REL Avian
Reticuloendotheliosis
Viral Oncogene

RELB

Transcription co-repressor, transcription
regulator

Protein Kinase C, Zeta
Form

PRKC
Z

Potassium channel regulator, protein kinase
C, protein serine/threonine kinase

Protein Kinase C, Delta

PRKC
D

Protein kinase binding, protein kinase C,
protein serine/threonine kinase

Polo-like Kinase 3

PLK3

Protein binding, protein kinase , protein
serine/threonine kinase

Phospholipase A2, Group
II D

PLA2
G2D

Enzyme, phospholipase A2

Nuclear Factor Kappa B
Subunit 2

NFKB
2

Transcription co-activator, transcription
regulator

Nuclear Factor,
Interleukin 3-Regulated

NFIL3

Transcription co-repressor, transcription
factor, transcription regulator

Interferon Gamma
Receptor 1

IFNG
R1

STAT binding domain, transmembrane
domain, transmembrane receptor

Immediate-Early
Response 3

IER3

Fxfp sequence, nuclear localization
sequence, protein binding

Endoglin

ENG

Activin binding, protein binding,
cytoplasmic, cytosolic tail, extracellular
domain, galactose binding,
glycosaminoglycan binding

Copine 8

CPNE
8

Calcium-binding membrane-binding protein
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Table 4.9 Prion Disease Database (PDDB) cross-referenced RKD-R up regulated
genes associated with published prion literature.

	
  

Gene Name

Gene
Symbol

Function

TATA Box Binding
Protein

TBT

Activation domain, core domain, DNA binding
domain, inhibitory DNA-binding domain, p53binding domain, polyglutamine repeat,
transcriptional regulator

Complement
Component 4
Binding Protein
alpha

C4BPA

Protein Binding

X-Box Binding
Protein 1

XBP1

DNA Binding, pXBP(U) degradation motif,
transcription factor, transcription regulator

Adenylate Cyclase 3

ADCY
3

Calcium/Calmadulin-response adenylate cyclase,
protein binding

Myristoylated
alanine-rich Protein
Kinase C substrate

MARC
KS

Protein kinase C substrate

Mitotic ArrestDeficient 2

MAD2
L1

Protein binding, protein homodimerization

Ccto-NOX disulfideThiolexchanger 2

ENOX
2

Enzyme, protein disulfide oxidoreductase

Amyotrophic
Lateral Sclerosis 2
(juvenile)
Chromosome
region, candidate 2

ALS2C
R4

Transmembrane protein 237, protein binding

Apoptosis-inducing
Factor
Mitochondrionassociated, 3

AIFM3

Caspase activator, enzyme, protein binding,
thioredoxin-disulfide reductase

Casein Kinase II
Beta

CSNK2
B

Acidic loop domain, destruction box, kinase,
positive regulatory domain, protein binding,
receptor binding, transcription factor binding,
zinc-finger domain

Clathrin Heavy
Polypeptide

CLTC

Ankyrin binding, clathrin trimerization domain,
globular tail domain, heat shock protein binding.
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Table 4.10 Extrapolated gene list grouped by functional association. Negative sign in
the FC column indicates down regulation of gene expression in the RKD-Resistant clone
(Up-regulated in RKD-Sensitive) Abbreviations, Fold Change (FC), Not Associated
(NA), Endoplasmic Reticulum (ER), Plasma Membrane (PM)
Protein/Gene
FC
Function/Class
Localization
Symbol

Transport/Trafficking-Mechanisms
Lysosome motility,
Late-Endosome,	
  Lysosome	
  
Intracellular Protein
Cytoplasm	
  
-‐2.12	
  
Transport/GTPBinding
Ras-associated
Vesicle	
  transport/ER-‐
Endocytic
-‐1.60	
  
protein 1A/ RAB1A	
  
Transport/GTP-binding	
  
Golgi	
  
Ras-associated
Endocytic
Late-Endosome, lysosome
-1.56
protein 7A/ RAB7A
Transport/GTP-binding
Ras-associated
Endocytic
Late-Endosome, lysosome
-1.57
protein 7/ RAB7
Transport/GTP-binding
Ras-associated
Membrane, Cytoplasmic
-1.56
Transport/GTPase
protein 8B/ RAB8B
side
Ras-associated
Membrane, Cytoplasmic side
protein 7 Like-1/
-1.52
Transport/GTPase
RAB7L1
Caveolin-2/ CAV2
1.87
Caveolae/Scaffold
Lipid Rafts/Vesicle
Flotillin-1/ FLOT1
2.95
Caveolae/Scaffold
Caveolae-Vesicle
Ras-Like Family
Membrane/ Intracellular
-1.58 Transport/GTP-binding
12/ RASL12
Ras-related
PM
protein, M-Ras/
-1.63 Signaling/GTP-binding
MRAS
Ras-associated
Vesicle-Membrane
2.02
Transport/GTPase
protein 15/ RAB15
Clathrin, Heavy
Cytoplasmic vesicles
1.92
Trafficking/ Structural
Chain/ CLTC
Sortilin-1/ SORT1
Signaling/Sorting
ER, Endosomes, Lysosomes
1.76
Receptor
Sorting Nexin 17/
TraffickingEndosome, Cytoplasm,
AP1B
1.76
Sorting/ReceptorGolgi
Binding (LRP1)
Adaptor-Related
TraffickingEndosomes, Vesicle
Protein 1, Subunit
2.2
Sorting/Clathrin
3/ AP1S3
Binding
ATPase,
Membrane
Aminophospholipid
Aminophospholipid
Transporter, Class -3.56
Transport/ATPase
I, type 8B, member
1/ ATP8B1
ADP-ribosylation
factor-like
8B/ARL8B
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Huntingtin/ HTT
Copine 8/ CPNE8
Copine 9/ CPNE9
Solute Carrier
Family11, Member
2/ DMT1
Ceruloplasmin/ CP
Superoxide
dismutase copper
chaperone/ CCS
ATPase Type
13A3/ ATP13A3
Bicaudal D
homolog 1/ BICD1
Exosome
Component 8/
EXOSC8
Exocyst
Component 5/
EXOC5
Exosome
Component 3/
Exosc3
TNFAIP3
interacting protein
3/ TNIP3
TNFAIP3
interacting protein/
TNIP
Syntaxin 1B/
STX1B
VAMP (vesicleassociated
membrane
protein)-associated
protein A, 33kDa/
VAPA
Chromatinmodifying protein
2a/ CHMP2A
	
  

1.78
-1.68
-1.54
-2.23
-3.37

Microtubule-Transport
Membrane Trafficking/
Phospholipid Binding
Membrane Trafficking/
Phospholipid Binding
Metal
Transport/NEDD4
ProteasomeDegradation
Ion-Transport/
Metalloprotein

Cytoplasm
PM
PM
Endosome, Lysosome,
Lysosome Membrane
Extracellular Space, PM
Cytoplasm

-1.69

Ion Transport to SOD

-1.65

Cation Transport

2.29

Transport/Motor
Protein Recruitment

1.87

RNA Degradation

-1.80

Transport, Exocytic
Vesicle Docking

Membrane
ER-Golgi
Nucleus, Cytoplasm
Cytoplasm
Nucleus, Cytoplasm

1.58

-3.41

-2.07
-1.69

RNA Degradation
HIV-1 Matrix Protein
Interaction
(GAG)/Virion
Incorporation
HIV-1 Matrix Protein
Interaction
(GAG)/Virion
Incorporation
Vesicle
Transport/Docking

Intracellular, Nucleus,
Cytoplasm
Intracellular, Nucleus,
Cytoplasm
Membrane
ER Membrane, Vesicles

-1.59

Vesicle Transport/
Membrane Fusion

1.51

ESCRTIII/Degradation of
Surface receptor
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Late Endosome Membrane

proteins/MVB
formation/HIV-1 Gag
(p6)

Cell Adhesion/Plasma-Membrane	
  
67-kDa Laminin
-‐1.89	
  
Cell	
  Adhesion/Signaling
receptor 1/
Receptor	
  
LAMR1/RPSA
Tenascin –C/ TNC -2.8
Extracellular
Matrix/Neurite
Outgrowth
Neural precursor -2.11
cell expressed,
Docking/ Tyrdevelopmentally
Kinase Signaling Focal
down-regulated 9/
Adhesion
NEDD9
Integrin, beta 1/ 1.78 Collagen Receptor/Focal
ITGB1
Adhesion
Integrin, beta 4/
1.7
Laminin Receptor
ITGB4
RAS p21 protein 1.62
GTPase-Activating
activator/ RASA1
A Disintegrin and 2.37
Metalloproteinase
with
Thrombospondin
Metalloproteinase
Motifs 8/
/COMP Degradation
ADAMTS8
Motifs 12/
1.83
ADAMTS12
Motifs 17/
1.77
ADAMTS17
Low density
-1.81
lipoprotein
Endocytic Receptor/APP
receptor-related
Regulation/Signaling
protein 1/ LRP1
Matrix
-1.52
Extracellular matrix
Metallopeptidase
Endopeptidase
16/ MMP16
Matrix
-3.17
Metallopeptidase
Collagen Degradation
13/ MMP13
Matrix
-2.5
Extracellular matrix
Metallopeptidase 2/
Endopeptidase/ Interacts
MMP2
with TIMP2
A Disintegrin and -3.3 Metalloproteinase/Extrav
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PM,	
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Extracellular Space
Cytoplasm, Golgi,
Projection

Membrane
Membrane
Cytoplasm

Extracellular Space

Membrane, Coated-Pits

Extracellular Space, CellSurface

Metalloproteinase
Domain 8/ ADAM8
Motifs 1/
-2.78
ADAMTS1
A Disintegrin and -1.8
Metalloproteinase
Domain 9/ ADAM9
Motifs 9/
-2.56
ADAMTS9

asation
Metalloproteinase/
Proteoglycan cleavage
Metalloproteinase/Zinc
Protease, cell-cell
interaction
Metalloproteinase/
Cleaves Aggregating
Proteoglycans

Membrane
-6.45
MetalloThermolysin/ Elastase
Endopeptidase/
Activity
MME
Tissue inhibitor of -2.11
Inactivation of MMP
metalloproteinases
(1,2,3,7,8,9,10,13,14,15,1
2/ TIMP2
6,19)
Protein C/ PROC
5.3
Serine Protease
Low density
3.64
lipoprotein
receptor-related
protein 3/ LRP3
Chymase-1/ CMA1 -2.14
Activated leukocyte -2.75
cell adhesion
molecule/ ALCAM
Glycoprotein IIIb/ -2.54
CD36

Secreted
ER, Golgi, PM,
Extracellular
Membrane, Coated-Pits

Predicted Receptor
EM Degradation/
Protease
Adhesion/Neurite
extension

Thrombospondin
Receptor/Adhesion/Fatty
Acid Transport
CD47 glycoprotein/ -2.02
Adhesion/ Membrane
CD47
Transport
2+
Cadherin-9/ CDH9 -1.70 Ca dependent Adhesion
Protocadherin 1/ 2.58
Adhesion
PCDH1
Protocadherin
2.07
alpha subfamily C,
Ca2+ dependent Adhesion
2/ PCDHAC2
Tetraspanin-29/ 1.87
Adhesion/
CD9
Transmembrane
Glycoprotein
Plastin-1/ PLS1
3.60
Actin-Binding
Lipoma-preferred -1.66
Adhesion/ Scaffolding
partner/ LPP
Protein
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Secreted
Membrane
Membrane
Membrane
Membrane
Cell Junction, Membrane
Membrane
Membrane
Cytoplasm
Cytoplasm, Membrane, Cell
Junction

Ubiquitin-Proteasome Pathway/Protein Degradation/Apoptosis	
  
Cathepsin L1/
CTSL
Palmitoyl-protein
hydrolase 1/ PPT1
Programmed cell
death 2/ PDCD2
Apoptosis-inducing
factor,
mitochondrionassociated, 3/
AIFM3
Neural precursor
cell expressed,
developmentally
down-regulated 4/
NEDD4
Ataxin 7-Like/
ATXN7L1
Ataxin 7/ ATXN7
Ubiquitinconjugating
enzyme E2H/
UBE2H
Ubiquitin protein
ligase E3A/ UBE3A

-2.1
-1.62
1.59
2.76

Lysosome
Lysosome
Nucleus
Mitochondrion

Caspase-dependent
Apoptosis
-1.86

-1.78

E3-Ubiquitin
Ligase/Receptor
Internalization and
Degradation
NA

-1.72
-1.59

Histone Modification

-1.6

E3-Ubiquitin Acceptor/
UPS

Ubiquitin specific -3.84
peptidase 18/
USP18
Ubiquitin specific -1.52
peptidase 4/ USP4
Ubiquitin2.15
conjugating
enzyme E2M/
UBE2M
Proteasome
1.55
(prosome,
macropain) 26S
subunit, nonATPase, 5/ PSMD5
Proteasome
1.51
(prosome,
macropain) 26S

	
  

Protein Degradation
/Cysteine Proteinase
Lipid-modified Protein
Degradation
DNA-Binding
Regulatory/ Survival

Ubiquitin Acceptor/
Misfolded Protein
Degradation UPS

Deubiquitinating
protease
Deubiquitinating
protease/ER Quality
Control

Cytoplasm, Membrane,
Endosome, Exosome

NA
Cytoplasm, Nucleus
Cytoplasm, Nucleus,

Cytoplasm,
Cytoplasm, Nucleus
Cytoplasm, ER
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Ubiquitin AcceptorNEDD8/UPS
Proteasome Complex
Chaperone/26s
Proteasome/UPS
Chaperone/26s
Proteasome/UPS
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Proteasome Complex

subunit, ATPase, 6/
PSMC6
Ubiquitin specific 1.64
peptidase 5
(isopeptidase T)/
USP5
BCL2-associated -2.00
transcription factor
1/ BCLAF1
CASP8 and FADD- -1.69
like apoptosis
regulator/ CFLAR
TP53 apoptosis -1.97
effector/ PERP
F-box protein 32/ -3.76
FBXO32
F-box protein 10/ 1.55
FBXO10
F-box protein 48/ -2.13
FBXO48
F-box protein 21/ 1.68
FBXO21
F-box protein 42/ -1.52
FBXO42
Ring-‐Finger	
  
-‐1.50	
  
Protein	
  
139/RFN139	
  
Ring-‐Finger	
  
1.56	
  
Protein	
  4/RFN4	
  
Ring-‐Finger	
  
Protein	
  
217/RFN217	
  
Ring-‐Finger	
  
Protein	
  
123/RFN123	
  

Ubiquitin thiolesterase
activity/ positive
regulation ubiquitindependent protein
catabolic process UPS
Death-promoting
transcriptional repressor
Apoptosis Regulation/
TNFRSF-triggered
apoptosis
TP53-dependent
apoptotic pathway
Ubiquitin-protein ligase
activity/UPS
Ubiquitin-protein ligase
activity/UPS

Cytoplasm

Cytoplasm, Nucleus
Cytoplasm
Membrane, Golgi
Ubiquitin ligase complex
Ubiquitin ligase complex
NA

NA

Ubiquitin-protein ligase
activity/UPS
Ubiquitin-protein ligase
activity/UPS
E3-ubiquitin ligase/
negative regulator of
Growth
E3-ubiquitin
ligase/Protein
degradation	
  
-‐1.95	
  
E3-ubiquitin
ligase/Protein
degradation	
  
-‐1.88	
  
E3-ubiquitin ligase/
proteasome-mediated
degradation of CDKN1B	
  

Ubiquitin ligase complex
Ubiquitin ligase complex
ER	
  Membrane	
  
Cytoplasm	
  
Membrane	
  
Cytoplasm	
  

Chaperone/Protein Homeostasis	
  

	
  

Clusterin/ CLU

-1.67

HtrA serine
peptidase 4/
HTRA4

-1.78

Extracellular
Chaperone/StressInduced Aggregation
Chaperone Serine
Protease
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PM, ER, Vesicle,
Cytoplasm
Extracellular

Chaperonin
containing Tcomplex subunit 6/
CCT6A
BCL2-associated
athanogene 3/
BAG3
Heat shock 22kDa
protein 8/ HSPB8

-2.01

Cytoplasm
Molecular Chaperone/
Actin/Tubulin

-1.54
-3.78

Inhibits HSP70/AntiApoptotic
Chaperone/ Binds
BAG3 (Cofactor)/
Macroautophagy

Heat shock protein -1.6
90kDa beta
Chaperone/ ERAD/
(Grp94), member
Process & Transport
1/ HSP90B1
Heat shock protein -1.53
90kDa alpha
(cytosolic), class B
Protein Maturation
member 1/
Chaperone
HSP90AB1
(HSP83)
Chaperonin
1.77
containing TMolecular Chaperone/
complex subunit 2
Actin/Tubulin
(beta)/ CCT2
Protein
1.89
phosphatase 4,
Protein Phosphorylation/
regulatory subunit
Signaling
1/ PPP4R1
J-domain1.78
containing protein
Protein Folding /Codisulfide isomeraseChaperone with HSPA5
like protein/
DNAJC10
Heat shock 70kDa 2.09
protein 12A/
Chaperone/UPS
HSPA12A
Heat shock 70kDa 3.89
Chaperone
protein 2/ HSPA2
BCL2-associated
1.68
Inhibits HSP70/Antiathanogene 2/
Apoptotic
BAG2
BCL2-associated
1.62
Apoptotic
athanogene 6/
Chaperone/Interacts
BAG6
with HSPA2 and
AIFM1
FK506-binding
-‐1.82	
  
Accelerates protein
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Cytoplasm
ER

Cytoplasm

Cytoplasm

NA

ER, Secreted

Cytoplasm
Cell-Surface,
Mitochondrion
Cytoplasm
Cytoplasm/BAT3 Complex

ER	
  

protein 14/FKBP14
FK506-binding
protein
3,25kDa/FKBP3	
  

folding/ peptidyl-prolyl
cis-trans isomerase
Accelerates protein
1.71	
  
folding/ peptidyl-prolyl
cis-trans isomerase	
  

Membrane	
  

Signaling/Transcription Activation Pathway	
  
Lipopolysaccharide
-induced TNF
factor/ LITAF
Frizzled family
receptor 6/ FZD6
Amyloid beta
precursor protein
binding protein 1,
59kDa/
NAE1(APPBP1)
Interferon
regulatory factor 7/
IRF7
Eukaryotic
translation
initiation factor 2C,
3/ EIF2C3
Eukaryotic
translation
initiation factor 2alpha kinase 3/
EIF2AK3
Eukaryotic
translation
initiation factor 2alpha kinase 2/
EIF2AK2
Protein kinase C,
delta/ PRKCD
Protein kinase C,
zeta/ PRKCZ
p38/ CRK
Casein kinase II
beta subunit/
CSNK2B
Cyclin-dependent
kinase 8/ CDK8
Cyclin-dependent

	
  

-1.83
Apoptosis, Signaling
-1.81

Wnt-Signaling

1.62

Lysosome, Golgi,
Membrane
Membrane
Membrane

Cell-Surface Signaling/
Apoptosis
-4.83

Cytoplasm
Transcriptional activator

-1.58

Cytoplasm
RNA-mediated gene
silencing (RNAi)

-1.50

ER
Phosphorylates/ unfolded
protein response (UPR)

-3.92

-1.81
-1.95
-1.60
1.86
1.72
1.53

Autophosphorylated
protein serine/threonine
kinase, Autophagy
Induction
Protein serine/threonine
kinase
Protein serine/threonine
kinase
Adapter-protein
Protein serine/threonine
kinase
Protein serine/threonine
kinase/ Transcription
Activation

252	
  

Cytoplasm

Cytoplasm, Membrane
Cytoplasm, Membrane
Cytoplasm, PM
Cytoplasm, Nucleus
Nucleus
Cytoplasm

kinase 16/ CDK16
Cyclin-dependent
kinase-like 2
(CDC2-related
kinase)/ CDKL2
Mitogen-activated
protein kinase 12/
MAPK12
Mitogen-activated
protein kinaseactivated protein
kinase 3/
MAPKAPK3
Mitogen-activated
protein kinase 1
interacting protein
1-like/
MAPK1IP1L
Mitogen-activated
protein kinaseactivated protein
kinase 5/ MAP3K5	
  
Protein kinase,
cAMP-dependent,
regulatory, type II,
alpha/ Prkar2a
A kinase (PRKA)
anchor protein 12/
AKAP12
A kinase (PRKA)
anchor protein 13/
AKAP13
A kinase (PRKA)
anchor protein 11/
AKAP11

Transport Exocytosis
1.50

1.76
-1.68

-1.54

-‐
1.81	
  
-2.62

Phosphorylates and
activates MAP2K4 and
MAP2K6/Apoptosis
Induction	
  
Binds Anchoring
Proteins/Regulates
protein transport

	
  

Cytoplasm, Membrane

-2.04
-1.66
1.67

Anchoring protein/
subcellular
compartmentation of
PKA and PKC

Cytoplasm

Autophagy-Related Genes	
  
Programmed cell -1.98
death 6 interacting
protein/ PDCD6IP

Cell Death
Inhibitor/HIV-1
Budding/ApoptosisAutophagy Adhesion
Polo-like kinase 4/ 2.34 Serine/threonine-protein
PLK4
kinase/ Cell Division
Regulation
Kinase 3/ PLK3 -1.61
SNF-related
-1.55 Serine/threonine-protein
serine/threoninekinase / mediator of
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Cytoplasm, Nucleus,
Membrane
Nucleus

protein kinase/
SNRK
Functional
spliceosomeassociated protein
79/ THOC5
Myosin, heavy
chain 10/ Myh10
Ubiquitin-like
modifier
activating enzyme
2/ UBA2
Vimentin/ Vim

neuronal
Apoptosis
2.07

Nucleus, Cytoplasm
Nuclear export of
HSP70 mRNA

1.65

Motor Protein

1.6

Nucleus
E1 ligase / Ubiquitin
mediated proteolysis

Intermediate
filament/Lysosomal
Transport
F-box protein 30/ -2.45 Ubiquitin-protein ligase
FBXO30
activity/UPS
Autophagy-related -2.78
cysteine
Cysteine protease
Endopeptidase/
required for autophagy
ATG4a
Apurinic1.56
Cellular response to
apyrimidinic (AP)
oxidative stress/
endonuclease 1/
endodeoxyribonuclease
Apex1
Microtubule
-1.63
associated
Cytoskeletal regulator
monoxygenase,
that connects NEDD9 to
calponin and LIM
intermediate filaments
domain/ Mical1
TATA element
-1.77
STAT3 degradation/
modulatory factor
RAB6-dependent
1/ Tmf1
retrograde transport
process/Inhibits TBP
Ataxia
1.56
Serine/threonine protein
telangiectasia and
kinase/ Activated by
Rad3 related/
DNA damage
ATR
Transformation/tr 1.59
anscription
Adapter protein/
domain-associated
Transcription factor
protein/ TRRAP
BCL22.13
antagonist/killer 1/
Apoptosis Regulator
BAK1
Disks large
1.55
Guanylate kinase
	
  

Cytoplasm

-1.81
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Cytoplasm
Ubiquitin ligase complex
Cytoplasm

Nucleus, Cytoplasm

Cytoplasm

ER, Golgi, Cytoplasm,
Nucleus
Nucleus

Nucleus

Mitochondrion
Cytoplasm, PM

homolog 3/ Dlg3
Syntrophin, alpha
1/ SNTA1
Syntrophin, beta 2/
SNTB2
Ras-associated
protein 1A/ RAB1A
Sequestosome 1/
SQSTM1

activity/ negative
regulation of cell
proliferation
1.74
1.5
-1.6
-1.75

Karyopherin alpha -1.52
1/ KPNA1

Adapter protein/
Regulation of secretory
granules

Cytoplasm, PM, Vesicles,
Cell Junction
ER, Golgi

Transport/GTPase
Adapter protein binds
ubiquitin,
Regulation of
Signaling cascades
through ubiquitination
Nuclear protein import
adapter protein

Cytoplasm, Late endosome,
Nucleus
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Cytoplasm, Nucleus

Chapter 5
Discussion & Future Directions

Prion Infectivity Using Different Cell Culture Models: In these studies, we utilized cell
culture models to characterize prion strain diversity and initiated the search for
endogenous host factors that confer prion susceptibility. Three different cell lines were
genetically modulated to ectopically express heterologous PrPC, which were used for
infection studies with species specific PrPSc. These cell lines included the HEK293A,
N2a and RK13 cells. Several heterologous PrPC’s were chosen for ectopic expression in
the cells. These expressed proteins included cervid (elk/deer), hamster and mouse. Prion
infections used infectious isolates derived from the respective species to keep the PrPC
primary sequence equivalent to the prion isolate.
The cell culture infection experiments recapitulated in vivo results demonstrating
prion species-barrier and interfering effect of endogenously expressed PrPC. N2a cells
demonstrated resistance towards replicating CWD and hamster-adapted TME prions. No
inhibition

for

replicating

mouse-adapted

RML

scrapie

prions

was

showed

notwithstanding the cells over-expressed the ectopic PrPC transgene. Endogenous
expression of PrPC in N2a cells appeared to interfere with the co-expressed heterologous
PrPC for the cellular host factors that mediate the replicating process, which is
reminiscent of the initial in vivo studies exhibiting the interfering effect (Telling, Scott et
al. 1994; Telling, Scott et al. 1995). We hypothesized that prion replication was inhibited
as a result of endogenous interference of mouse PrPC. Recent studies have demonstrated
N2a capacity to replicate heterologous CWD prions. Isolation of N2a cells lacking
endogenous PrPC expression permitted transient CWD prion replication (Pulford, Reim et
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al. 2010). Several steps were taken to identify CWD prion susceptible N2a cells. First,
these cells were sorted five individual times to identify a population of N2a cells that do
not express detectable PrP levels. Second, the sorted cells were genetically modulated to
ectopically express cervid PrP. These methods allowed the identification of cells with the
capacity to convert and replicate CWD prions. It is not surprising that the abrogation of
endogenous PrP resulted in heterologous replication of prions because these cells have
been well established to generally be permissive towards prions. This method, closely
recapitulates the in vivo PrP interference data (Telling, Scott et al. 1995), except for
N2a’s inability to sustain CWD prion infectivity (personal communication with Dr.
Zabel). Together, this data suggests that N2a cells express and maintain the host
conversion factors that are required for prion replication.
The inability to sustain detectable levels of PK resistant CerPrPSc in N2a cells led
us to try RK13 cells next. These cells do not express endogenous PrPC and have
previously been shown to replicate ovine derived prions (Vilette, Andreoletti et al. 2001).
Initial experiments demonstrated inefficient CWD prion replication using these cells. To
enhance RK13 cells we exploited previously published evidence suggesting retroviral
elements enhance scrapie infection (Leblanc, Alais et al. 2006). RK13 cells were
genetically modulated to co-express HIV-1 Gag and cervid (elk/deer) PrPC. This
modification permitted the cells to replicate both elk and deer CWD-prions. In addition to
replicating CWD-prions, RK13 cells readily replicated mouse-adapted RML-prions, and
demonstrated the capacity to replicate SHa HY-prions but not DY-prions. Unlike N2a
cells, the interference of endogenous PrPC were not an issue with RK13 cells, but other
similarities could be drawn. Similar to CWD prion replicating N2a cells (Pulford, Reim
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et al. 2010), our RK13 cells lost prion infectivity with certain strains upon continuous
passage. RKE cells not expressing HIV-1 Gag eventually lost CWD prion infectivity and
RK13 cells expressing SHaPrP lost infectivity with HY with irrespective of HIV-1 Gag
expression. It would be interesting to test the effects HIV-1 Gag would have on N2a cells
that lack endogenous PrP because the neuronal origins of N2a cells enhanced with Gag
could lead to new cell line considerably more prion susceptible than any characterized
cell line we currently have to work with.
We reasoned that ectopic expression of PrPC in other cells lacking endogenous
expression of PrP would also enable them to replicate prions. HEK293 cells were used in
similar infectivity experiment to follow up the proposed hypothesis. Unlike RK13 cells,
HEK293 cells did not exhibit the capacity to replicate prions. The lack of detectable PK
resistant PrPSc material in 293 cells provided supplementary evidence to support the
hypothesis that PrPC expression alone is not sufficient to sustain prion infectivity.
Moreover, cells derived from Prnp0/0 mice genetically modulated to ectopically express
PrPC exhibited similar prion susceptibility outcomes (Raeber, Sailer et al. 1999).
Similarly, PrPC expression levels in cells known for their susceptibility do not
automatically confer prion susceptibility. Beyond that, cellular susceptibility to prions in
general is a rare event, which in some, not most cases requires extensive cellular cloning
to identify the single cell with “all the conversion tools” to efficiently replicate prions
without inducing apoptosis (Butler, Scott et al. 1988; Race, Caughey et al. 1988; Bosque
and Prusiner 2000; Bian, Napier et al. 2010).
Our RK13 characterization studies led us to discover that single cell cloning is
crucial to sustaining chronic infectivity. Incidentally, the abovementioned work using
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N2a cells exhibited evidence suggesting significant variation in prion susceptible N2a
cells (Bosque and Prusiner 2000). This phenotypic variation towards prion susceptibility
could be used as a cellular tool to identify host factors responsible for the modulating
effects. Conforming these observations to our cell culture system, we identified 78 RK13
(RKM) clones that differentially expressed Mouse PrPC. Several methods were used to
characterize these clones for total PrPC expression. Mouse-adapted RML-prions infection
revealed diverse susceptibility amongst individual clones. Similar expression of PrPC in
conjunction with differential susceptibility led us to formulate the working hypothesis for
subsequent experiments, which states that, while expression of PrPC is required for
infectivity, it is not sufficient to render the cell permissive. Therefore, endogenous host
factors are necessary to sustained prion replication.
Transcriptional Differences Amongst PrPSc Susceptible And Resistant Clones: Two
experimental approaches were used to identify differences in the molecular basis for
susceptibility amongst clonal cells. Both methods relied on transcriptional difference
between cell lines to help elucidate the protein and/or pathways that enable prion
replication. RDA was used as a pilot approach to analyze two phenotypically distinct
clones sensitive or resistant to RML prions. We were able to isolate several unique
transcripts. The isolated transcripts encoded hypothetical and/or poorly annotated
proteins. Furthermore, subsequent analysis of the two clones revealed phenotypic
reversion. The resistant clone exhibited permissiveness to prions, which led us towards a
newer and quicker microarray method. The lack of throughput, statistical insignificance
and experimental setback led us to abandon this approach.
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We utilized high-throughput microarray genome analysis as the second
experimental to identify transcriptional differences between clones. Clonal cells that were
susceptible and/or resistant to CWD-prion were characterized prior to microarray
profiling. As part of our experimental design, we isolated the RNA for transcriptional
analysis from uninfected clones. Previously studies have showed that the transcription
stability of cells pre- and post- prion infection were not altered (Julius, Hutter et al.
2008). Therefore, transcriptional differences that dictate clonal susceptibility are
constitutively active. In the time course of the study, two clones deemed susceptible lost
detectable CerPrPSc implying an incomplete molecular phenotype for susceptibility. This
was subsequently confirmed with microarray results.
Microarray transcriptional profiling revealed significant difference between
susceptible and resistant clones. Two distinct criteria were set to identify unique
transcripts, which include FC differences and statistical t-test p-value stringency cut-off.
The derivation of gene lists for prediction based analyses required the use of
mathematical confinements to set selection stringency. The most stringent mathematical
confinements utilized t-test p-value of ≤0.001 and FC of ≥2.0. These values generated a
list consisting of 100 differentially regulated genes, listed in tables 4.6 and 4.7.
Stringency reduction to the p-value of ≤0.05 and FC of ≥1.5 generated a gene lists
consisting of 1,375 differentially expressed genes. Both lists enabled us to gain insight
into the global perspective of the cellular physiology.
The primary difficulty with the microarray analysis was gene annotation. The
rabbit genome is poorly annotated, which required manual conversion of each rabbit gene
to the mouse/human ortholog. Subsequently, the second challenge of microarray analysis
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is acquiring meaningful information from the derived gene lists. The annotated rabbit
gene lists were bioinformatically analyzed using three different databases. These
databases include the Prion Disease Database (PDDB), Database for Annotation,
Visualization and Integrated Discovery (DAVID) and Protein ANalysis THrough
Evolutionary Relationships (PANTHER). Using PDDB, we identified 314 genes that
matched in vivo longitudinal gene expression studies characterizing prion pathogenesis.
In addition, a handful of matched genes have experimental evidence that functionally
connects them to prion disease. These genes are listed in tables 4.8 and 4.9. Unlike
PDDB that is designed to deal with prion disease associations only, DAVID and
PANTHER are designed to deal with large-scale transcriptional microarray data sets.
Gene pathway association and function analyses by DAVID and PANTHER databases
reveal metabolic pathways involved in protein homeostasis and cell division as primary
targets for subsequent validation.
The Phenotype Of A PrPSc Susceptible Cell: The gene expression data indicate that prion
sensitivity in RKD cells stem from pathways that regulate protein homeostasis. These
pathways include differentially regulated genes that partake in protein folding,
degradation, trafficking and cellular compartmentalization sorting. On the other hand,
cellular resistance amongst RKD clones is indicated by accelerated cell division.
Experimental precedence to both of these observations has been established but it is
highly possible that a combination of these attributes concurrently with prion strains
dictates the outcome of susceptibility (Ghaemmaghami, Phuan et al. 2007; Nunziante,
Ackermann et al. 2011). In vivo, prions preferentially propagate in post-mitotic neurons
of the CNS. It is intuitive that continuous cell division would eventually cause prions to
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dilute out beyond detectability, however cells in culture growing at various rates maintain
the ability to replicate prions (Butler, Scott et al. 1988; Race, Caughey et al. 1988;
Bosque and Prusiner 2000; Ghaemmaghami, Phuan et al. 2007; Nunziante, Ackermann et
al. 2011). Both exogenous and endogenous factors dictate susceptibility. Therefore,
cellular capacity to chronically sustain detectable PrPSc depends on a highly interrelated
balancing act between cellular mechanisms that maintain protein synthesis, protein
degradation, cell division and compatibility of the infecting prion strain. Our microarray
results suggest that CWD prion resistant clones upregulate gene clusters that modulate
and promote cell division. We have not experimentally addressed cell division rate
differences between the sensitive and resistant clones. Earlier studies have shown that
cell division actively dilutes detectable levels of PK resistant PrPSc, reducing the total
amount by half after each division (Race, Fadness et al. 1987). Moreover, systematic
analysis comparing cell division to prion replication kinetics revealed direct evidence for
steady-state reduction of prion levels in rapidly dividing cells (Ghaemmaghami, Phuan et
al. 2007). Interestingly, the steady-state reduction of prions by cell division was not
absolute indicating that other cellular mechanisms were undertaking the task to sustaining
low-levels of prions.
Our sensitive cells upregulate proteins that control mechanisms responsible for
protein. Careful analysis of the gene lists revealed macroautophagy as one of the
prevalent pathway activated in susceptible cells. This upregulated autophagy pathway
does not rely on the classical stress response proteins. The genes upregulated by RKD-S
cells activate a selective non-canonical pathway specific to aggregation-prone proteins.
Moreover, this pathway has a secondary function that transiently arrests cell growth.
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Aggregated protein response and growth arrest makes this pathway pertinent to the global
phenotype of the prion sensitive cell. In addition to autophagy activation, other chaperone
proteins were also upregulated by sensitive cells. It is likely that a skewed stress response
in susceptible cells is mediating the overall PrPSc conversion process. To support this
hypothesis, recently published findings indicate that proteasomal dysfunction and
endoplasmic reticulum stress in prion infected cells leads to enhanced accumulation of
PrPSc (Nunziante, Ackermann et al. 2011). By inducing ER stress and impairing
proteasomal regulatory pathways in cells, significant increase of misfolded protein
fractions were observed. Furthermore, the accumulated PrPSc was efficiently trafficked to
the plasma membrane using intracellular vesicle transport mechanisms. These studies
imply that ER environment together with protein quality control mechanisms tightly
modulate PrP maturation and PrPSc formation (Nunziante, Ackermann et al. 2011).
Understanding the cellular mechanisms that render cells susceptible to prion replication
could be used to explore mechanisms that govern other protein misfolding
proteinopathies.
Prion Propagation Under Cell Free Conditions: Several in vitro assays have been
described, which use purified components to catalyze PrPC to PrPSc conversion and
propagate infectious prions (Kocisko, Priola et al. 1995; Saborio, Permanne et al. 2001;
Wong, Xiong et al. 2001; Deleault, Geoghegan et al. 2005; Atarashi, Moore et al. 2007;
Deleault, Harris et al. 2007; Abid, Morales et al. 2010; Kim, Cali et al. 2010; Wang,
Wang et al. 2010). These assays rely on using PrPC substrate that has been purified from
brain tissue or generated recombinantly in bacteria combined with PrPSc to seed the
converting reaction. The CFCA was first to show that PrPC could be converted to PrPSc in
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the absence of cellular factors but the reaction required a 50-fold molar excess PrPSc,
which makes it highly inefficient (Kocisko, Come et al. 1994). Mammalian prions have
also been generated using recombinant SHaPrP (rPrPPMCA) in a seeded PMCA reaction
using 263K hamster purified PrP27-30 (Kim, Cali et al. 2010). The infectivity of these
prions was confirmed by bioassay, which resulted in variable attack rates, and long
incubation times, suggesting low prion titer. Although infectious prions can be generated
without additional cofactors, the low infectivity titers suggest that the process is
inefficient. Therefore suggesting that even in a cell free system, prions require additional
cofactors to accelerate the conversion process.
This in vitro prion conversion data compliments our prion cell culture system
because it demonstrates de novo generation of infectious prions is rare event requiring
cofactors. Therefore, supplementing cofactors into the prion conversion reaction may
accelerate or enhance the process. This is supported by findings that show how additional
cofactors can be applied to enhance PrPSc conversion efficiency (Abid, Morales et al.
2010; Kim, Cali et al. 2010; Wang, Wang et al. 2010). PMCA was crucial in identifying
cofactor components that accelerate prion conversion. RNA molecules were first to show
enhancement of prion conversion by PMCA (Deleault, Lucassen et al. 2003).
Subsequent studies using an overnight rapid shaking incubation assay demonstrated that
optimal prion amplification could be achieved using polyanions that include RNA and
HSPG’s (Deleault, Geoghegan et al. 2005). RNA length (>4kb) and not the source was
the important determinant of enhancing amplification. Several conclusions were made
from this data (Deleault, Geoghegan et al. 2005). First, adoption of a supporting structure
in 3D space was the probable mechanisms that regulated polyanions enhancement of
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PrPSc conversion in vitro. Second, the structure or scaffold that was forming by these
polyanions in 3D space was of specific length/size. Finally, once the amplified fibrils
reached a certain size in the scaffolded structure, disaggregation would occur causing the
fibrils to break and generate smaller, more infectious particle to drive the amplification
reaction forward (Deleault, Geoghegan et al. 2005;Silveira, Raymond et al. 2005).
Upregulation of cell-surface proteins in RK13 susceptible cells coincide with these
hypothesis driven predictions. The upregulated receptor, adhesion, enzyme and
chaperone proteins discussed in Chapter 4, were predicted to execute scaffolding and
stabilization functions in the PrPC-PrPSc conversion process. The polyanion-enhancing
component data was applied towards successfully generating unseeded de novo infectious
prions (rPrP-res) with bacterially expressed rPrP, anion-phospholipids, and RNA using
PMCA (Wang, Wang et al. 2010). Like rPrPPMCA, rPrP-res ability to cause prion disease
was confirmed by bioassay.
The generation of de novo prions using rPrP with the addition of lipids and RNA
molecules suggest that different molecules may help without specificity to enhance prion
conversion. Therefore, it is probable that within the confinements of a susceptible cell,
several molecules of different composition, work together to allow prion accumulation to
occur. Our predicted cofactor data supports this hypothesis. The scenario our susceptible
RK13 cells reveal requires the combination of extra- and intracellular components to
become activated for prions to accumulate. The intracellular recycling proteins combined
with overly activated macroautophagy would provide plenty of anion-phospholipids and
cytoplasmic RNA molecules to enhance PrPSc conversion (Figs. 4.7 and 4.8).
Investigation for cellular components that mediate prion replication activity led to several
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interesting discoveries, which helps provide experimental evidence to support our data
(Abid, Morales et al. 2010). To address species-specificity of cellular prion conversion
factors, brain homogenates from various species, including Prnp0/0 mice, was used in
PMCA to show efficient prion amplification (Abid, Morales et al. 2010). This finding
indicates that prion conversion factors are not species specific, because extracts from
every species used in the experiment efficiently amplified SHa-PrPSc. The PMCA data is
analogues to our system, which uses rabbit cells to replicate CWD, HY and RML prions,
again demonstrating the lack of species-specificity. Secondly, extracts derived from
various tissue sources (heart, liver, kidney, heart, muscle and brain) were applied to
PMCA experiments demonstrating efficient conversion irrespective of tissue source
(Abid, Morales et al. 2010). Another similarity can be drawn to our data, we use cells that
are of kidney epithelial origin and not neuronal origin.
Lastly, it is the third and fourth PMCA experiment of this report that provides
experimental evidence to support our predicted prion susceptibility cofactor data (Abid,
Morales et al. 2010). Using cellular fractions for PMCA, it was shown that lipid rafts
were the dominant conversion factors that achieved successful amplification. This can be
correlated to our prediction because every mechanism described in our hypothesis driven
prediction has association with membranes and perhaps lipid rafts. At cell surface, where
the initial PrPC-PrPSc interaction occurs, the upregulated proteins described in Chapter 4
localize to lipid rafts, which also happen to be one of the criterion for selecting the
molecules from the 1,375 gene list. Once internalized, the upregulated intracellular
recycling proteins have all been predicted to regulate membrane formed vesicles to dock,
fuse and trafficking molecules intracellularly. Concurrently, the primary indication of
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macroautophagy activation is the formation of autophagosomes, which require
intracellular double-layered membrane formation to enclose the molecules destined for
degradation. The described processes that occur in susceptible cells require lipid
membranes.
The chemical nature of conversion factors was determined using sequential
inactivation of molecule classes (proteins, nucleic acids, HSPG...etc.) in supplemental
extracts used for PMCA (Abid, Morales et al. 2010). The results of these experiments
revealed that inactivation of single molecule classes did not inhibit prion replication. This
implies that the composition of converting cofactors cannot be specified to individual
molecules. It is more probable that various molecule classes work together to positively
enhance prion conversion. Our gene expression data supports the described PMCA data.
The mechanisms that enhance prion replication in susceptible cells are complex, and are
likely to use various pathways and proteins. Beyond the predicted process hypothesized
to regulate prion susceptibility, other physiological factors should also be considered.
These factors should include pH conditions that are inside and outside the cell,
temperature fluctuations, and the presence of ROS. Any one of those factors alone or
combined could have affect cells capacity to replicate and sustain prions.
Cellular Aneuploidy: This study is not without caveats that must be addressed in future
experiments. One such caveat is the genetic composition of transformed cells.
Transformed cells tend to be aneuploidy, which have considerable variation in
chromosomal number. Approaches to circumvent and validate this drawback would be to
increase the n-value of samples analyzed. Moreover, It will be crucial to identify clonal
populations that exhibit susceptibility phenotypes to prion strains from different species.
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The use of next-generation sequencing technology for transcriptome analysis could help
validate the findings and consolidate identified host factors. Consequently, any
endogenous protein that is deemed a cofactor in prion replication will have to be
functionally validated both in vitro and in vivo to demonstrate its role in the process.
Consequently, the aneuploid genetic composition will become irrelevant if the protein is
validated.
Future Direction
Secondary Confirmation Of Target Gene Expression: The first approach towards taking
this data forward is secondary confirmation of the genes identified in the microarray
experiments. Genes listed in table 4.10 are the ideal targets for preliminary validation.
Table 4.10 represent carefully selected genes involved in pathways relevant to protein
homeostasis. These experiments should include quantitative real-time PCR (qRT-PCR)
assay to confirm the differential expression of genes discussed in chapter 4. The
measuring expression levels of target genes would have to be achieved in susceptible,
resistant and un-transfected parent cell line. Furthermore, the qRT-PCR analysis could be
done at several time points of infection. This mode of validation has the potential to be
used in both animal tissues and cell culture models. A different approach to validate
possible target genes is through western immunoblotting. This method would indicate
that the cell is making the target protein. Although, this form of analysis would require a
specific antibody for the protein in question, which is not always available. Both
approaches provide rapid results to support or negate the microarray results.
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Cell-Culture Based Experiments: Following secondary confirmation, cell culture based
analyses can be used to assess predicted host factor capacity to modulate prion
infectivity. For example, PrPSc-resistant clones could be genetically modulated to overexpress genes associated with PrPSc susceptibility. These might include the
macroautophagy genes such as HSPB8, BAG3 and/or eIF2ak or vesicular transport genes
such as the Rab genes. Preceding the infectivity experiments, all transfected genes would
have to be assessed for stable expression. These genetically modified PrPSc resistant cells
would then be infected with PrPSc and assessed for susceptibility using the standard PK
resistance western-immuno blotting readout. Inversely, inhibitors of these pathways
could be applied to PrPSc susceptible cells in an attempt to cure cells of infectivity. In
addition to inhibitors, gene-silencing approaches using siRNA techniques can also be
applied to cure PrPSc infected cells. Co-immuno precipitation (co-IP) is an approach,
which can be used to ascertain physical interactions between target genes and PrP
molecules. Co-localization studies using light microscopy can be applied to determine
cellular processes that are modulating replication. This combination of assays would be
beneficial for identifying cellular sites for PrPSc replication.
It will be imperative to produce additional cell lines with similar PrPSc phenotypes
from other species. RK13 cellular permissiveness towards replicating prions is a
characteristic, which can be applied towards generating sensitive cell line (Vilette,
Andreoletti et al. 2001; Bian, Napier et al. 2010). In initial attempts to develop such a cell
line, we utilized the Cre-Lox recombination system to selectively interchange species
specific PrPC ORF in a clonally selected RK13 cell. The Cre-Lox site-specific
recombination system is originally derived from bacteriophage P1, which utilizes the
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Cre-recombinase enzyme to remove stretches of DNA flanked by recognition sequences
(loxP) in an enzyme-mediated cleavage and ligation mechanism (Sauer 1987). We
engineered a PrPC expression vector with flanking loxP sites. This construct is referred to
as the floxed-PrPC ORF (Fig. 5.1A). The construct allows selective deletion of PrPC from
cells through the use of Cre-recombinase. The floxed-Mouse-PrPC was cloned into
pIRESpuro expression vector and stably transfected into RK13 cells (floxed-RKM cells).
The proper positioning of loxP sites and expression of murine PrPC was verified using
adeno-viral vector carrying the Cre-recombinase transgene at the multiplicity of infection
(MOI) of 15. The cells were kept in minimally supplemented media to reduce the growth
rate for 8 days. Lysate samples were collected for analysis at designated time points (Fig.
5.1B). This proof-of-principle experiment validates normal expression and processing of
loxP-flanked PrPC (Fig. 5.1B).
Clones of floxed-murine PrPC cells were derived by limited dilution cloning
technique. Clones were infected with mouse-adapted RML and at third passage assessed
using the mSCA. Floxed-RKM-11D4 clone was chosen for further studies as the most
sensitive PrPSc clone. Infected (RML) and uninfected cells were treated with the Ad-Cre
viral vector (MOI 15) and the kinetics of prion reduction was measured over a 72h time
frame (Fig. 5.1C). Western blot results revealed reduction of PrPSc in the RML infected
11D4 cells as the expression of PrPC is reduced (Fig. 5.1C). The data implies that PrPSc
persistence in RK13 cells goes beyond PrPC deletion.
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Figure 5.1 Generating a prion permissive susceptible cell line. A. Schematic
representation of the PrPC ORF with the addition of Lox-p (floxed) and restriction
endonuclease sites for versatile cloning into various expression and/or transgenic vectors.
The red (BsiWI, NheI, BglII, FseI) and blue (HindIII, AflII, EcoRI, SalI) boxes represent
restriction sites for down stream cloning strategies. The green box represents the addition
of the Kozak consensus sequence for initiation of the translation process. B. RK13 cells
expressing the floxed-mouse PrPC ORF expression vector (RKM Floxed), pIRESpuromouse PrPC (RKM7, clonaly selected and described in Chapter 3) or pIRESpuro-vector
only control (RKV) were transduced with the Adeno viral vector carrying the Crerecombinase (Ad-Cre) trans gene at the MOI of 15. Cell lysates were collected at
designated time points represented by numerical values on the blot (in hours). PrPC
expression was detected by western blotting using mAb 6H4. Actin expression is used for
total protein control Pan-Actin mAb-5. C. Time course (72h) assessment of PrPC and
PrPSc reduction in RKM, RKV, 11D4 (Single cell RKM-floxed clone) and 11D4-RML
(Chronically infected with mouse adapted RML scrapie) post Adeno virus transduction
(Ad-Cre (Cre-recombinase), MOI of 15). PrP was detected by western blotting using
mAb 6H4.
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Figure 5.1 Generating a prion permissive susceptible cell line
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High-Throughput Analysis: Next-generation sequencing technology can be used to
profile the transcriptome quantitatively with incredible accuracy. Although, microarray
gene expression profiling is very informative, it is not without limitations. Microarray
limitations are both technical and biological in type. Transcriptional sequencing
drastically bypasses both types of limitations. Transcriptional sequence output designates
numerical frequency of each transcript within each clone, which can subsequently be
averaged and correlated to other analyzed samples. Transcriptional screening can be
complemented with the use of protein array experiment for additional validation
purposes.
Other biochemical approaches that can be used to identify and validate the
cellular host factors would include the in vitro conversion assays discussed in the
introduction. Particularly the use of protein misfolding cyclical amplification (PMCA)
and the real-time quaking induced conversion assay (RT-QuIC). Using PMCA,
subcellular fractions purified from cells could be used to identify infectious cellular
compartments. Subsequently, amplified fractions would become subject to proteomic
analysis for comparison using tandem mass spectrometry to elucidate composition of
these fractions. Moreover, the RT-QuIC assay can be used to measure the kinetics of
prion replication from these identified sub-cellular fractions.
In conclusion, high throughput experiments using prion cell culture models will
provide greater insight into the mechanism that drive neurodegenerative disease at the
cellular level. Ultimately, PrPSc modulating host factors identified at in cells would have
to be applied and validated in vivo.
Copyright © Vadim Khaychuk 2012
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